BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol. 1999;94:2467-2474. [PMID: 10484010 DOI: 10.1111/j.1572-0241.1999.01377.x] [Cited by in Crossref: 2456] [Cited by in F6Publishing: 2366] [Article Influence: 106.8] [Reference Citation Analysis]
Number Citing Articles
1 Qadri S, Lallukka-Brück S, Luukkonen PK, Zhou Y, Gastaldelli A, Orho-Melander M, Sammalkorpi H, Juuti A, Penttilä AK, Perttilä J, Hakkarainen A, Lehtimäki TE, Orešič M, Hyötyläinen T, Hodson L, Olkkonen VM, Yki-Järvinen H. The PNPLA3-I148M variant increases polyunsaturated triglycerides in human adipose tissue. Liver Int 2020;40:2128-38. [PMID: 32386450 DOI: 10.1111/liv.14507] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
2 Takagi H, Hagiwara S, Hashizume H, Kanda D, Sato K, Sohara N, Kakizaki S, Takahashi H, Mori M, Kaneko H, Ohwada S, Ushikai M, Kobayashi K, Saheki T. Adult onset type II citrullinemia as a cause of non-alcoholic steatohepatitis. Journal of Hepatology 2006;44:236-9. [DOI: 10.1016/j.jhep.2005.08.024] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 1.6] [Reference Citation Analysis]
3 Lewis JR, Mohanty SR. Nonalcoholic Fatty Liver Disease: A Review and Update. Dig Dis Sci 2010;55:560-78. [DOI: 10.1007/s10620-009-1081-0] [Cited by in Crossref: 212] [Cited by in F6Publishing: 211] [Article Influence: 17.7] [Reference Citation Analysis]
4 Feldstein AE, Canbay A, Angulo P, Taniai M, Burgart LJ, Lindor KD, Gores GJ. Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology. 2003;125:437-443. [PMID: 12891546 DOI: 10.1016/s0016-5085(03)00907-7] [Cited by in Crossref: 704] [Cited by in F6Publishing: 341] [Article Influence: 37.1] [Reference Citation Analysis]
5 Esmat G, Metwally M, Zalata KR, Gadalla S, Abdel-Hamid M, Abouzied A, Shaheen AA, El-Raziky M, Khatab H, El-Kafrawy S. Evaluation of serum biomarkers of fibrosis and injury in Egyptian patients with chronic hepatitis C. J Hepatol. 2007;46:620-627. [PMID: 17316875 DOI: 10.1016/j.jhep.2006.12.010] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 2.2] [Reference Citation Analysis]
6 Tahan V, Atug O, Akin H, Eren F, Tahan G, Tarcin O, Uzun H, Ozdogan O, Tarcin O, Imeryuz N. Melatonin ameliorates methionine- and choline-deficient diet-induced nonalcoholic steatohepatitis in rats. J Pineal Res. 2009;46:401-407. [PMID: 19552763 DOI: 10.1111/j.1600-079x.2009.00676.x] [Cited by in Crossref: 34] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
7 Saif M, Kwanten WJ, Carr JA, Chen IX, Posada JM, Srivastava A, Zhang J, Zheng Y, Pinter M, Chatterjee S, Softic S, Kahn CR, van Leyen K, Bruns OT, Jain RK, Bawendi MG. Non-invasive monitoring of chronic liver disease via near-infrared and shortwave-infrared imaging of endogenous lipofuscin. Nat Biomed Eng 2020;4:801-13. [PMID: 32572196 DOI: 10.1038/s41551-020-0569-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
8 Sundaram SS, Zeitler P, Nadeau K. The metabolic syndrome and nonalcoholic fatty liver disease in children. Curr Opin Pediatr 2009;21:529-35. [PMID: 19444112 DOI: 10.1097/MOP.0b013e32832cb16f] [Cited by in Crossref: 58] [Cited by in F6Publishing: 22] [Article Influence: 4.5] [Reference Citation Analysis]
9 Zeuzem S, Sulkowski MS, Lawitz EJ, Rustgi VK, Rodriguez-Torres M, Bacon BR, Grigorescu M, Tice AD, Lurie Y, Cianciara J. Albinterferon Alfa-2b was not inferior to pegylated interferon-α in a randomized trial of patients with chronic hepatitis C virus genotype 1. Gastroenterology. 2010;139:1257-1266. [PMID: 20600013 DOI: 10.1053/j.gastro.2010.06.066] [Cited by in Crossref: 58] [Cited by in F6Publishing: 53] [Article Influence: 4.8] [Reference Citation Analysis]
10 Dossi CG, Cadagan C, San Martín M, Espinosa A, González-Mañán D, Silva D, Mancilla RA, Tapia GS. Effects of rosa mosqueta oil supplementation in lipogenic markers associated with prevention of liver steatosis. Food Funct 2017;8:832-41. [PMID: 28128380 DOI: 10.1039/c6fo01762b] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 1.8] [Reference Citation Analysis]
11 Karmakar S, Das D, Maiti A, Majumdar S, Mukherjee P, Das AS, Mitra C. Black tea prevents high fat diet-induced non-alcoholic steatohepatitis. Phytother Res. 2011;25:1073-1081. [PMID: 21452373 DOI: 10.1002/ptr.3466] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
12 Sanmartín R, Tor J, Sanvisens A, López JJ, Jou A, Muga R, Ojanguren I, Barluenga E, Videla S, Planas R, Clotet B, Tural C. Progression of liver fibrosis in HIV/hepatitis C virus-coinfected individuals on antiretroviral therapy with early stages of liver fibrosis at baseline. HIV Med 2014;15:203-12. [PMID: 24245909 DOI: 10.1111/hiv.12105] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
13 Guidorizzi de Siqueira AC, Cotrim HP, Rocha R, Carvalho FM, de Freitas LA, Barreto D, Gouveia L, Landeiro L. Non-alcoholic fatty liver disease and insulin resistance: importance of risk factors and histological spectrum. Eur J Gastroenterol Hepatol. 2005;17:837-841. [PMID: 16003133 DOI: 10.1097/00042737-200508000-00010] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 1.7] [Reference Citation Analysis]
14 Horoz M, Bolukbas C, Bolukbas FF, Sabuncu T, Aslan M, Sarifakiogullari S, Gunaydin N, Erel O. Measurement of the total antioxidant response using a novel automated method in subjects with nonalcoholic steatohepatitis. BMC Gastroenterol 2005;5:35. [PMID: 16283935 DOI: 10.1186/1471-230X-5-35] [Cited by in Crossref: 37] [Cited by in F6Publishing: 18] [Article Influence: 2.2] [Reference Citation Analysis]
15 Fassio E, Álvarez E, Domínguez N, Landeira G, Longo C. Natural history of nonalcoholic steathepatitis: A longitudinal study of repeat liver biopsies. Hepatology 2004;40:820-6. [DOI: 10.1002/hep.1840400411] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
16 Mock K, Lateef S, Benedito VA, Tou JC. High-fructose corn syrup-55 consumption alters hepatic lipid metabolism and promotes triglyceride accumulation. J Nutr Biochem 2017;39:32-9. [PMID: 27768909 DOI: 10.1016/j.jnutbio.2016.09.010] [Cited by in Crossref: 41] [Cited by in F6Publishing: 33] [Article Influence: 6.8] [Reference Citation Analysis]
17 Koo HJ, Lee S, Chang KJ, Sohn E, Sohn EH, Kang SC, Pyo S. Hepatic anti-inflammatory effect of hexane extracts of Dioscorea batatas Decne: Possible suppression of toll-like receptor 4-mediated signaling. Biomed Pharmacother 2017;92:157-67. [PMID: 28538192 DOI: 10.1016/j.biopha.2017.05.036] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
18 Castera L. Non-invasive diagnosis of steatosis and fibrosis. Diabetes Metab. 2008;34:674-679. [PMID: 19195629 DOI: 10.1016/s1262-3636(08)74603-2] [Cited by in Crossref: 46] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
19 Watanabe S, Hashimoto E, Ikejima K, Uto H, Ono M, Sumida Y, Seike M, Takei Y, Takehara T, Tokushige K, Nakajima A, Yoneda M, Saibara T, Shiota G, Sakaida I, Nakamuta M, Mizuta T, Tsubouchi H, Sugano K, Shimosegawa T. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Hepatol Res. 2015;45:363-377. [PMID: 25832328 DOI: 10.1111/hepr.12511] [Cited by in Crossref: 59] [Cited by in F6Publishing: 109] [Article Influence: 8.4] [Reference Citation Analysis]
20 Kismet K, Ozcan C, Kuru S, Gencay Celemli O, Celepli P, Senes M, Guclu T, Sorkun K, Hucumenoglu S, Besler T. Does propolis have any effect on non-alcoholic fatty liver disease? Biomedicine & Pharmacotherapy 2017;90:863-71. [DOI: 10.1016/j.biopha.2017.04.062] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
21 Gill RM, Belt P, Wilson L, Bass NM, Ferrell LD. Centrizonal arteries and microvessels in nonalcoholic steatohepatitis. Am J Surg Pathol. 2011;35:1400-1404. [PMID: 21836480 DOI: 10.1097/pas.0b013e3182254283] [Cited by in Crossref: 35] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]
22 Al-sharhan F, Dohan A, Barat M, Feddal A, Terris B, Pol S, Mallet V, Soyer P. MRI presentation of hepatocellular carcinoma in non-alcoholic steatohepatitis (NASH). European Journal of Radiology 2019;119:108648. [DOI: 10.1016/j.ejrad.2019.108648] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
23 Feldstein AE, Lopez R, Tamimi TA, Yerian L, Chung YM, Berk M, Zhang R, McIntyre TM, Hazen SL. Mass spectrometric profiling of oxidized lipid products in human nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. J Lipid Res. 2010;51:3046-3054. [PMID: 20631297 DOI: 10.1194/jlr.m007096] [Cited by in Crossref: 170] [Cited by in F6Publishing: 86] [Article Influence: 14.2] [Reference Citation Analysis]
24 Jin X, Yu CH, Lv GC, Li YM. Increased intestinal permeability in pathogenesis and progress of nonalcoholic steatohepatitis in rats. World J Gastroenterol 2007; 13(11): 1732-1736 [PMID: 17461479 DOI: 10.3748/wjg.v13.i11.1732] [Cited by in CrossRef: 27] [Cited by in F6Publishing: 27] [Article Influence: 1.8] [Reference Citation Analysis]
25 Miele L, Beale G, Patman G, Nobili V, Leathart J, Grieco A, Abate M, Friedman SL, Narla G, Bugianesi E. The Kruppel-like factor 6 genotype is associated with fibrosis in nonalcoholic fatty liver disease. Gastroenterology. 2008;135:282-291.e1. [PMID: 18515091 DOI: 10.1053/j.gastro.2008.04.004] [Cited by in Crossref: 130] [Cited by in F6Publishing: 123] [Article Influence: 9.3] [Reference Citation Analysis]
26 Su W, Wang Y, Jia X, Wu W, Li L, Tian X, Li S, Wang C, Xu H, Cao J. Comparative proteomic study reveals 17β-HSD13 as a pathogenic protein in nonalcoholic fatty liver disease. Proc Natl Acad Sci USA. 2014;111:11437-11442. [PMID: 25028495 DOI: 10.1073/pnas.1410741111] [Cited by in Crossref: 92] [Cited by in F6Publishing: 92] [Article Influence: 11.5] [Reference Citation Analysis]
27 Skoien R, Richardson MM, Jonsson JR, Powell EE, Brunt EM, Neuschwander-tetri BA, Bhathal PS, Dixon JB, O'brien PE, Tilg H, Moschen AR, Baumann U, Brown RM, Couper RT, Manton ND, Ee LC, Weltman M, Clouston AD. Heterogeneity of fibrosis patterns in non-alcoholic fatty liver disease supports the presence of multiple fibrogenic pathways. Liver Int 2013;33:624-32. [DOI: 10.1111/liv.12100] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 4.0] [Reference Citation Analysis]
28 Esmat G, El Akel W, Metwally M, Soliman A, Doss W, Hamid MA, Kamal M, Zalata K, Khattab H, El-Kassas M, Esmat M, Hasan A, El-Raziky M. Improvement of steatosis after interferon therapy in HCV genotype 4 is related to weight loss. Indian J Gastroenterol 2009;28:45-8. [PMID: 19696987 DOI: 10.1007/s12664-009-0016-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
29 Shenoy KT, Balakumaran LK, Mathew P, Prasad M, Prabhakar B, Sood A, Singh SP, Rao NP, Zargar SA, Bignamini AA. Metadoxine Versus Placebo for the Treatment of Non-alcoholic Steatohepatitis: A Randomized Controlled Trial. J Clin Exp Hepatol 2014;4:94-100. [PMID: 25755546 DOI: 10.1016/j.jceh.2014.03.041] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
30 Ishida JH, Peters MG, Jin C, Louie K, Tan V, Bacchetti P, Terrault NA. Influence of cannabis use on severity of hepatitis C disease. Clin Gastroenterol Hepatol. 2008;6:69-75. [PMID: 18166478 DOI: 10.1016/j.cgh.2007.10.021] [Cited by in Crossref: 100] [Cited by in F6Publishing: 78] [Article Influence: 7.1] [Reference Citation Analysis]
31 Caldwell S, Ikura Y, Dias D, Isomoto K, Yabu A, Moskaluk C, Pramoonjago P, Simmons W, Scruggs H, Rosenbaum N. Hepatocellular ballooning in NASH. J Hepatol. 2010;53:719-723. [PMID: 20624660 DOI: 10.1016/j.jhep.2010.04.031] [Cited by in Crossref: 118] [Cited by in F6Publishing: 112] [Article Influence: 9.8] [Reference Citation Analysis]
32 Riley TR, Kahn A. Risk factors and ultrasound can predict chronic hepatitis caused by nonalcoholic fatty liver disease. Dig Dis Sci. 2006;51:41-44. [PMID: 16416209 DOI: 10.1007/s10620-006-3082-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
33 Ratziu V, Giral P, Jacqueminet S, Charlotte F, Hartemann-Heurtier A, Serfaty L, Podevin P, Lacorte JM, Bernhardt C, Bruckert E, Grimaldi A, Poynard T;  LIDO Study Group. Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial. Gastroenterology. 2008;135:100-110. [PMID: 18503774 DOI: 10.1053/j.gastro.2008.03.078] [Cited by in Crossref: 421] [Cited by in F6Publishing: 382] [Article Influence: 30.1] [Reference Citation Analysis]
34 Schulz M, Tacke F. Identifying High-Risk NASH Patients: What We Know so Far. Hepat Med 2020;12:125-38. [PMID: 32982495 DOI: 10.2147/HMER.S265473] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
35 Vali Y, Lee J, Boursier J, Spijker R, Löffler J, Verheij J, Brosnan MJ, Böcskei Z, Anstee QM, Bossuyt PM, Zafarmand MH, Pavlides M, Levick C, Duffin K, Hyde C, Bauer T, Bedossa P, Leeming D, Daly A, Hanf R, Ortiz P, Oresic M, Schuppan D, Hanauer G, Chen Y, Shumbayawonda E, Bjerring PN, Zwinderman K. Enhanced liver fibrosis test for the non-invasive diagnosis of fibrosis in patients with NAFLD: A systematic review and meta-analysis. Journal of Hepatology 2020;73:252-62. [DOI: 10.1016/j.jhep.2020.03.036] [Cited by in Crossref: 32] [Cited by in F6Publishing: 36] [Article Influence: 16.0] [Reference Citation Analysis]
36 Georgoulis M, Kontogianni MD, Tileli N, Margariti A, Fragopoulou E, Tiniakos D, Zafiropoulou R, Papatheodoridis G. The impact of cereal grain consumption on the development and severity of non-alcoholic fatty liver disease. Eur J Nutr 2014;53:1727-35. [DOI: 10.1007/s00394-014-0679-y] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 2.9] [Reference Citation Analysis]
37 Abou-Beih S, Masson S, Saunders R, Haugk B, Oakley F, Tiniakos D. Sinusoidal and pericellular fibrosis in adult post-transplant liver biopsies: association with hepatic stellate cell activation and patient outcome. Virchows Arch 2019;475:233-43. [PMID: 31201503 DOI: 10.1007/s00428-019-02585-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
38 Ohashi T, Kato M, Yamasaki A, Kuwano A, Suzuki H, Kohjima M, Ogawa Y. Effects of high fructose intake on liver injury progression in high fat diet induced fatty liver disease in ovariectomized female mice. Food Chem Toxicol 2018;118:190-7. [PMID: 29751074 DOI: 10.1016/j.fct.2018.05.006] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
39 Himoto T, Yoneyama H, Kurokohchi K, Mori H, Inukai M, Masugata H, Goda F, Haba R, Watanabe S, Senda S, Masaki T. Clinical relevance of antibodies to cardiolipin in patients with chronic hepatitis C. J Clin Lab Anal 2012;26:342-8. [PMID: 23001979 DOI: 10.1002/jcla.21529] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
40 Kakuda Y, Harada K, Nakanuma Y. Canals of Hering loss relates to the progression of the histological stages of primary biliary cirrhosis. J Clin Pathol 2015;68:141-7. [DOI: 10.1136/jclinpath-2014-202417] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
41 Gogia S, Neuschwander-tetri BA. Unexplained CK elevations in patients with nonalcoholic steatohepatitis. Liver Int 2006;26:899-900. [DOI: 10.1111/j.1478-3231.2006.01299.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
42 Koch LK, Yeh MM. Nonalcoholic fatty liver disease (NAFLD): Diagnosis, pitfalls, and staging. Ann Diagn Pathol 2018;37:83-90. [PMID: 30312882 DOI: 10.1016/j.anndiagpath.2018.09.009] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
43 Mizuno N, Seko Y, Kataoka S, Okuda K, Furuta M, Takemura M, Taketani H, Hara T, Umemura A, Nishikawa T, Yamaguchi K, Moriguchi M, Itoh Y. Increase in the skeletal muscle mass to body fat mass ratio predicts the decline in transaminase in patients with nonalcoholic fatty liver disease. J Gastroenterol 2019;54:160-70. [PMID: 29948305 DOI: 10.1007/s00535-018-1485-8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
44 Alazmi WM, Regev A, Molina EG, Schiff ER. Predictors of cirrhosis in Hispanic patients with nonalcoholic steatohepatitis. Dig Dis Sci 2006;51:1725-9. [PMID: 16958001 DOI: 10.1007/s10620-005-9065-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
45 Kim YS, Jung ES, Hur W, Bae SH, Choi JY, Song MJ, Kim CW, Jo SH, Lee CD, Lee YS, Choi SW, Yang JM, Jang JW, Kim SG, Jung SW, Kim HK, Chae HB, Yoon SK. Noninvasive predictors of nonalcoholic steatohepatitis in Korean patients with histologically proven nonalcoholic fatty liver disease. Clin Mol Hepatol 2013;19:120-30. [PMID: 23837136 DOI: 10.3350/cmh.2013.19.2.120] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
46 Ding ZM, Xiao Y, Wu X, Zou H, Yang S, Shen Y, Xu J, Workman HC, Usborne AL, Hua H. Progression and Regression of Hepatic Lesions in a Mouse Model of NASH Induced by Dietary Intervention and Its Implications in Pharmacotherapy. Front Pharmacol. 2018;9:410. [PMID: 29765319 DOI: 10.3389/fphar.2018.00410] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
47 Denkmayr L, Feldman A, Stechemesser L, Eder SK, Zandanell S, Schranz M, Strasser M, Huber-Schönauer U, Buch S, Hampe J, Paulweber B, Lackner C, Haufe H, Sotlar K, Datz C, Aigner E. Lean Patients with Non-Alcoholic Fatty Liver Disease Have a Severe Histological Phenotype Similar to Obese Patients. J Clin Med 2018;7:E562. [PMID: 30562976 DOI: 10.3390/jcm7120562] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 6.0] [Reference Citation Analysis]
48 Li JF, Liu S, Ren F, Liu M, Wu HL, Chen Y, Zou HB, Bai L, Li Y, Zheng SJ. Fibrosis progression in interferon treatment-naive Chinese plasma donors with chronic hepatitis C for 20 years: a cohort study. Int J Infect Dis. 2014;27:49-53. [PMID: 25168642 DOI: 10.1016/j.ijid.2014.07.003] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
49 Kanno R, Koshizuka T, Miyazaki N, Kobayashi T, Ishioka K, Ozaki C, Chiba H, Suzutani T. Protection of Fatty Liver by the Intake of Fermented Soybean Paste, Miso, and Its Pre-Fermented Mixture. Foods 2021;10:291. [PMID: 33535476 DOI: 10.3390/foods10020291] [Reference Citation Analysis]
50 Hamaguchi M, Kojima T, Itoh Y, Harano Y, Fujii K, Nakajima T, Kato T, Takeda N, Okuda J, Ida K, Kawahito Y, Yoshikawa T, Okanoue T. The severity of ultrasonographic findings in nonalcoholic fatty liver disease reflects the metabolic syndrome and visceral fat accumulation. Am J Gastroenterol. 2007;102:2708-2715. [PMID: 17894848 DOI: 10.1111/j.1572-0241.2007.01526.x] [Cited by in Crossref: 414] [Cited by in F6Publishing: 421] [Article Influence: 27.6] [Reference Citation Analysis]
51 Zamin I Jr, Mattos AA, Mattos AZ, Coral G, Santos D, Rhoden C. The vitamin E reduces liver lipoperoxidation and fibrosis in a model of nonalcoholic steatohepatitis. Arq Gastroenterol 2010;47:86-92. [PMID: 20520981 DOI: 10.1590/s0004-28032010000100015] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
52 Yu SJ, Kim W, Kim D, Yoon JH, Lee K, Kim JH, Cho EJ, Lee JH, Kim HY, Kim YJ. Visceral Obesity Predicts Significant Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. Medicine (Baltimore). 2015;94:e2159. [PMID: 26632897 DOI: 10.1097/md.0000000000002159] [Cited by in Crossref: 46] [Cited by in F6Publishing: 24] [Article Influence: 7.7] [Reference Citation Analysis]
53 Syn WK, Nightingale P, Bateman JM. Nonalcoholic fatty liver disease in a district general hospital: clinical presentation and risk factors. Hepatol Int 2008;2:190-5. [PMID: 19669303 DOI: 10.1007/s12072-008-9044-7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
54 Kazemi-Shirazi L, Veloso MP, Frommlet F, Steindl-Munda P, Wrba F, Zehetmayer S, Marsik C, Ferenci P. Differentiation of nonalcoholic from alcoholic steatohepatitis: are routine laboratory markers useful? Wien Klin Wochenschr. 2008;120:25-30. [PMID: 18239988 DOI: 10.1007/s00508-007-0921-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
55 Kukuk GM, Hittatiya K, Sprinkart AM, Eggers H, Gieseke J, Block W, Moeller P, Willinek WA, Spengler U, Trebicka J, Fischer HP, Schild HH, Träber F. Comparison between modified Dixon MRI techniques, MR spectroscopic relaxometry, and different histologic quantification methods in the assessment of hepatic steatosis. Eur Radiol 2015;25:2869-79. [PMID: 25903702 DOI: 10.1007/s00330-015-3703-6] [Cited by in Crossref: 69] [Cited by in F6Publishing: 74] [Article Influence: 9.9] [Reference Citation Analysis]
56 Francque SM. The Role of Non-alcoholic Fatty Liver Disease in Cardiovascular Disease. Eur Cardiol 2014;9:10-5. [PMID: 30310479 DOI: 10.15420/ecr.2014.9.1.10] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
57 Chen CH, Nien CK, Yang CC, Yeh YH. Association between nonalcoholic fatty liver disease and coronary artery calcification. Dig Dis Sci. 2010;55:1752-1760. [PMID: 19688595 DOI: 10.1007/s10620-009-0935-9] [Cited by in Crossref: 65] [Cited by in F6Publishing: 63] [Article Influence: 5.0] [Reference Citation Analysis]
58 Pulzi FB, Cisternas R, Melo MR, Ribeiro CM, Malheiros CA, Salles JE. New clinical score to diagnose nonalcoholic steatohepatitis in obese patients. Diabetol Metab Syndr. 2011;3:3. [PMID: 21345221 DOI: 10.1186/1758-5996-3-3] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 2.6] [Reference Citation Analysis]
59 Soroida Y, Nakatsuka T, Sato M, Nakagawa H, Tanaka M, Yamauchi N, Wake T, Nakagomi R, Kinoshita MN, Minami T, Uchino K, Enooku K, Asaoka Y, Tanaka Y, Endo M, Nakamura A, Kobayashi T, Kurihara M, Hikita H, Sato M, Gotoh H, Iwai T, Fukayama M, Ikeda H, Tateishi R, Yatomi Y, Koike K. A Novel Non-invasive Method for Predicting Liver Fibrosis by Quantifying the Hepatic Vein Waveform. Ultrasound in Medicine & Biology 2019;45:2363-71. [DOI: 10.1016/j.ultrasmedbio.2019.05.028] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
60 Vonghia L, Magrone T, Verrijken A, Michielsen P, Van Gaal L, Jirillo E, Francque S. Peripheral and Hepatic Vein Cytokine Levels in Correlation with Non-Alcoholic Fatty Liver Disease (NAFLD)-Related Metabolic, Histological, and Haemodynamic Features. PLoS One 2015;10:e0143380. [PMID: 26599575 DOI: 10.1371/journal.pone.0143380] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 4.6] [Reference Citation Analysis]
61 Salueña I, Ortega L, Devesa MJ, López-Alonso G, Taxonera C, Díaz-Rubio M, Ladero JM. [Utility of liver biopsy in the etiologic diagnosis of biochemical liver abnormalities of unknown cause]. Gastroenterol Hepatol 2007;30:325-30. [PMID: 17662214 DOI: 10.1157/13107566] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
62 Lassailly G, Caiazzo R, Ntandja-Wandji LC, Gnemmi V, Baud G, Verkindt H, Ningarhari M, Louvet A, Leteurtre E, Raverdy V, Dharancy S, Pattou F, Mathurin P. Bariatric Surgery Provides Long-term Resolution of Nonalcoholic Steatohepatitis and Regression of Fibrosis. Gastroenterology. 2020. [PMID: 32553765 DOI: 10.1053/j.gastro.2020.06.006] [Cited by in Crossref: 50] [Cited by in F6Publishing: 48] [Article Influence: 25.0] [Reference Citation Analysis]
63 Hupfeld S, Pischel D, Jechorek D, Janicová A, Pech M, Fischbach F. MRI-based fat quantification of the liver: Is it time for commercially available products? Eur J Radiol 2021;144:109993. [PMID: 34656047 DOI: 10.1016/j.ejrad.2021.109993] [Reference Citation Analysis]
64 Fabris C, Vandelli C, Toniutto P, Minisini R, Colletta C, Falleti E, Smirne C, Pirisi M. Apolipoprotein E genotypes modulate fibrosis progression in patients with chronic hepatitis C and persistently normal transaminases. J Gastroenterol Hepatol. 2011;26:328-333. [PMID: 21261723 DOI: 10.1111/j.1440-1746.2010.06403.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
65 Richardson MM, Jonsson JR, Powell EE, Brunt EM, Neuschwander-Tetri BA, Bhathal PS, Dixon JB, Weltman MD, Tilg H, Moschen AR, Purdie DM, Demetris AJ, Clouston AD. Progressive fibrosis in nonalcoholic steatohepatitis: association with altered regeneration and a ductular reaction. Gastroenterology. 2007;133:80-90. [PMID: 17631134 DOI: 10.1053/j.gastro.2007.05.012] [Cited by in Crossref: 317] [Cited by in F6Publishing: 295] [Article Influence: 21.1] [Reference Citation Analysis]
66 Yu W, Hu S, Qi Y, Li B. The correlation between sonographic diagnosis and laparoscopic observations on fatty liver. J Laparoendosc Adv Surg Tech A 2009;19:163-9. [PMID: 19216696 DOI: 10.1089/lap.2008.0311] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
67 Zhou J, Zhao Y, Guo YJ, Zhao YS, Liu H, Ren J, Li JR, Ji ES. A rapid juvenile murine model of nonalcoholic steatohepatitis (NASH): Chronic intermittent hypoxia exacerbates Western diet-induced NASH. Life Sci 2021;276:119403. [PMID: 33785339 DOI: 10.1016/j.lfs.2021.119403] [Reference Citation Analysis]
68 Andrade GCD, Fujise LH, Santana Filho JED, Oliveira F, Silva RDCMAD. Non-alcoholic fatty liver disease (NAFLD) in different populations: A clinical and epidemiological study – sample of São José do Rio Preto. Rev Assoc Med Bras 2016;62:218-26. [DOI: 10.1590/1806-9282.62.03.218] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
69 Everson GT, Hoefs JC, Seeff LB, Bonkovsky HL, Naishadham D, Shiffman ML, Kahn JA, Lok AS, Di Bisceglie AM, Lee WM. Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C trial. Hepatology. 2006;44:1675-1684. [PMID: 17133499 DOI: 10.1002/hep.21440] [Cited by in Crossref: 117] [Cited by in F6Publishing: 97] [Article Influence: 7.8] [Reference Citation Analysis]
70 Aron-Wisnewsky J, Clement K, Pépin JL. Nonalcoholic fatty liver disease and obstructive sleep apnea. Metabolism 2016;65:1124-35. [PMID: 27324067 DOI: 10.1016/j.metabol.2016.05.004] [Cited by in Crossref: 55] [Cited by in F6Publishing: 48] [Article Influence: 9.2] [Reference Citation Analysis]
71 Nakagawa T, Ramdhan DH, Tanaka N, Naito H, Tamada H, Ito Y, Li Y, Hayashi Y, Yamagishi N, Yanagiba Y, Aoyama T, Gonzalez FJ, Nakajima T. Modulation of ammonium perfluorooctanoate-induced hepatic damage by genetically different PPARα in mice. Arch Toxicol 2012;86:63-74. [PMID: 21499893 DOI: 10.1007/s00204-011-0704-3] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
72 Palma-Duran SA, Kontogianni MD, Vlassopoulos A, Zhao S, Margariti A, Georgoulis M, Papatheodoridis G, Combet E. Serum levels of advanced glycation end-products (AGEs) and the decoy soluble receptor for AGEs (sRAGE) can identify non-alcoholic fatty liver disease in age-, sex- and BMI-matched normo-glycemic adults. Metabolism. 2018;83:120-127. [PMID: 29409822 DOI: 10.1016/j.metabol.2018.01.023] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 7.3] [Reference Citation Analysis]
73 Tian Y, Arai E, Makiuchi S, Tsuda N, Kuramoto J, Ohara K, Takahashi Y, Ito N, Ojima H, Hiraoka N, Gotoh M, Yoshida T, Kanai Y. Aberrant DNA methylation results in altered gene expression in non-alcoholic steatohepatitis-related hepatocellular carcinomas. J Cancer Res Clin Oncol 2020;146:2461-77. [PMID: 32685988 DOI: 10.1007/s00432-020-03298-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
74 Udelsman BV, Corey KE, Lindvall C, Gee DW, Meireles OR, Hutter MM, Chang DC, Witkowski ER. Risk factors and prevalence of liver disease in review of 2557 routine liver biopsies performed during bariatric surgery. Surg Obes Relat Dis 2019;15:843-9. [PMID: 31014948 DOI: 10.1016/j.soard.2019.01.035] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
75 Suzuki-Kemuriyama N, Abe A, Uno K, Ogawa S, Watanabe A, Sano R, Yuki M, Miyajima K, Nakae D. A trans fatty acid substitute enhanced development of liver proliferative lesions induced in mice by feeding a choline-deficient, methionine-lowered, L-amino acid-defined, high-fat diet. Lipids Health Dis 2020;19:251. [PMID: 33317575 DOI: 10.1186/s12944-020-01423-3] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
76 Shigefuku R, Takahashi H, Nakano H, Watanabe T, Matsunaga K, Matsumoto N, Kato M, Morita R, Michikawa Y, Tamura T, Hiraishi T, Hattori N, Noguchi Y, Nakahara K, Ikeda H, Ishii T, Okuse C, Sase S, Itoh F, Suzuki M. Correlations of Hepatic Hemodynamics, Liver Function, and Fibrosis Markers in Nonalcoholic Fatty Liver Disease: Comparison with Chronic Hepatitis Related to Hepatitis C Virus. Int J Mol Sci 2016;17:E1545. [PMID: 27649152 DOI: 10.3390/ijms17091545] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
77 Macêdo SMD, Antunes Guimarães T, Feltenberger JD, Santos SHS. The role of renin-angiotensin system modulation on treatment and prevention of liver diseases. Peptides 2014;62:189-96. [DOI: 10.1016/j.peptides.2014.10.005] [Cited by in Crossref: 61] [Cited by in F6Publishing: 56] [Article Influence: 7.6] [Reference Citation Analysis]
78 Suwa K, Yamaguchi T, Yoshida K, Murata M, Ichimura M, Tsuneyama K, Seki T, Okazaki K. Smad Phospho-Isoforms for Hepatocellular Carcinoma Risk Assessment in Patients with Nonalcoholic Steatohepatitis. Cancers (Basel) 2020;12:E286. [PMID: 31991602 DOI: 10.3390/cancers12020286] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
79 Kashireddy PR, Rao MS. Sex differences in choline-deficient diet-induced steatohepatitis in mice. Exp Biol Med (Maywood) 2004;229:158-62. [PMID: 14734794 DOI: 10.1177/153537020422900204] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 1.1] [Reference Citation Analysis]
80 Honma M, Sawada S, Ueno Y, Murakami K, Yamada T, Gao J, Kodama S, Izumi T, Takahashi K, Tsukita S, Uno K, Imai J, Kakazu E, Kondo Y, Mizuno K, Kawagishi N, Shimosegawa T, Katagiri H. Selective insulin resistance with differential expressions of IRS-1 and IRS-2 in human NAFLD livers. Int J Obes (Lond) 2018;42:1544-55. [PMID: 29717275 DOI: 10.1038/s41366-018-0062-9] [Cited by in Crossref: 39] [Cited by in F6Publishing: 32] [Article Influence: 9.8] [Reference Citation Analysis]
81 Adams LA, Sanderson S, Lindor KD, Angulo P. The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J Hepatol. 2005;42:132-138. [PMID: 15629518 DOI: 10.1016/j.jhep.2004.09.012] [Cited by in Crossref: 596] [Cited by in F6Publishing: 553] [Article Influence: 35.1] [Reference Citation Analysis]
82 van Rijn RR, Nievelstein RA. Paediatric ultrasonography of the liver, hepatobiliary tract and pancreas. Eur J Radiol 2014;83:1570-81. [PMID: 24780818 DOI: 10.1016/j.ejrad.2014.03.025] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
83 Shi JP, Fan JG, Wu R, Gao XQ, Zhang L, Wang H, Farrell GC. Prevalence and risk factors of hepatic steatosis and its impact on liver injury in Chinese patients with chronic hepatitis B infection. J Gastroenterol Hepatol. 2008;23:1419-1425. [PMID: 18853998 DOI: 10.1111/j.1440-1746.2008.05531.x] [Cited by in Crossref: 64] [Cited by in F6Publishing: 56] [Article Influence: 4.9] [Reference Citation Analysis]
84 Ramadori P, Kroy D, Streetz KL. Immunoregulation by lipids during the development of non-alcoholic steatohepatitis. Hepatobiliary Surg Nutr 2015;4:11-23. [PMID: 25713801 DOI: 10.3978/j.issn.2304-3881.2015.01.02] [Cited by in F6Publishing: 16] [Reference Citation Analysis]
85 Arata M, Nakajima J, Nishimata S, Nagata T, Kawashima H. Nonalcoholic steatohepatitis and insulin resistance in children. World J Diabetes 2014; 5(6): 917-923 [PMID: 25512797 DOI: 10.4239/wjd.v5.i6.917] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
86 Ekstedt M, Franzén LE, Mathiesen UL, Thorelius L, Holmqvist M, Bodemar G, Kechagias S. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology. 2006;44:865-873. [PMID: 17006923 DOI: 10.1002/hep.21327] [Cited by in Crossref: 1498] [Cited by in F6Publishing: 1400] [Article Influence: 93.6] [Reference Citation Analysis]
87 Dixon JB, Bhathal PS, Hughes NR, O'Brien PE. Nonalcoholic fatty liver disease: Improvement in liver histological analysis with weight loss. Hepatology 2004;39:1647-54. [PMID: 15185306 DOI: 10.1002/hep.20251] [Cited by in Crossref: 530] [Cited by in F6Publishing: 456] [Article Influence: 29.4] [Reference Citation Analysis]
88 Sawczyn T, Stygar D, Nabrdalik K, Kukla M, Masri O, Magrowski Ł, Karcz W, Jochem J. Effect of Ileal Transposition (IT) on Angiopoietin-Like Protein-8 (ANGPTL8) and Pentraxin (PTX3) Plasma Level in Sprague-Dawley Rats Fed High-Fat Diet (HFD). Int J Endocrinol 2021;2021:6699923. [PMID: 34035808 DOI: 10.1155/2021/6699923] [Reference Citation Analysis]
89 Ling J, Chaba T, Zhu LF, Jacobs RL, Vance DE. Hepatic ratio of phosphatidylcholine to phosphatidylethanolamine predicts survival after partial hepatectomy in mice. Hepatology 2012;55:1094-102. [PMID: 22095799 DOI: 10.1002/hep.24782] [Cited by in Crossref: 45] [Cited by in F6Publishing: 44] [Article Influence: 4.5] [Reference Citation Analysis]
90 Jiang M, Wu N, Chen X, Wang W, Chu Y, Liu H, Li W, Chen D, Li X, Xu B. Pathogenesis of and major animal models used for nonalcoholic fatty liver disease. J Int Med Res 2019;47:1453-66. [PMID: 30871397 DOI: 10.1177/0300060519833527] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
91 Werling K, Schaff Z, Dinya E, Tulassay Z. Effect of liver steatosis on therapeutic response in chronic hepatitis C virus genotype 1 infected patients in hungary. Pathol Oncol Res 2010;16:149-57. [PMID: 19757200 DOI: 10.1007/s12253-009-9195-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
92 Siddiqui MS, Charlton M. Liver Transplantation for Alcoholic and Nonalcoholic Fatty Liver Disease: Pretransplant Selection and Posttransplant Management. Gastroenterology 2016;150:1849-62. [DOI: 10.1053/j.gastro.2016.02.077] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.7] [Reference Citation Analysis]
93 Sharma P, Balan V, Hernandez J, Rosati M, Williams J, Rodriguez-Luna H, Schwartz J, Harrison E, Anderson M, Byrne T. Hepatic steatosis in hepatitis C virus genotype 3 infection: does it correlate with body mass index, fibrosis, and HCV risk factors? Dig Dis Sci. 2004;49:25-29. [PMID: 14992430 DOI: 10.1023/b:ddas.0000011597.92851.56] [Cited by in Crossref: 40] [Cited by in F6Publishing: 15] [Article Influence: 2.2] [Reference Citation Analysis]
94 Klaikeaw N, Wongphoom J, Werawatganon D, Chayanupatkul M, Siriviriyakul P. Anti-inflammatory and anti-oxidant effects of aloe vera in rats with non-alcoholic steatohepatitis. World J Hepatol 2020; 12(7): 363-377 [PMID: 32821335 DOI: 10.4254/wjh.v12.i7.363] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
95 Shimada M, Kawahara H, Ozaki K, Fukura M, Yano H, Tsuchishima M, Tsutsumi M, Takase S. Usefulness of a combined evaluation of the serum adiponectin level, HOMA-IR, and serum type IV collagen 7S level to predict the early stage of nonalcoholic steatohepatitis. Am J Gastroenterol. 2007;102:1931-1938. [PMID: 17511754 DOI: 10.1111/j.1572-0241.2007.01322.x] [Cited by in Crossref: 103] [Cited by in F6Publishing: 107] [Article Influence: 6.9] [Reference Citation Analysis]
96 Hamaguchi E, Takamura T, Sakurai M, Mizukoshi E, Zen Y, Takeshita Y, Kurita S, Arai K, Yamashita T, Sasaki M, Nakanuma Y, Kaneko S. Histological course of nonalcoholic fatty liver disease in Japanese patients: tight glycemic control, rather than weight reduction, ameliorates liver fibrosis. Diabetes Care 2010;33:284-6. [PMID: 19880582 DOI: 10.2337/dc09-0148] [Cited by in Crossref: 55] [Cited by in F6Publishing: 45] [Article Influence: 4.2] [Reference Citation Analysis]
97 Yalamanchili K, Saadeh S, Klintmalm GB, Jennings LW, Davis GL. Nonalcoholic fatty liver disease after liver transplantation for cryptogenic cirrhosis or nonalcoholic fatty liver disease. Liver Transpl. 2010;16:431-439. [PMID: 20373454 DOI: 10.1002/lt.22004] [Cited by in Crossref: 145] [Cited by in F6Publishing: 115] [Article Influence: 12.1] [Reference Citation Analysis]
98 Himoto T, Masaki T. Current Trends of Essential Trace Elements in Patients with Chronic Liver Diseases. Nutrients 2020;12:E2084. [PMID: 32674425 DOI: 10.3390/nu12072084] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
99 Aly FZ, Kleiner DE. Update on fatty liver disease and steatohepatitis. Adv Anat Pathol 2011;18:294-300. [PMID: 21654360 DOI: 10.1097/PAP.0b013e318220f59b] [Cited by in Crossref: 35] [Cited by in F6Publishing: 19] [Article Influence: 3.2] [Reference Citation Analysis]
100 Da Silva HE, Teterina A, Comelli EM, Taibi A, Arendt BM, Fischer SE, Lou W, Allard JP. Nonalcoholic fatty liver disease is associated with dysbiosis independent of body mass index and insulin resistance. Sci Rep. 2018;8:1466. [PMID: 29362454 DOI: 10.1038/s41598-018-19753-9] [Cited by in Crossref: 102] [Cited by in F6Publishing: 96] [Article Influence: 25.5] [Reference Citation Analysis]
101 Werawatganon D, Linlawan S, Thanapirom K, Somanawat K, Klaikeaw N, Rerknimitr R, Siriviriyakul P. Aloe vera attenuated liver injury in mice with acetaminophen-induced hepatitis. BMC Complement Altern Med. 2014;14:229. [PMID: 25005608 DOI: 10.1186/1472-6882-14-229] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
102 Clarke CN, Choi H, Hou P, Davis CH, Ma J, Rashid A, Vauthey JN, Aloia TA. Using MRI to non-invasively and accurately quantify preoperative hepatic steatosis. HPB (Oxford) 2017;19:706-12. [PMID: 28528267 DOI: 10.1016/j.hpb.2017.04.009] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
103 Hamaguchi M, Kojima T, Ohbora A, Takeda N, Fukui M, Kato T. Aging is a risk factor of nonalcoholic fatty liver disease in premenopausal women. World J Gastroenterol 2012; 18(3): 237-243 [PMID: 22294826 DOI: 10.3748/wjg.v18.i3.237] [Cited by in CrossRef: 70] [Cited by in F6Publishing: 69] [Article Influence: 7.0] [Reference Citation Analysis]
104 Angelico F, Burattin M, Alessandri C, Del Ben M, Lirussi F, Angelico F. Drugs improving insulin resistance for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis. Cochrane Database of Systematic Reviews. Chichester: John Wiley & Sons, Ltd; 1996. [DOI: 10.1002/14651858.cd005166.pub2] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 2.1] [Reference Citation Analysis]
105 Hsu CS, Liu CH, Liu CJ, Wang CC, Chen CL, Lai MY, Chen PJ, Chen DS, Kao JH. Association of lipid profiles with hepatitis C viral load in chronic hepatitis C patients with genotype 1 or 2 infection. Am J Gastroenterol. 2009;104:598-604. [PMID: 19262519 DOI: 10.1038/ajg.2008.125] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 1.9] [Reference Citation Analysis]
106 Gentile CL, Nivala AM, Gonzales JC, Pfaffenbach KT, Wang D, Wei Y, Jiang H, Orlicky DJ, Petersen DR, Pagliassotti MJ, Maclean KN. Experimental evidence for therapeutic potential of taurine in the treatment of nonalcoholic fatty liver disease. Am J Physiol Regul Integr Comp Physiol 2011;301:R1710-22. [PMID: 21957160 DOI: 10.1152/ajpregu.00677.2010] [Cited by in Crossref: 68] [Cited by in F6Publishing: 60] [Article Influence: 6.2] [Reference Citation Analysis]
107 Liew PL, Lee WJ, Wang W, Lee YC, Chen WY, Fang CL, Huang MT. Fatty liver disease: predictors of nonalcoholic steatohepatitis and gallbladder disease in morbid obesity. Obes Surg. 2008;18:847-853. [PMID: 18459024 DOI: 10.1007/s11695-007-9355-0] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 1.8] [Reference Citation Analysis]
108 Irie R, Nakazawa A, Sakamoto S, Takeda M, Yanagi Y, Shimizu S, Uchida H, Fukuda A, Kasahara M. Outcome for Pediatric Recipients of Macrosteatotic Liver Grafts From Living Donors. Liver Transpl 2020;26:899-905. [PMID: 32314485 DOI: 10.1002/lt.25784] [Reference Citation Analysis]
109 Kitamori K, Naito H, Tamada H, Kobayashi M, Miyazawa D, Yasui Y, Sonoda K, Tsuchikura S, Yasui N, Ikeda K. Development of novel rat model for high-fat and high-cholesterol diet-induced steatohepatitis and severe fibrosis progression in SHRSP5/Dmcr. Environ Health Prev Med. 2012;17:173-182. [PMID: 21853259 DOI: 10.1007/s12199-011-0235-9] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 3.2] [Reference Citation Analysis]
110 Yokomori H, Oda M, Ando W, Inagaki Y, Okazaki I. Hepatic progenitor cell expansion in early-stage nonalcoholic steatohepatitis: evidence from immunohistochemistry and immunoelectron microscopy of matrix metalloproteinase-1. Med Mol Morphol 2017;50:238-42. [PMID: 28577062 DOI: 10.1007/s00795-017-0162-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
111 Wang HN, Wang YR, Liu GQ, Liu Z, Wu PX, Wei XL, Hong TP. Inhibition of hepatic interleukin-18 production by rosiglitazone in a rat model of nonalcoholic fatty liver disease. World J Gastroenterol 2008; 14(47): 7240-7246 [PMID: 19084941 DOI: 10.3748/wjg.14.7240] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 20] [Article Influence: 1.8] [Reference Citation Analysis]
112 Schumacher JD, Guo GL. Pharmacologic Modulation of Bile Acid-FXR-FGF15/FGF19 Pathway for the Treatment of Nonalcoholic Steatohepatitis. Handb Exp Pharmacol 2019;256:325-57. [PMID: 31201553 DOI: 10.1007/164_2019_228] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 5.3] [Reference Citation Analysis]
113 Takeshita Y, Kanamori T, Tanaka T, Kaikoi Y, Kita Y, Takata N, Iida N, Arai K, Yamashita T, Harada K, Gabata T, Nakamura H, Kaneko S, Takamura T. Study Protocol for Pleiotropic Effects and Safety of Sodium-Glucose Cotransporter 2 Inhibitor Versus Sulfonylurea in Patients with Type 2 Diabetes and Nonalcoholic Fatty Liver Disease. Diabetes Ther 2020;11:549-60. [PMID: 31956961 DOI: 10.1007/s13300-020-00762-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
114 Okajima A, Sumida Y, Taketani H, Hara T, Seko Y, Ishiba H, Nishimura T, Umemura A, Nishikawa T, Yamaguchi K, Moriguchi M, Mitsuyoshi H, Yasui K, Minami M, Itoh Y. Liver stiffness measurement to platelet ratio index predicts the stage of liver fibrosis in non-alcoholic fatty liver disease. Hepatol Res 2017;47:721-30. [PMID: 27539017 DOI: 10.1111/hepr.12793] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
115 Ichikawa T, Nakao K, Hamasaki K, Furukawa R, Tsuruta S, Ueda Y, Taura N, Shibata H, Fujimoto M, Toriyama K. Role of growth hormone, insulin-like growth factor 1 and insulin-like growth factor-binding protein 3 in development of non-alcoholic fatty liver disease. Hepatol Int. 2007;1:287-294. [PMID: 19669352 DOI: 10.1007/s12072-007-9007-4] [Cited by in Crossref: 67] [Cited by in F6Publishing: 64] [Article Influence: 4.5] [Reference Citation Analysis]
116 Ando W, Yokomori H, Otori K, Oda M. The Apelin Receptor APJ in Hematopoietic Stem Cells/Progenitor Cells in the Early Stage of Non-Alcoholic Steatohepatitis. J Clin Med Res 2017;9:809-11. [PMID: 28811860 DOI: 10.14740/jocmr3103w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
117 Yoneda M, Suzuki K, Kato S, Fujita K, Nozaki Y, Hosono K, Saito S, Nakajima A. Nonalcoholic fatty liver disease: US-based acoustic radiation force impulse elastography. Radiology. 2010;256:640-647. [PMID: 20529989 DOI: 10.1148/radiol.10091662] [Cited by in Crossref: 259] [Cited by in F6Publishing: 222] [Article Influence: 21.6] [Reference Citation Analysis]
118 Ma X, Holalkere NS, Kambadakone R A, Mino-Kenudson M, Hahn PF, Sahani DV. Imaging-based quantification of hepatic fat: methods and clinical applications. Radiographics. 2009;29:1253-1277. [PMID: 19755595 DOI: 10.1148/rg.295085186] [Cited by in Crossref: 196] [Cited by in F6Publishing: 162] [Article Influence: 15.1] [Reference Citation Analysis]
119 Alisi A, Manco M, Devito R, Nobili V. Fatty Liver Disease. In: Freemark M, editor. Pediatric Obesity. New York: Springer; 2010. pp. 201-22. [DOI: 10.1007/978-1-60327-874-4_15] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
120 Roldan-Valadez E, Favila R, Martínez-López M, Uribe M, Ríos C, Méndez-Sánchez N. In vivo 3T spectroscopic quantification of liver fat content in nonalcoholic fatty liver disease: Correlation with biochemical method and morphometry. J Hepatol. 2010;53:732-737. [PMID: 20594607 DOI: 10.1016/j.jhep.2010.04.018] [Cited by in Crossref: 49] [Cited by in F6Publishing: 44] [Article Influence: 4.1] [Reference Citation Analysis]
121 Tsai MC, Liu YY, Lin CC, Wang CC, Wu YJ, Yong CC, Chen KD, Chuah SK, Yao CC, Huang PY, Chen CH, Hu TH, Chen CL. Gut Microbiota Dysbiosis in Patients with Biopsy-Proven Nonalcoholic Fatty Liver Disease: A Cross-Sectional Study in Taiwan. Nutrients 2020;12:E820. [PMID: 32204538 DOI: 10.3390/nu12030820] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
122 Syn WK, Choi SS, Diehl AM. Apoptosis and cytokines in non-alcoholic steatohepatitis. Clin Liver Dis 2009;13:565-80. [PMID: 19818305 DOI: 10.1016/j.cld.2009.07.003] [Cited by in Crossref: 77] [Cited by in F6Publishing: 80] [Article Influence: 5.9] [Reference Citation Analysis]
123 Oshita A, Tashiro H, Amano H, Kobayashi T, Onoe T, Ide K, Takaki S, Takahashi S, Arihiro K, Chayama K, Ohdan H. Safety and feasibility of diet-treated donors with steatotic livers at the initial consultation for living-donor liver transplantation. Transplantation. 2012;93:1024-1030. [PMID: 22495493 DOI: 10.1097/tp.0b013e31824c9e25] [Cited by in Crossref: 20] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
124 Leporq B, Ratiney H, Pilleul F, Beuf O. Liver fat volume fraction quantification with fat and water T1 and T 2* estimation and accounting for NMR multiple components in patients with chronic liver disease at 1.5 and 3.0 T. Eur Radiol 2013;23:2175-86. [PMID: 23588583 DOI: 10.1007/s00330-013-2826-x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
125 Miele L, Forgione A, La Torre G, Vero V, Cefalo C, Racco S, Vellone VG, Vecchio FM, Gasbarrini G, Rapaccini GL, Neuman MG, Grieco A. Serum levels of hyaluronic acid and tissue metalloproteinase inhibitor-1 combined with age predict the presence of nonalcoholic steatohepatitis in a pilot cohort of subjects with nonalcoholic fatty liver disease. Transl Res. 2009;154:194-201. [PMID: 19766963 DOI: 10.1016/j.trsl.2009.06.007] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 2.2] [Reference Citation Analysis]
126 Puri P, Sanyal AJ. Nonalcoholic fatty liver disease: Definitions, risk factors, and workup.Clin Liver Dis (Hoboken). 2012;1:99-103. [PMID: 31186860 DOI: 10.1002/cld.81] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 3.6] [Reference Citation Analysis]
127 Zhang C, Wang G, Zheng Z, Maddipati KR, Zhang X, Dyson G, Williams P, Duncan SA, Kaufman RJ, Zhang K. Endoplasmic reticulum-tethered transcription factor cAMP responsive element-binding protein, hepatocyte specific, regulates hepatic lipogenesis, fatty acid oxidation, and lipolysis upon metabolic stress in mice. Hepatology 2012;55:1070-82. [PMID: 22095841 DOI: 10.1002/hep.24783] [Cited by in Crossref: 125] [Cited by in F6Publishing: 127] [Article Influence: 12.5] [Reference Citation Analysis]
128 Koruk M, Savaş MC, Yilmaz Ö, Tayşi S, Karakok M, Gündoğdu C, Yilmaz A. Serum Lipids, Lipoproteins and Apolipoproteins Levels in Patients With Nonalcoholic Steatohepatitis: . Journal of Clinical Gastroenterology 2003;37:177-82. [DOI: 10.1097/00004836-200308000-00017] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 2.2] [Reference Citation Analysis]
129 Falcon A, Doege H, Fluitt A, Tsang B, Watson N, Kay MA, Stahl A. FATP2 is a hepatic fatty acid transporter and peroxisomal very long-chain acyl-CoA synthetase. Am J Physiol Endocrinol Metab 2010;299:E384-93. [PMID: 20530735 DOI: 10.1152/ajpendo.00226.2010] [Cited by in Crossref: 101] [Cited by in F6Publishing: 94] [Article Influence: 8.4] [Reference Citation Analysis]
130 Wu N, McDaniel K, Zhou T, Ramos-Lorenzo S, Wu C, Huang L, Chen D, Annable T, Francis H, Glaser S, Alpini G, Meng F. Knockout of microRNA-21 attenuates alcoholic hepatitis through the VHL/NF-κB signaling pathway in hepatic stellate cells. Am J Physiol Gastrointest Liver Physiol 2018;315:G385-98. [PMID: 29848019 DOI: 10.1152/ajpgi.00111.2018] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
131 Kukla M, Zalewska-Ziob M, Adamek B, Kasperczyk J, Bułdak RJ, Sawczyn T, Stygar D, Sobala-Szczygieł B, Stachowska M, Gabriel A, Wiczkowski A. Visfatin serum concentration and hepatic mRNA expression in chronic hepatitis C. Clin Exp Hepatol 2019;5:147-54. [PMID: 31501791 DOI: 10.5114/ceh.2019.85074] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
132 Eslam M, Sarin SK, Wong VW, Fan JG, Kawaguchi T, Ahn SH, Zheng MH, Shiha G, Yilmaz Y, Gani R, Alam S, Dan YY, Kao JH, Hamid S, Cua IH, Chan WK, Payawal D, Tan SS, Tanwandee T, Adams LA, Kumar M, Omata M, George J. The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. Hepatol Int. 2020;14:889-919. [PMID: 33006093 DOI: 10.1007/s12072-020-10094-2] [Cited by in Crossref: 61] [Cited by in F6Publishing: 67] [Article Influence: 30.5] [Reference Citation Analysis]
133 van Asseldonk DP, Simsek M, de Boer NKH, Jharap B, Bloemena E, den Hartog G, Westerveld DB, Becx MC, Russel MG, Lissenberg-witte BI, van Nieuwkerk CM, Mulder CJJ, Verheij J, van Bodegraven AA. Limited relevance and progression of histological alterations in the liver during thioguanine therapy in inflammatory bowel disease patients. Scandinavian Journal of Gastroenterology 2019;54:753-60. [DOI: 10.1080/00365521.2019.1629006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
134 Seko Y, Yamaguchi K, Mizuno N, Okuda K, Takemura M, Taketani H, Hara T, Umemura A, Nishikawa T, Moriguchi M, Yasui K, Kamaguchi M, Nishioji K, Mochizuki N, Kobayashi M, Mori K, Tanaka S, Matsuura K, Tanaka Y, Itoh Y. Combination of PNPLA3 and TLL1 polymorphism can predict advanced fibrosis in Japanese patients with nonalcoholic fatty liver disease. J Gastroenterol 2018;53:438-48. [PMID: 28744823 DOI: 10.1007/s00535-017-1372-8] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
135 Vu V, Muthuramalingam K, Singh V, Hyun C, Kim YM, Unno T, Cho M. Effects of β-glucan, probiotics, and synbiotics on obesity-associated colitis and hepatic manifestations in C57BL/6J mice. Eur J Nutr 2021. [PMID: 34561722 DOI: 10.1007/s00394-021-02668-z] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
136 Chiu CC, Ching YH, Li YP, Liu JY, Huang YT, Huang YW, Yang SS, Huang WC, Chuang HL. Nonalcoholic Fatty Liver Disease Is Exacerbated in High-Fat Diet-Fed Gnotobiotic Mice by Colonization with the Gut Microbiota from Patients with Nonalcoholic Steatohepatitis. Nutrients 2017;9:E1220. [PMID: 29113135 DOI: 10.3390/nu9111220] [Cited by in Crossref: 62] [Cited by in F6Publishing: 56] [Article Influence: 12.4] [Reference Citation Analysis]
137 Hu DS, Zhu SH, Liu WY, Pan XY, Zhu PW, Li YY, Zheng KI, Ma HL, You J, Targher G, Byrne CD, Chen YP, Zheng MH. PNPLA3 polymorphism influences the association between high-normal TSH level and NASH in euthyroid adults with biopsy-proven NAFLD. Diabetes Metab 2020;46:496-503. [PMID: 32035968 DOI: 10.1016/j.diabet.2020.02.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
138 Spahis S, Alvarez F, Ahmed N, Dubois J, Jalbout R, Paganelli M, Grzywacz K, Delvin E, Peretti N, Levy E. Non-alcoholic fatty liver disease severity and metabolic complications in obese children: impact of omega-3 fatty acids. The Journal of Nutritional Biochemistry 2018;58:28-36. [DOI: 10.1016/j.jnutbio.2018.03.025] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
139 Oliva MR, Mortele KJ, Segatto E, Glickman JN, Erturk SM, Ros PR, Silverman SG. Computed Tomography Features of Nonalcoholic Steatohepatitis With Histopathologic Correlation. Journal of Computer Assisted Tomography 2006;30:37-43. [DOI: 10.1097/01.rct.0000193818.31749.84] [Cited by in Crossref: 66] [Cited by in F6Publishing: 55] [Article Influence: 4.1] [Reference Citation Analysis]
140 Hubert C, Fervaille C, Sempoux C, Horsmans Y, Humblet Y, Machiels J, Zech F, Ceratti A, Gigot J. Prevalence and clinical relevance of pathological hepatic changes occurring after neoadjuvant chemotherapy for colorectal liver metastases. Surgery 2010;147:185-94. [DOI: 10.1016/j.surg.2009.01.004] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 2.3] [Reference Citation Analysis]
141 Chen JR, Chao YP, Tsai YW, Chan HJ, Wan YL, Tai DI, Tsui PH. Clinical Value of Information Entropy Compared with Deep Learning for Ultrasound Grading of Hepatic Steatosis. Entropy (Basel) 2020;22:E1006. [PMID: 33286775 DOI: 10.3390/e22091006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
142 Martín-castillo A, Castells MT, Adánez G, Polo MTS, Pérez BG, Ayala I. Effect of atorvastatin and diet on non-alcoholic fatty liver disease activity score in hyperlipidemic chickens. Biomedicine & Pharmacotherapy 2010;64:275-81. [DOI: 10.1016/j.biopha.2009.06.003] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
143 Hamad EM, Taha SH, Abou Dawood AG, Sitohy MZ, Abdel-Hamid M. Protective effect of whey proteins against nonalcoholic fatty liver in rats. Lipids Health Dis 2011;10:57. [PMID: 21489294 DOI: 10.1186/1476-511X-10-57] [Cited by in Crossref: 49] [Cited by in F6Publishing: 21] [Article Influence: 4.5] [Reference Citation Analysis]
144 Sundaram SS, Halbower A, Pan Z, Robbins K, Capocelli KE, Klawitter J, Shearn CT, Sokol RJ. Nocturnal hypoxia-induced oxidative stress promotes progression of pediatric non-alcoholic fatty liver disease. J Hepatol 2016;65:560-9. [PMID: 27501738 DOI: 10.1016/j.jhep.2016.04.010] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 6.0] [Reference Citation Analysis]
145 Kodama K, Tokushige K, Hashimoto E, Taniai M, Shiratori K. Hepatic and extrahepatic malignancies in cirrhosis caused by nonalcoholic steatohepatitis and alcoholic liver disease. Alcohol Clin Exp Res. 2013;37 Suppl 1:E247-E252. [PMID: 23320802 DOI: 10.1111/j.1530-0277.2012.01900.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 2.4] [Reference Citation Analysis]
146 Wang M, Tan J, Zhou J, Yi B, Huang Z. Farnesoid X receptor mediates hepatic steatosis induced by PM2.5. Environ Sci Pollut Res Int 2020;27:34412-20. [PMID: 32557026 DOI: 10.1007/s11356-020-09676-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
147 Brunt EM. Liver biopsy interpretation for the gastroenterologist. Curr Gastroenterol Rep. 2000;2:27-32. [PMID: 10981000 DOI: 10.1007/s11894-000-0048-2] [Cited by in Crossref: 19] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
148 Westerbacka J, Kotronen A, Fielding BA, Wahren J, Hodson L, Perttilä J, Seppänen-Laakso T, Suortti T, Arola J, Hultcrantz R. Splanchnic balance of free fatty acids, endocannabinoids, and lipids in subjects with nonalcoholic fatty liver disease. Gastroenterology. 2010;139:1961-1971.e1. [PMID: 20600015 DOI: 10.1053/j.gastro.2010.06.064] [Cited by in Crossref: 47] [Cited by in F6Publishing: 42] [Article Influence: 3.9] [Reference Citation Analysis]
149 Sáez-López C, Salcedo-Allende MT, Hernandez C, Simó-Servat O, Simó R, Selva DM. Sex Hormone-Binding Globulin Expression Correlates With Acetyl-Coenzyme A Carboxylase and Triglyceride Content in Human Liver. J Clin Endocrinol Metab 2019;104:1500-7. [PMID: 30496542 DOI: 10.1210/jc.2018-00740] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
150 Feagins LA, Flores A, Arriens C, Park C, Crook T, Reimold A, Brown G. Nonalcoholic fatty liver disease: a potential consequence of tumor necrosis factor-inhibitor therapy. Eur J Gastroenterol Hepatol. 2015;27:1154-1160. [PMID: 26148245 DOI: 10.1097/meg.0000000000000421] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
151 Ballestri S, Nascimbeni F, Romagnoli D, Lonardo A. The independent predictors of non-alcoholic steatohepatitis and its individual histological features.: Insulin resistance, serum uric acid, metabolic syndrome, alanine aminotransferase and serum total cholesterol are a clue to pathogenesis and candidate targets for treatment. Hepatol Res. 2016;46:1074-1087. [PMID: 26785389 DOI: 10.1111/hepr.12656] [Cited by in Crossref: 74] [Cited by in F6Publishing: 73] [Article Influence: 12.3] [Reference Citation Analysis]
152 Stättermayer AF, Rutter K, Beinhardt S, Wrba F, Scherzer TM, Strasser M, Hofer H, Steindl-Munda P, Trauner M, Ferenci P. Role of FDFT1 polymorphism for fibrosis progression in patients with chronic hepatitis C. Liver Int. 2014;34:388-395. [PMID: 23870067 DOI: 10.1111/liv.12269] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
153 Asaoka Y, Terai S, Sakaida I, Nishina H. The expanding role of fish models in understanding non-alcoholic fatty liver disease. Dis Model Mech. 2013;6:905-914. [PMID: 23720231 DOI: 10.1242/dmm.011981] [Cited by in Crossref: 46] [Cited by in F6Publishing: 52] [Article Influence: 5.1] [Reference Citation Analysis]
154 Le TA, Chen J, Changchien C, Peterson MR, Kono Y, Patton H, Cohen BL, Brenner D, Sirlin C, Loomba R; San Diego Integrated NAFLD Research Consortium (SINC). Effect of colesevelam on liver fat quantified by magnetic resonance in nonalcoholic steatohepatitis: a randomized controlled trial. Hepatology 2012;56:922-32. [PMID: 22431131 DOI: 10.1002/hep.25731] [Cited by in Crossref: 169] [Cited by in F6Publishing: 165] [Article Influence: 16.9] [Reference Citation Analysis]
155 Africa JA, Behling CA, Brunt EM, Zhang N, Luo Y, Wells A, Hou J, Belt PH, Kohil R, Lavine JE, Molleston JP, Newton KP, Whitington PF, Schwimmer JB; Nonalcoholic Steatohepatitis Clinical Research Network. In Children With Nonalcoholic Fatty Liver Disease, Zone 1 Steatosis Is Associated With Advanced Fibrosis. Clin Gastroenterol Hepatol 2018;16:438-446.e1. [PMID: 28286193 DOI: 10.1016/j.cgh.2017.02.030] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 6.6] [Reference Citation Analysis]
156 Clark JM, Alkhuraishi AR, Solga SF, Alli P, Diehl AM, Magnuson TH. Roux-en-Y gastric bypass improves liver histology in patients with non-alcoholic fatty liver disease. Obes Res. 2005;13:1180-1186. [PMID: 16076987 DOI: 10.1038/oby.2005.140] [Cited by in Crossref: 131] [Cited by in F6Publishing: 117] [Article Influence: 8.2] [Reference Citation Analysis]
157 Pereira ENGDS, Silvares RR, Flores EEI, Rodrigues KL, Ramos IP, da Silva IJ, Machado MP, Miranda RA, Pazos-Moura CC, Gonçalves-de-Albuquerque CF, Faria-Neto HCC, Tibiriça E, Daliry A. Hepatic microvascular dysfunction and increased advanced glycation end products are components of non-alcoholic fatty liver disease. PLoS One 2017;12:e0179654. [PMID: 28628674 DOI: 10.1371/journal.pone.0179654] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 4.8] [Reference Citation Analysis]
158 Teramoto T, Shinohara T, Takiyama A. Computer-aided classification of hepatocellular ballooning in liver biopsies from patients with NASH using persistent homology. Comput Methods Programs Biomed 2020;195:105614. [PMID: 32650090 DOI: 10.1016/j.cmpb.2020.105614] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
159 Akuta N, Kawamura Y, Fujiyama S, Sezaki H, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Suzuki F, Suzuki Y, Arase Y, Ikeda K, Kumada H. SGLT2 Inhibitor Treatment Outcome in Nonalcoholic Fatty Liver Disease Complicated with Diabetes Mellitus: The Long-term Effects on Clinical Features and Liver Histopathology. Intern Med 2020;59:1931-7. [PMID: 32448832 DOI: 10.2169/internalmedicine.4398-19] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
160 Allende DS, Gawrieh S, Cummings OW, Belt P, Wilson L, Van Natta M, Behling CA, Carpenter D, Gill RM, Kleiner DE, Yeh MM, Chalasani N, Guy CD; NASH Clinical Research Network. Glycogenosis is common in nonalcoholic fatty liver disease and is independently associated with ballooning, but lower steatosis and lower fibrosis. Liver Int 2021;41:996-1011. [PMID: 33354866 DOI: 10.1111/liv.14773] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
161 Zen Y, Kondou H, Nakazawa A, Tanikawa K, Hasegawa Y, Bessho K, Imagawa K, Ishige T, Inui A, Suzuki M, Kasahara M, Yamamoto K, Yoshioka T, Kage M, Hayashi H. Proposal of a liver histology-based scoring system for bile salt export pump deficiency. Hepatol Res 2020;50:754-62. [PMID: 32073700 DOI: 10.1111/hepr.13494] [Reference Citation Analysis]
162 Duman DG, Celikel C, Tüney D, Imeryüz N, Avsar E, Tözün N. Computed tomography in nonalcoholic fatty liver disease: a useful tool for hepatosteatosis assessment? Dig Dis Sci 2006;51:346-51. [PMID: 16534679 DOI: 10.1007/s10620-006-3136-9] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 2.2] [Reference Citation Analysis]
163 Bateman AC. Patterns of histological change in liver disease: my approach to ‘medical’ liver biopsy reporting. Histopathology 2007;51:585-96. [DOI: 10.1111/j.1365-2559.2007.02765.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
164 Russo MF, Lembo E, Mari A, Angelini G, Verrastro O, Nanni G, Pompili M, Raffaelli M, Vecchio FM, Bornstein SR, Mingrone G. Insulin Resistance Is Central to Long-Term Reversal of Histologic Nonalcoholic Steatohepatitis After Metabolic Surgery. J Clin Endocrinol Metab 2021;106:750-61. [PMID: 33248441 DOI: 10.1210/clinem/dgaa892] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
165 Paradis V, Bedossa P. Definition and natural history of metabolic steatosis: histology and cellular aspects. Diabetes & Metabolism 2008;34:638-42. [DOI: 10.1016/s1262-3636(08)74598-1] [Cited by in Crossref: 29] [Cited by in F6Publishing: 6] [Article Influence: 2.1] [Reference Citation Analysis]
166 Franzén LE, Ekstedt M, Kechagias S, Bodin L. Semiquantitative evaluation overestimates the degree of steatosis in liver biopsies: a comparison to stereological point counting. Mod Pathol. 2005;18:912-916. [PMID: 15920560 DOI: 10.1038/modpathol.3800370] [Cited by in Crossref: 81] [Cited by in F6Publishing: 76] [Article Influence: 4.8] [Reference Citation Analysis]
167 Polyzos SA, Mantzoros CS. Adiponectin as a target for the treatment of nonalcoholic steatohepatitis with thiazolidinediones: A systematic review. Metabolism. 2016;65:1297-1306. [PMID: 27506737 DOI: 10.1016/j.metabol.2016.05.013] [Cited by in Crossref: 57] [Cited by in F6Publishing: 55] [Article Influence: 9.5] [Reference Citation Analysis]
168 Sen P, Qadri S, Luukkonen PK, Ragnarsdottir O, McGlinchey A, Jäntti S, Juuti A, Arola J, Schlezinger JJ, Webster TF, Orešič M, Yki-Järvinen H, Hyötyläinen T. Exposure to environmental contaminants is associated with altered hepatic lipid metabolism in non-alcoholic fatty liver disease. J Hepatol 2021:S0168-8278(21)02104-8. [PMID: 34627976 DOI: 10.1016/j.jhep.2021.09.039] [Reference Citation Analysis]
169 Besutti G, Valenti L, Ligabue G, Bassi MC, Pattacini P, Guaraldi G, Giorgi Rossi P. Accuracy of imaging methods for steatohepatitis diagnosis in non‐alcoholic fatty liver disease patients: A systematic review. Liver Int 2019;39:1521-34. [DOI: 10.1111/liv.14118] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
170 Seko Y, Yamaguchi K, Tochiki N, Yano K, Takahashi A, Okishio S, Kataoka S, Okuda K, Umemura A, Moriguchi M, Tanaka S, Mori K, Okanoue T, Itoh Y. Attenuated effect of PNPLA3 on hepatic fibrosis by HSD17B13 in Japanese patients with non-alcoholic fatty liver disease. Liver Int 2020;40:1686-92. [PMID: 32342668 DOI: 10.1111/liv.14495] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
171 Uygun A, Kadayifci A, Isik AT, Ozgurtas T, Deveci S, Tuzun A, Yesilova Z, Gulsen M, Dagalp K. Metformin in the treatment of patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2004;19:537-544. [PMID: 14987322 DOI: 10.1111/j.1365-2036.2004.01888.x] [Cited by in Crossref: 280] [Cited by in F6Publishing: 253] [Article Influence: 15.6] [Reference Citation Analysis]
172 Sebastiani G, Alshaalan R, Wong P, Rubino M, Salman A, Metrakos P, Deschenes M, Ghali P. Prognostic Value of Non-Invasive Fibrosis and Steatosis Tools, Hepatic Venous Pressure Gradient (HVPG) and Histology in Nonalcoholic Steatohepatitis. PLoS One. 2015;10:e0128774. [PMID: 26083565 DOI: 10.1371/journal.pone.0128774] [Cited by in Crossref: 35] [Cited by in F6Publishing: 36] [Article Influence: 5.0] [Reference Citation Analysis]
173 Matsumoto T, Terai S, Oishi T, Kuwashiro S, Fujisawa K, Yamamoto N, Fujita Y, Hamamoto Y, Furutani-Seiki M, Nishina H, Sakaida I. Medaka as a model for human nonalcoholic steatohepatitis. Dis Model Mech 2010;3:431-40. [PMID: 20371730 DOI: 10.1242/dmm.002311] [Cited by in Crossref: 40] [Cited by in F6Publishing: 39] [Article Influence: 3.3] [Reference Citation Analysis]
174 Wong VW, Chan WK, Chitturi S, Chawla Y, Dan YY, Duseja A, Fan J, Goh KL, Hamaguchi M, Hashimoto E, Kim SU, Lesmana LA, Lin YC, Liu CJ, Ni YH, Sollano J, Wong SK, Wong GL, Chan HL, Farrell G. Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017-Part 1: Definition, risk factors and assessment. J Gastroenterol Hepatol. 2018;33:70-85. [PMID: 28670712 DOI: 10.1111/jgh.13857] [Cited by in Crossref: 165] [Cited by in F6Publishing: 154] [Article Influence: 55.0] [Reference Citation Analysis]
175 Paredes AH, Torres DM, Harrison SA. Nonalcoholic Fatty Liver Disease. Clinics in Liver Disease 2012;16:397-419. [DOI: 10.1016/j.cld.2012.03.005] [Cited by in Crossref: 49] [Cited by in F6Publishing: 47] [Article Influence: 4.9] [Reference Citation Analysis]
176 Brunt EM, Tiniakos DG. Pathology of steatohepatitis. Best Practice & Research Clinical Gastroenterology 2002;16:691-707. [DOI: 10.1053/bega.2002.0326] [Cited by in Crossref: 43] [Cited by in F6Publishing: 40] [Article Influence: 2.2] [Reference Citation Analysis]
177 Molloy JW, Calcagno CJ, Williams CD, Jones FJ, Torres DM, Harrison SA. Association of coffee and caffeine consumption with fatty liver disease, nonalcoholic steatohepatitis, and degree of hepatic fibrosis. Hepatology. 2012;55:429-436. [PMID: 21987293 DOI: 10.1002/hep.24731] [Cited by in Crossref: 198] [Cited by in F6Publishing: 169] [Article Influence: 18.0] [Reference Citation Analysis]
178 Veteläinen R, van Vliet A, Gouma DJ, van Gulik TM. Steatosis as a risk factor in liver surgery. Ann Surg. 2007;245:20-30. [PMID: 17197961 DOI: 10.1097/01.sla.0000225113.88433.cf] [Cited by in Crossref: 193] [Cited by in F6Publishing: 183] [Article Influence: 12.9] [Reference Citation Analysis]
179 Gianturco V, Troisi G, Bellomo A, Bernardini S, D'Ottavio E, Formosa V, Iacono CL, Verrusio W, Marigliano B, Marigliano V. Impact of combined therapy with alpha-lipoic and ursodeoxycolic acid on nonalcoholic fatty liver disease: double-blind, randomized clinical trial of efficacy and safety. Hepatol Int 2013;7:570-6. [PMID: 26201789 DOI: 10.1007/s12072-012-9387-y] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
180 Carotti S, Lettieri-Barbato D, Piemonte F, Ruggiero S, Rosina M, Zalfa F, Zingariello M, Arciprete F, Valentini F, Francesconi M, D'Amico J, De Vincentis A, Baiocchini A, Perrone G, Antonelli-Incalzi R, Morini S, Picardi A, Aquilano K, Vespasiani-Gentilucci U. Molecular and histological traits of reduced lysosomal acid lipase activity in the fatty liver. Cell Death Dis 2021;12:1092. [PMID: 34795230 DOI: 10.1038/s41419-021-04382-4] [Reference Citation Analysis]
181 Yeh MM. Nonalcoholic Fatty Liver Disease. Practical Hepatic Pathology: A Diagnostic Approach. Elsevier; 2011. pp. 435-40. [DOI: 10.1016/b978-0-443-06803-4.00031-9] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
182 Simon G, Heckmann V, Tóth D, Pauka D, Petrus K, Molnár TF. The effect of hepatic steatosis and fibrosis on liver weight and dimensions. Leg Med (Tokyo) 2020;47:101781. [PMID: 32889367 DOI: 10.1016/j.legalmed.2020.101781] [Reference Citation Analysis]
183 Giannitrapani L, Soresi M, Ingrao S, La Spada E, Vuturo O, Florena AM, Cervello M, Montalto G. Response to antiviral therapy and hepatic expression of cyclooxygenases in chronic hepatitis C. Eur J Gastroenterol Hepatol. 2007;19:927-933. [PMID: 18049160 DOI: 10.1097/meg.0b013e3282f01e91] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
184 Shima T, Uto H, Ueki K, Takamura T, Kohgo Y, Kawata S, Yasui K, Park H, Nakamura N, Nakatou T, Tanaka N, Umemura A, Mizuno M, Tanaka J, Okanoue T. Clinicopathological features of liver injury in patients with type 2 diabetes mellitus and comparative study of histologically proven nonalcoholic fatty liver diseases with or without type 2 diabetes mellitus. J Gastroenterol 2013;48:515-25. [PMID: 22911170 DOI: 10.1007/s00535-012-0653-5] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
185 Solga SF, Clark JM, Alkhuraishi AR, Torbenson M, Tabesh A, Schweitzer M, Diehl AM, Magnuson TH. Race and comorbid factors predict nonalcoholic fatty liver disease histopathology in severely obese patients. Surg Obes Relat Dis 2005;1:6-11. [PMID: 16925194 DOI: 10.1016/j.soard.2004.12.006] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 2.3] [Reference Citation Analysis]
186 Gómez-Zorita S, Milton-Laskibar I, Macarulla MT, Biasutto L, Fernández-Quintela A, Miranda J, Lasa A, Segues N, Bujanda L, Portillo MP. Pterostilbene modifies triglyceride metabolism in hepatic steatosis induced by high-fat high-fructose feeding: a comparison with its analog resveratrol. Food Funct 2021;12:3266-79. [PMID: 33877249 DOI: 10.1039/d0fo03320k] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
187 Rudler M, Mouri S, Charlotte F, Cluzel P, Ngo Y, Munteanu M, Lebray P, Ratziu V, Thabut D, Poynard T. Validation of AshTest as a Non-Invasive Alternative to Transjugular Liver Biopsy in Patients with Suspected Severe Acute Alcoholic Hepatitis. PLoS One 2015;10:e0134302. [PMID: 26252713 DOI: 10.1371/journal.pone.0134302] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
188 Li Y, Zhao J, Zheng H, Zhong X, Zhou J, Hong Z. Treatment of Nonalcoholic Fatty Liver Disease with Total Alkaloids in Rubus aleaefolius Poir through Regulation of Fat Metabolism. Evid Based Complement Alternat Med. 2014;2014:768540. [PMID: 25404949 DOI: 10.1155/2014/768540] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
189 Carulli L, Ballestri S, Lonardo A, Lami F, Violi E, Losi L, Bonilauri L, Verrone AM, Odoardi MR, Scaglioni F. Is nonalcoholic steatohepatitis associated with a high-though-normal thyroid stimulating hormone level and lower cholesterol levels? Intern Emerg Med. 2013;8:297-305. [PMID: 21559749 DOI: 10.1007/s11739-011-0609-4] [Cited by in Crossref: 47] [Cited by in F6Publishing: 48] [Article Influence: 4.3] [Reference Citation Analysis]
190 Tanaka S, Miyanishi K, Kobune M, Kawano Y, Hoki T, Kubo T, Hayashi T, Sato T, Sato Y, Takimoto R. Increased hepatic oxidative DNA damage in patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma. J Gastroenterol. 2013;48:1249-1258. [PMID: 23329365 DOI: 10.1007/s00535-012-0739-0] [Cited by in Crossref: 45] [Cited by in F6Publishing: 42] [Article Influence: 5.0] [Reference Citation Analysis]
191 Senturk O, Kocaman O, Hulagu S, Sahin T, Aygun C, Konduk T, Celebi A. Endothelial dysfunction in Turkish patients with non-alcoholic fatty liver disease. Intern Med J. 2008;38:183-189. [PMID: 17725609 DOI: 10.1111/j.1445-5994.2007.01481.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 1.7] [Reference Citation Analysis]
192 Bae JS, Lee JM, Park SJ, Lee KB, Han JK. Magnetic resonance elastography of healthy livers at 3.0 T: Normal liver stiffness measured by SE-EPI and GRE. Eur J Radiol 2018;107:46-53. [PMID: 30292272 DOI: 10.1016/j.ejrad.2018.08.015] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
193 Quintana-Castro R, Aguirre-Maldonado I, Soto-Rodríguez I, Deschamps-Lago RA, Gruber-Pagola P, Urbina de Larrea YK, Juárez-Rivera VE, Ramos-Manuel LE, Alexander-Aguilera A. Cd36 gene expression in adipose and hepatic tissue mediates the lipids accumulation in liver of obese rats with sucrose-induced hepatic steatosis. Prostaglandins Other Lipid Mediat 2020;147:106404. [PMID: 31838198 DOI: 10.1016/j.prostaglandins.2019.106404] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
194 Lacerda DR, Moraes MM, Nunes-silva A, Costa KA, Rodrigues DF, Sabino JL, Cordeiro LMDS, Pinho V, Teixeira MM, Wanner SP, Soares DD, Ferreira AVM. Aerobic training reduces immune cell recruitment and cytokine levels in adipose tissue in obese mice. Appl Physiol Nutr Metab 2019;44:512-20. [DOI: 10.1139/apnm-2018-0523] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
195 Halász T, Horváth G, Kiss A, Pár G, Szombati A, Gelley F, Nemes B, Kenessey I, Piurkó V, Schaff Z. Evaluation of Histological and non-Invasive Methods for the Detection of Liver Fibrosis: The Values of Histological and Digital Morphometric Analysis, Liver Stiffness Measurement and APRI Score. Pathol Oncol Res 2016;22:1-6. [PMID: 26189126 DOI: 10.1007/s12253-015-9964-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
196 Lonardo A, Leoni S, Alswat KA, Fouad Y. History of Nonalcoholic Fatty Liver Disease. Int J Mol Sci 2020;21:E5888. [PMID: 32824337 DOI: 10.3390/ijms21165888] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 9.0] [Reference Citation Analysis]
197 Marchesini G, Pagotto U, Bugianesi E, De Iasio R, Manini R, Vanni E, Pasquali R, Melchionda N, Rizzetto M. Low ghrelin concentrations in nonalcoholic fatty liver disease are related to insulin resistance. J Clin Endocrinol Metab. 2003;88:5674-5679. [PMID: 14671152 DOI: 10.1210/jc.2003-031094] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 1.9] [Reference Citation Analysis]
198 Yakaryilmaz F, Guliter S, Ozenirler S, Erdem O, Akyol G. Vitamin E treatment in patients with nonalcoholic steatohepatitis: A six-month, open-label study of sixteen patients. Curr Ther Res Clin Exp 2004;65:266-77. [PMID: 24672082 DOI: 10.1016/S0011-393X(04)80077-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
199 Nilsson E, Matte A, Perfilyev A, de Mello VD, Käkelä P, Pihlajamäki J, Ling C. Epigenetic Alterations in Human Liver From Subjects With Type 2 Diabetes in Parallel With Reduced Folate Levels. J Clin Endocrinol Metab 2015;100:E1491-501. [PMID: 26418287 DOI: 10.1210/jc.2015-3204] [Cited by in Crossref: 91] [Cited by in F6Publishing: 81] [Article Influence: 13.0] [Reference Citation Analysis]
200 Polyzos SA, Aronis KN, Kountouras J, Raptis DD, Vasiloglou MF, Mantzoros CS. Circulating leptin in non-alcoholic fatty liver disease: a systematic review and meta-analysis. Diabetologia. 2016;59:30-43. [PMID: 26407715 DOI: 10.1007/s00125-015-3769-3] [Cited by in Crossref: 110] [Cited by in F6Publishing: 108] [Article Influence: 15.7] [Reference Citation Analysis]
201 Bharath R, Rajalakshmi P, Mateen MA. Multi-modal framework for automatic detection of diagnostically important regions in nonalcoholic fatty liver ultrasonic images. Biocybernetics and Biomedical Engineering 2018;38:586-601. [DOI: 10.1016/j.bbe.2018.03.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
202 Yamamoto K, Kogiso T, Taniai M, Hashimoto E, Tokushige K. Differences in the genetic backgrounds of patients with alcoholic liver disease and non-alcoholic fatty liver disease. JGH Open 2019;3:17-24. [PMID: 30834336 DOI: 10.1002/jgh3.12097] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
203 Ratziu V, Bugianesi E, Dixon J, Fassio E, Ekstedt M, Charlotte F, Kechagias S, Poynard T, Olsson R. Histological progression of non-alcoholic fatty liver disease: a critical reassessment based on liver sampling variability. Aliment Pharmacol Ther 2007;26:821-30. [PMID: 17767466 DOI: 10.1111/j.1365-2036.2007.03425.x] [Cited by in Crossref: 45] [Cited by in F6Publishing: 42] [Article Influence: 3.0] [Reference Citation Analysis]
204 González IA, Fuller LD, Zhang X, Papke DJ, Zhao L, Zhang D, Liao X, Liu X, Fiel MI, Zhang X. Development of a Scoring System to Differentiate Amiodarone-Induced Liver Injury From Alcoholic Steatohepatitis. Am J Clin Pathol 2021:aqab142. [PMID: 34596220 DOI: 10.1093/ajcp/aqab142] [Reference Citation Analysis]
205 Brouwers MCGJ, Jacobs C, Bast A, Stehouwer CDA, Schaper NC. Modulation of Glucokinase Regulatory Protein: A Double-Edged Sword? Trends Mol Med 2015;21:583-94. [PMID: 26432016 DOI: 10.1016/j.molmed.2015.08.004] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 5.5] [Reference Citation Analysis]
206 Syn WK, Jung Y, Omenetti A, Abdelmalek M, Guy CD, Yang L, Wang J, Witek RP, Fearing CM, Pereira TA, Teaberry V, Choi SS, Conde-Vancells J, Karaca GF, Diehl AM. Hedgehog-mediated epithelial-to-mesenchymal transition and fibrogenic repair in nonalcoholic fatty liver disease. Gastroenterology 2009;137:1478-1488.e8. [PMID: 19577569 DOI: 10.1053/j.gastro.2009.06.051] [Cited by in Crossref: 179] [Cited by in F6Publishing: 173] [Article Influence: 13.8] [Reference Citation Analysis]
207 Sookoian S, Castaño GO, Burgueño AL, Rosselli MS, Gianotti TF, Mallardi P, Martino JS, Pirola CJ. Circulating levels and hepatic expression of molecular mediators of atherosclerosis in nonalcoholic fatty liver disease. Atherosclerosis 2010;209:585-91. [PMID: 19896127 DOI: 10.1016/j.atherosclerosis.2009.10.011] [Cited by in Crossref: 77] [Cited by in F6Publishing: 76] [Article Influence: 5.9] [Reference Citation Analysis]
208 Oeda S, Takahashi H, Imajo K, Seko Y, Ogawa Y, Moriguchi M, Yoneda M, Anzai K, Aishima S, Kage M, Itoh Y, Nakajima A, Eguchi Y. Accuracy of liver stiffness measurement and controlled attenuation parameter using FibroScan® M/XL probes to diagnose liver fibrosis and steatosis in patients with nonalcoholic fatty liver disease: a multicenter prospective study. J Gastroenterol 2020;55:428-40. [PMID: 31654131 DOI: 10.1007/s00535-019-01635-0] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 6.3] [Reference Citation Analysis]
209 Zardi EM, De Sio I, Ghittoni G, Sadun B, Palmentieri B, Roselli P, Persico M, Caturelli E. Which clinical and sonographic parameters may be useful to discriminate NASH from steatosis? J Clin Gastroenterol. 2011;45:59-63. [PMID: 20502351 DOI: 10.1097/mcg.0b013e3181dc25e3] [Cited by in Crossref: 20] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
210 Wang Y, Ganger DR, Levitsky J, Sternick LA, McCarthy RJ, Chen ZE, Fasanati CW, Bolster B, Shah S, Zuehlsdorff S. Assessment of chronic hepatitis and fibrosis: comparison of MR elastography and diffusion-weighted imaging. AJR Am J Roentgenol. 2011;196:553-561. [PMID: 21343496 DOI: 10.2214/ajr.10.4580] [Cited by in Crossref: 161] [Cited by in F6Publishing: 94] [Article Influence: 14.6] [Reference Citation Analysis]
211 Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD single topic conference. Hepatology. 2003;37:1202-1219. [PMID: 12717402 DOI: 10.1053/jhep.2003.50193] [Cited by in Crossref: 1410] [Cited by in F6Publishing: 1313] [Article Influence: 74.2] [Reference Citation Analysis]
212 Abd El-Kader SM, El-Den Ashmawy EMS. Non-alcoholic fatty liver disease: The diagnosis and management. World J Hepatol 2015; 7(6): 846-858 [PMID: 25937862 DOI: 10.4254/wjh.v7.i6.846] [Cited by in Crossref: 166] [Cited by in F6Publishing: 148] [Article Influence: 23.7] [Reference Citation Analysis]
213 Attia A, Ragheb A, Sylwestrowicz T, Shoker A. Attenuation of high cholesterol-induced oxidative stress in rabbit liver by thymoquinone: . European Journal of Gastroenterology & Hepatology 2010;22:826-34. [DOI: 10.1097/meg.0b013e328336000d] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
214 Morisco F, Stroffolini T, Mele A, Taliani G, Smedile A, Caronna S, Tosti ME, Niro G, Levrero M, Fiorillo MT, Amoruso DC, Ascione A, Caporaso N. Etiology of and risk factors for transient and persistent aminotransferase elevation in a population of virus-free blood donors: a multicentre study. Dig Liver Dis 2010;42:441-5. [PMID: 19643684 DOI: 10.1016/j.dld.2009.06.017] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
215 Vali Y, Lee J, Boursier J, Spijker R, Verheij J, Brosnan MJ, Anstee QM, Bossuyt PM, Zafarmand MH, On Behalf Of The Litmus Systematic Review Team. FibroTest for Evaluating Fibrosis in Non-Alcoholic Fatty Liver Disease Patients: A Systematic Review and Meta-Analysis. J Clin Med 2021;10:2415. [PMID: 34072480 DOI: 10.3390/jcm10112415] [Reference Citation Analysis]
216 Takeuchi-yorimoto A, Yamaura Y, Kanki M, Ide T, Nakata A, Noto T, Matsumoto M. MicroRNA-21 is associated with fibrosis in a rat model of nonalcoholic steatohepatitis and serves as a plasma biomarker for fibrotic liver disease. Toxicology Letters 2016;258:159-67. [DOI: 10.1016/j.toxlet.2016.06.012] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
217 Malaguarnera L, Di Rosa M, Zambito AM, dell’Ombra N, Nicoletti F, Malaguarnera M. Chitotriosidase gene expression in Kupffer cells from patients with non-alcoholic fatty liver disease. Gut. 2006;55:1313-1320. [PMID: 16825325 DOI: 10.1136/gut.2005.075697] [Cited by in Crossref: 67] [Cited by in F6Publishing: 68] [Article Influence: 4.2] [Reference Citation Analysis]
218 Das S, Alhasson F, Dattaroy D, Pourhoseini S, Seth RK, Nagarkatti M, Nagarkatti PS, Michelotti GA, Diehl AM, Kalyanaraman B, Chatterjee S. NADPH Oxidase-Derived Peroxynitrite Drives Inflammation in Mice and Human Nonalcoholic Steatohepatitis via TLR4-Lipid Raft Recruitment. Am J Pathol 2015;185:1944-57. [PMID: 25989356 DOI: 10.1016/j.ajpath.2015.03.024] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 4.1] [Reference Citation Analysis]
219 Maurice JB, Garvey L, Tsochatzis EA, Wiltshire M, Cooke G, Guppy N, McDonald J, Marchesi J, Nelson M, Kelleher P, Goldin R, Thursz M, Lemoine M. Monocyte-macrophage activation is associated with nonalcoholic fatty liver disease and liver fibrosis in HIV monoinfection independently of the gut microbiome and bacterial translocation. AIDS 2019;33:805-14. [PMID: 30882489 DOI: 10.1097/QAD.0000000000002133] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
220 Hano H, Takasaki S, Kobayashi H, Koyama T, Lu T, Nagatsuma K. In the non-cirrhotic stage of nonalcoholic steatohepatitis, angioarchitecture of portal veins and lobular architecture are maintained. Virchows Arch 2013;462:533-40. [PMID: 23536281 DOI: 10.1007/s00428-013-1402-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
221 Georgoulis M, Fragopoulou E, Kontogianni MD, Margariti A, Boulamatsi O, Detopoulou P, Tiniakos D, Zafiropoulou R, Papatheodoridis G. Blood redox status is associated with the likelihood of nonalcoholic fatty liver disease irrespectively of diet's total antioxidant capacity. Nutr Res 2015;35:41-8. [PMID: 25530013 DOI: 10.1016/j.nutres.2014.11.004] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
222 Reha JL, Lee S, Hofmann LJ. Prevalence and Predictors of Nonalcoholic Steatohepatitis in Obese Patients Undergoing Bariatric Surgery: A Department of Defense Experience. The American Surgeon 2014;80:595-9. [DOI: 10.1177/000313481408000624] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 8.5] [Reference Citation Analysis]
223 Benini F, Pigozzi MG, Pozzi A, Bercich L, Reggiani A, Quattrocchi D, Distefano L, Donati P, Cesana BM, Lanzini A. Elevation of serum gamma-glutamyltranspeptidase activity is frequent in chronic hepatitis C, and is associated with insulin resistance. Dig Liver Dis. 2009;41:586-590. [PMID: 19131283 DOI: 10.1016/j.dld.2008.11.016] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
224 Zheng Y, Zhong X, Huang Y, Zheng C. HCBP6 Is Involved in the Development of Hepatic Steatosis Induced by High-Fat Diet and CCL4 in Rats. Annals of Hepatology 2018;17:511-8. [DOI: 10.5604/01.3001.0011.7396] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
225 Carneiro MV, Souza FF, Teixeira AC, Figueiredo JF, Villanova MG, Secaf M, Passos AD, Ramalho LN, Carneiro FP, Zucoloto S. The H63D genetic variant of the HFE gene is independently associated with the virological response to interferon and ribavirin therapy in chronic hepatitis C. Eur J Gastroenterol Hepatol. 2010;22:1204-1210. [PMID: 20555268 DOI: 10.1097/meg.0b013e32833bec1e] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
226 Allard JP, Aghdassi E, Mohammed S, Raman M, Avand G, Arendt BM, Jalali P, Kandasamy T, Prayitno N, Sherman M, Guindi M, Ma DW, Heathcote JE. Nutritional assessment and hepatic fatty acid composition in non-alcoholic fatty liver disease (NAFLD): a cross-sectional study. J Hepatol. 2008;48:300-307. [PMID: 18086506 DOI: 10.1016/j.jhep.2007.09.009] [Cited by in Crossref: 145] [Cited by in F6Publishing: 138] [Article Influence: 9.7] [Reference Citation Analysis]
227 Saco A, Diaz A, Hernandez M, Martinez D, Montironi C, Castillo P, Rakislova N, del Pino M, Martinez A, Ordi J. Validation of whole-slide imaging in the primary diagnosis of liver biopsies in a University Hospital. Digestive and Liver Disease 2017;49:1240-6. [DOI: 10.1016/j.dld.2017.07.002] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
228 Hurtado del Pozo C, Vesperinas-García G, Rubio MÁ, Corripio-Sánchez R, Torres-García AJ, Obregon MJ, Calvo RM. ChREBP expression in the liver, adipose tissue and differentiated preadipocytes in human obesity. Biochim Biophys Acta 2011;1811:1194-200. [PMID: 21840420 DOI: 10.1016/j.bbalip.2011.07.016] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 4.0] [Reference Citation Analysis]
229 Jouët P, Sabaté J, Maillard D, Msika S, Mechler C, Ledoux S, Harnois F, Coffin B. Relationship between Obstructive Sleep Apnea and Liver Abnormalities in Morbidly Obese Patients: A Prospective Study. OBES SURG 2007;17:478-85. [DOI: 10.1007/s11695-007-9085-3] [Cited by in Crossref: 59] [Cited by in F6Publishing: 61] [Article Influence: 3.9] [Reference Citation Analysis]
230 Day CP, Saksena S. Non-alcoholic steatohepatitis: definitions and pathogenesis. J Gastroenterol Hepatol. 2002;17 Suppl 3:S377-S384. [PMID: 12472967 DOI: 10.1046/j.1440-1746.17.s3.31.x] [Cited by in Crossref: 103] [Cited by in F6Publishing: 109] [Article Influence: 7.4] [Reference Citation Analysis]
231 Kalinowski P, Paluszkiewicz R, Ziarkiewicz-Wróblewska B, Wróblewski T, Remiszewski P, Grodzicki M, Krawczyk M. Liver Function in Patients With Nonalcoholic Fatty Liver Disease Randomized to Roux-en-Y Gastric Bypass Versus Sleeve Gastrectomy: A Secondary Analysis of a Randomized Clinical Trial. Ann Surg 2017;266:738-45. [PMID: 28767558 DOI: 10.1097/SLA.0000000000002397] [Cited by in Crossref: 43] [Cited by in F6Publishing: 20] [Article Influence: 8.6] [Reference Citation Analysis]
232 Ibdah JA, Perlegas P, Zhao Y, Angdisen J, Borgerink H, Shadoan MK, Wagner JD, Matern D, Rinaldo P, Cline JM. Mice heterozygous for a defect in mitochondrial trifunctional protein develop hepatic steatosis and insulin resistance. Gastroenterology. 2005;128:1381-1390. [PMID: 15887119 DOI: 10.1053/j.gastro.2005.02.001] [Cited by in Crossref: 128] [Cited by in F6Publishing: 120] [Article Influence: 7.5] [Reference Citation Analysis]
233 Huang JF, Yeh ML, Yu ML, Huang CF, Dai CY, Hsieh MY, Hsieh MH, Huang CI, Lin ZY, Chen SC, Hsiao PJ, Shin SJ, Chuang WL. Hyperuricemia Inversely Correlates with Disease Severity in Taiwanese Nonalcoholic Steatohepatitis Patients. PLoS One 2015;10:e0139796. [PMID: 26441244 DOI: 10.1371/journal.pone.0139796] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
234 Tucci S, Flögel U, Sturm M, Borsch E, Spiekerkoetter U. Disrupted fat distribution and composition due to medium-chain triglycerides in mice with a β-oxidation defect. The American Journal of Clinical Nutrition 2011;94:439-49. [DOI: 10.3945/ajcn.111.012948] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 2.3] [Reference Citation Analysis]
235 Ninomiya M, Kondo Y, Shimosegawa T. Murine Models of Nonalcoholic Fatty Liver Disease and Steatohepatitis. ISRN Hepatol 2013;2013:237870. [PMID: 27335818 DOI: 10.1155/2013/237870] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
236 Kim JC, Jeon JY, Yang WS, Kim CH, Eom DW. Combined Amelioration of Ginsenoside (Rg1, Rb1, and Rg3)-enriched Korean Red Ginseng and Probiotic Lactobacillus on Non-alcoholic Fatty Liver Disease. Curr Pharm Biotechnol 2019;20:222-31. [PMID: 30854954 DOI: 10.2174/1389201020666190311143554] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
237 Gray J, Chattopadhyay D, Beale GS, Patman GL, Miele L, King BP, Stewart S, Hudson M, Day CP, Manas DM. A proteomic strategy to identify novel serum biomarkers for liver cirrhosis and hepatocellular cancer in individuals with fatty liver disease. BMC Cancer. 2009;9:271. [PMID: 19656391 DOI: 10.1186/1471-2407-9-271] [Cited by in Crossref: 47] [Cited by in F6Publishing: 47] [Article Influence: 3.6] [Reference Citation Analysis]
238 Charlotte F, Le Naour G, Bernhardt C, Poynard T, Ratziu V. A comparison of the fibrotic potential of nonalcoholic fatty liver disease and chronic hepatitis C. Hum Pathol. 2010;41:1178-1185. [PMID: 20413144 DOI: 10.1016/j.humpath.2009.10.025] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
239 Tordjman J, Divoux A, Prifti E, Poitou C, Pelloux V, Hugol D, Basdevant A, Bouillot JL, Chevallier JM, Bedossa P, Guerre-Millo M, Clement K. Structural and inflammatory heterogeneity in subcutaneous adipose tissue: relation with liver histopathology in morbid obesity. J Hepatol 2012;56:1152-8. [PMID: 22245892 DOI: 10.1016/j.jhep.2011.12.015] [Cited by in Crossref: 55] [Cited by in F6Publishing: 47] [Article Influence: 5.5] [Reference Citation Analysis]
240 Chitturi S, Weltman M, Farrell GC, McDonald D, Kench J, Liddle C, Samarasinghe D, Lin R, Abeygunasekera S, George J. HFE mutations, hepatic iron, and fibrosis: ethnic-specific association of NASH with C282Y but not with fibrotic severity. Hepatology. 2002;36:142-149. [PMID: 12085358 DOI: 10.1053/jhep.2002.33892] [Cited by in Crossref: 166] [Cited by in F6Publishing: 151] [Article Influence: 8.3] [Reference Citation Analysis]
241 Sookoian S, Castaño G, Burgueño AL, Gianotti TF, Rosselli MS, Pirola CJ. A diagnostic model to differentiate simple steatosis from nonalcoholic steatohepatitis based on the likelihood ratio form of Bayes theorem. Clin Biochem 2009;42:624-9. [PMID: 19071103 DOI: 10.1016/j.clinbiochem.2008.11.005] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
242 House MJ, Gan EK, Adams LA, Ayonrinde OT, Bangma SJ, Bhathal PS, Olynyk JK, St Pierre TG. Diagnostic performance of a rapid magnetic resonance imaging method of measuring hepatic steatosis. PLoS One 2013;8:e59287. [PMID: 23555650 DOI: 10.1371/journal.pone.0059287] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
243 Pan X, Zhang Y, Kim HG, Liangpunsakul S, Dong XC. FOXO transcription factors protect against the diet-induced fatty liver disease. Sci Rep 2017;7:44597. [PMID: 28300161 DOI: 10.1038/srep44597] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.6] [Reference Citation Analysis]
244 Charatcharoenwitthaya P, Lindor KD. Role of radiologic modalities in the management of non-alcoholic steatohepatitis. Clin Liver Dis. 2007;11:37-54, viii. [PMID: 17544971 DOI: 10.1016/j.cld.2007.02.014] [Cited by in Crossref: 127] [Cited by in F6Publishing: 115] [Article Influence: 8.5] [Reference Citation Analysis]
245 Ekstedt M, Nasr P, Kechagias S. Natural History of NAFLD/NASH. Curr Hepatol Rep. 2017;16:391-397. [PMID: 29984130 DOI: 10.1007/s11901-017-0378-2] [Cited by in Crossref: 51] [Cited by in F6Publishing: 53] [Article Influence: 10.2] [Reference Citation Analysis]
246 Dioguardi Burgio M, Ronot M, Reizine E, Rautou P, Castera L, Paradis V, Garteiser P, Van Beers B, Vilgrain V. Quantification of hepatic steatosis with ultrasound: promising role of attenuation imaging coefficient in a biopsy-proven cohort. Eur Radiol 2020;30:2293-301. [DOI: 10.1007/s00330-019-06480-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
247 Horowitz JM, Venkatesh SK, Ehman RL, Jhaveri K, Kamath P, Ohliger MA, Samir AE, Silva AC, Taouli B, Torbenson MS, Wells ML, Yeh B, Miller FH. Evaluation of hepatic fibrosis: A review from the society of abdominal radiology disease focus panel. Abdom Radiol (NY). 2017;42:2037-2053. [PMID: 28624924 DOI: 10.1007/s00261-017-1211-7] [Cited by in Crossref: 55] [Cited by in F6Publishing: 50] [Article Influence: 11.0] [Reference Citation Analysis]
248 Tan C, Al-kalifah N, Lee W, Ser K, Lee Y, Chen J. HSCRP as surrogate marker in predicting long term effect of bariatric surgery on resolution of non-alcoholic steatohepatitis. Asian Journal of Surgery 2019;42:203-8. [DOI: 10.1016/j.asjsur.2018.04.010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
249 Yasui K, Hashimoto E, Komorizono Y, Koike K, Arii S, Imai Y, Shima T, Kanbara Y, Saibara T, Mori T, Kawata S, Uto H, Takami S, Sumida Y, Takamura T, Kawanaka M, Okanoue T; Japan NASH Study Group, Ministry of Health, Labour, and Welfare of Japan. Characteristics of patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2011;9:428-433; quiz e50. [PMID: 21320639 DOI: 10.1016/j.cgh.2011.01.023] [Cited by in Crossref: 258] [Cited by in F6Publishing: 237] [Article Influence: 23.5] [Reference Citation Analysis]
250 Oliveira CP, de Lima Sanches P, de Abreu-Silva EO, Marcadenti A. Nutrition and Physical Activity in Nonalcoholic Fatty Liver Disease. J Diabetes Res. 2016;2016:4597246. [PMID: 26770987 DOI: 10.1155/2016/4597246] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 3.6] [Reference Citation Analysis]
251 Lima-Cabello E, García-Mediavilla MV, Miquilena-Colina ME, Vargas-Castrillón J, Lozano-Rodríguez T, Fernández-Bermejo M, Olcoz JL, González-Gallego J, García-Monzón C, Sánchez-Campos S. Enhanced expression of pro-inflammatory mediators and liver X-receptor-regulated lipogenic genes in non-alcoholic fatty liver disease and hepatitis C. Clin Sci (Lond). 2011;120:239-250. [PMID: 20929443 DOI: 10.1042/cs20100387] [Cited by in Crossref: 82] [Cited by in F6Publishing: 40] [Article Influence: 7.5] [Reference Citation Analysis]
252 Agúndez JA, García-Martin E, Maestro ML, Cuenca F, Martínez C, Ortega L, Carballo M, Vidaurreta M, Agreda M, Díaz-Zelaya G. Relation of IL28B gene polymorphism with biochemical and histological features in hepatitis C virus-induced liver disease. PLoS One. 2012;7:e37998. [PMID: 22666430 DOI: 10.1371/journal.pone.0037998] [Cited by in Crossref: 36] [Cited by in F6Publishing: 38] [Article Influence: 3.6] [Reference Citation Analysis]
253 Kaswala DH, Lai M, Afdhal NH. Fibrosis Assessment in Nonalcoholic Fatty Liver Disease (NAFLD) in 2016. Dig Dis Sci. 2016;61:1356-1364. [PMID: 27017224 DOI: 10.1007/s10620-016-4079-4] [Cited by in Crossref: 70] [Cited by in F6Publishing: 59] [Article Influence: 11.7] [Reference Citation Analysis]
254 Nehra V, Angulo P, Buchman AL, Lindor KD. Nutritional and metabolic considerations in the etiology of nonalcoholic steatohepatitis. Dig Dis Sci. 2001;46:2347-2352. [PMID: 11713934 DOI: 10.1023/a:1012338828418] [Cited by in Crossref: 107] [Cited by in F6Publishing: 66] [Article Influence: 5.1] [Reference Citation Analysis]
255 Ishiba H, Sumida Y, Seko Y, Tanaka S, Yoneda M, Hyogo H, Ono M, Fujii H, Eguchi Y, Suzuki Y, Yoneda M, Takahashi H, Nakahara T, Mori K, Kanemasa K, Shimada K, Imajo K, Yamaguchi K, Kawaguchi T, Nakajima A, Chayama K, Shima T, Fujimoto K, Okanoue T, Itoh Y; Japan Study Group of NAFLD. Type IV Collagen 7S Is the Most Accurate Test For Identifying Advanced Fibrosis in NAFLD With Type 2 Diabetes. Hepatol Commun 2021;5:559-72. [PMID: 33860115 DOI: 10.1002/hep4.1637] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
256 Tauriainen MM, Männistö V, Kaminska D, Vaittinen M, Kärjä V, Käkelä P, Venesmaa S, Gylling H, Pihlajamäki J. Serum, liver and bile sitosterol and sitostanol in obese patients with and without NAFLD. Biosci Rep 2018;38:BSR20171274. [PMID: 29540533 DOI: 10.1042/BSR20171274] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
257 Arhan M, Öztürk HS, Turhan N, Aytac B, Güven MC, Olcay E, Durak İ. Hepatic oxidant/antioxidant status in cholesterol-fed rabbits: Effects of garlic extract. Hepatology Research 2009;39:70-7. [DOI: 10.1111/j.1872-034x.2008.00401.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
258 Ohtsuka T, Tsutsumi M, Fukumura A, Tsuchishima M, Takase S. Use of serum carbohydrate-deficient transferrin values to exclude alcoholic hepatitis from non-alcoholic steatohepatitis: a pilot study. Alcohol Clin Exp Res. 2005;29:236S-239S. [PMID: 16385229 DOI: 10.1097/01.alc.0000190659.85025.b3] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
259 Helal KM, Taylor JN, Cahyadi H, Okajima A, Tabata K, Itoh Y, Tanaka H, Fujita K, Harada Y, Komatsuzaki T. Raman spectroscopic histology using machine learning for nonalcoholic fatty liver disease. FEBS Lett 2019;593:2535-44. [PMID: 31254349 DOI: 10.1002/1873-3468.13520] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
260 Suh CH, Kim SY, Kim KW, Lim YS, Lee SJ, Lee MG, Lee J, Lee SG, Yu E. Determination of normal hepatic elasticity by using real-time shear-wave elastography. Radiology. 2014;271:895-900. [PMID: 24555633 DOI: 10.1148/radiol.14131251] [Cited by in Crossref: 48] [Cited by in F6Publishing: 40] [Article Influence: 6.0] [Reference Citation Analysis]
261 Huang H, Lin W, Lee L, Wang H, Lee W, Huang K. Metabolic Syndrome Is Related to Nonalcoholic Steatohepatitis in Severely Obese Subjects. OBES SURG 2007;17:1457-63. [DOI: 10.1007/s11695-008-9423-0] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 2.6] [Reference Citation Analysis]
262 Sugihara T, Koda M, Kishina M, Kato J, Tokunaga S, Matono T, Ueki M, Murawaki Y. Fatty liver Shionogi-ob/ob mouse: A new candidate for a non-alcoholic steatohepatitis model. Hepatol Res. 2013;43:547-556. [PMID: 23057725 DOI: 10.1111/j.1872-034x.2012.01101.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
263 Luukkonen PK, Zhou Y, Nidhina Haridas PA, Dwivedi OP, Hyötyläinen T, Ali A, Juuti A, Leivonen M, Tukiainen T, Ahonen L, Scott E, Palmer JM, Arola J, Orho-Melander M, Vikman P, Anstee QM, Olkkonen VM, Orešič M, Groop L, Yki-Järvinen H. Impaired hepatic lipid synthesis from polyunsaturated fatty acids in TM6SF2 E167K variant carriers with NAFLD. J Hepatol 2017;67:128-36. [PMID: 28235613 DOI: 10.1016/j.jhep.2017.02.014] [Cited by in Crossref: 60] [Cited by in F6Publishing: 52] [Article Influence: 12.0] [Reference Citation Analysis]
264 Kong Q, Zhang H, Zhao T, Zhang W, Yan M, Dong X, Li P. Tangshen formula attenuates hepatic steatosis by inhibiting hepatic lipogenesis and augmenting fatty acid oxidation in db/db mice. Int J Mol Med 2016;38:1715-26. [PMID: 27840945 DOI: 10.3892/ijmm.2016.2799] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
265 Molina DK. Is steatosis a risk factor for hepatic blunt force injury? Am J Forensic Med Pathol 2011;32:263-5. [PMID: 24042070 DOI: 10.1097/PAF.0b013e3181d8e3bc] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
266 Horai Y, Utsumi H, Ono Y, Kishimoto T, Ono Y, Fukunari A. Pathological characterization and morphometric analysis of hepatic lesions in SHRSP5/Dmcr, an experimental non-alcoholic steatohepatitis model, induced by high-fat and high-cholesterol diet. Int J Exp Pathol 2016;97:75-85. [PMID: 27037502 DOI: 10.1111/iep.12169] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
267 Hashimoto E, Taniai M, Tokushige K. Characteristics and diagnosis of NAFLD/NASH. J Gastroenterol Hepatol. 2013;28 Suppl 4:64-70. [PMID: 24251707 DOI: 10.1111/jgh.12271] [Cited by in Crossref: 117] [Cited by in F6Publishing: 107] [Article Influence: 14.6] [Reference Citation Analysis]
268 Ilagan-Ying YC, Xu J, Lim JK, Do A. Low real-world eligibility rates for nonalcoholic steatohepatitis patients for phase 3 clinical trial criteria application in a large academic health system. Eur J Gastroenterol Hepatol 2021;33:424-9. [PMID: 32433419 DOI: 10.1097/MEG.0000000000001758] [Reference Citation Analysis]
269 Mallick P, Shah P, Ittmann MM, Trivedi M, Hu M, Gao S, Ghose R. Impact of diet on irinotecan toxicity in mice. Chemico-Biological Interactions 2018;291:87-94. [DOI: 10.1016/j.cbi.2018.06.018] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
270 Schina M, Koskinas J, Tiniakos D, Hadziyannis E, Savvas S, Karamanos B, Manesis E, Archimandritis A. Circulating and liver tissue levels of retinol-binding protein-4 in non-alcoholic fatty liver disease. Hepatol Res. 2009;39:972-978. [PMID: 19624771 DOI: 10.1111/j.1872-034x.2009.00534.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 8] [Article Influence: 1.9] [Reference Citation Analysis]
271 Tsolaki E, Athanasiou E, Gounari E, Zogas N, Siotou E, Yiangou M, Anagnostopoulos A, Yannaki E. Hematopoietic stem cells and liver regeneration: differentially acting hematopoietic stem cell mobilization agents reverse induced chronic liver injury. Blood Cells Mol Dis. 2014;53:124-132. [PMID: 24923531 DOI: 10.1016/j.bcmd.2014.05.003] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 3.5] [Reference Citation Analysis]
272 Noh H, Lee H, Kim E, Mu L, Rhee YK, Cho CW, Chung J. Inhibitory effect of a Cirsium setidens extract on hepatic fat accumulation in mice fed a high-fat diet via the induction of fatty acid β-oxidation. Biosci Biotechnol Biochem 2013;77:1424-9. [PMID: 23832362 DOI: 10.1271/bbb.130049] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
273 Israelsen M, Kim M, Suvitaival T, Madsen BS, Hansen CD, Torp N, Trost K, Thiele M, Hansen T, Legido-Quigley C, Krag A; MicrobLiver Consortium. Comprehensive lipidomics reveals phenotypic differences in hepatic lipid turnover in ALD and NAFLD during alcohol intoxication. JHEP Rep 2021;3:100325. [PMID: 34401690 DOI: 10.1016/j.jhepr.2021.100325] [Reference Citation Analysis]
274 Makovicky P, Tumova E, Volek Z, Makovicky P, Vodickova L, Slyskova J, Svoboda M, Rejhova A, Vodicka P, Samasca G, Kralova A, Nagy M, Mydlarova-Blascakova M, Poracova J. Histopathological aspects of liver under variable food restriction: has the intense one-week food restriction a protective effect on non-alcoholic-fatty-liver-disease (NAFLD) development? Pathol Res Pract 2014;210:855-62. [PMID: 25238938 DOI: 10.1016/j.prp.2014.08.007] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
275 Bell LN, Temm CJ, Saxena R, Vuppalanchi R, Schauer P, Rabinovitz M, Krasinskas A, Chalasani N, Mattar SG. Bariatric surgery-induced weight loss reduces hepatic lipid peroxidation levels and affects hepatic cytochrome P-450 protein content. Ann Surg. 2010;251:1041-1048. [PMID: 20485142 DOI: 10.1097/sla.0b013e3181dbb572] [Cited by in Crossref: 45] [Cited by in F6Publishing: 24] [Article Influence: 3.8] [Reference Citation Analysis]
276 Schleicher J, Dahmen U, Guthke R, Schuster S. Zonation of hepatic fat accumulation: insights from mathematical modelling of nutrient gradients and fatty acid uptake. J R Soc Interface 2017;14:20170443. [PMID: 28835543 DOI: 10.1098/rsif.2017.0443] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
277 Weingarten TN, Mantilla CB, Swain JM, Kendrick ML, Oberhansley JM, Burcham RJ, Ribeiro TC, Watt KD, Schroeder DR, Narr BJ. Nonalcoholic steatohepatitis in bariatric patients with a diagnosis of obstructive sleep apnea. Obes Facts. 2012;5:587-596. [PMID: 22986647 DOI: 10.1159/000342677] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
278 Serhal R, Hilal G, Boutros G, Sidaoui J, Wardi L, Ezzeddine S, Alaaeddine N. Nonalcoholic Steatohepatitis: Involvement of the Telomerase and Proinflammatory Mediators. Biomed Res Int 2015;2015:850246. [PMID: 26273651 DOI: 10.1155/2015/850246] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
279 Abe M, Miyake T, Kuno A, Imai Y, Sawai Y, Hino K, Hara Y, Hige S, Sakamoto M, Yamada G, Kage M, Korenaga M, Hiasa Y, Mizokami M, Narimatsu H. Association between Wisteria floribunda agglutinin-positive Mac-2 binding protein and the fibrosis stage of non-alcoholic fatty liver disease. J Gastroenterol 2015;50:776-84. [DOI: 10.1007/s00535-014-1007-2] [Cited by in Crossref: 104] [Cited by in F6Publishing: 102] [Article Influence: 13.0] [Reference Citation Analysis]
280 Lackner C, Tiniakos D. Fibrosis and alcohol-related liver disease. J Hepatol 2019;70:294-304. [PMID: 30658730 DOI: 10.1016/j.jhep.2018.12.003] [Cited by in Crossref: 61] [Cited by in F6Publishing: 48] [Article Influence: 30.5] [Reference Citation Analysis]
281 Masuoka HC, Chalasani N. Nonalcoholic fatty liver disease: an emerging threat to obese and diabetic individuals. Ann N Y Acad Sci. 2013;1281:106-122. [PMID: 23363012 DOI: 10.1111/nyas.12016] [Cited by in Crossref: 159] [Cited by in F6Publishing: 148] [Article Influence: 17.7] [Reference Citation Analysis]
282 Jaskiewicz K, Raczynska S, Rzepko R, Sledziński Z. Nonalcoholic fatty liver disease treated by gastroplasty. Dig Dis Sci 2006;51:21-6. [PMID: 16416204 DOI: 10.1007/s10620-006-3077-3] [Cited by in Crossref: 45] [Cited by in F6Publishing: 44] [Article Influence: 2.8] [Reference Citation Analysis]
283 Mookerjee RP, Wiesenthal A, Icking A, Hodges SJ, Davies NA, Schilling K, Sen S, Williams R, Novelli M, Müller-Esterl W, Jalan R. Increased gene and protein expression of the novel eNOS regulatory protein NOSTRIN and a variant in alcoholic hepatitis. Gastroenterology 2007;132:2533-41. [PMID: 17570224 DOI: 10.1053/j.gastro.2006.12.035] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 2.1] [Reference Citation Analysis]
284 Breuer DA, Pacheco MC, Washington MK, Montgomery SA, Hasty AH, Kennedy AJ. CD8+ T cells regulate liver injury in obesity-related nonalcoholic fatty liver disease. Am J Physiol Gastrointest Liver Physiol 2020;318:G211-24. [PMID: 31709830 DOI: 10.1152/ajpgi.00040.2019] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
285 Kuzu N, Bahcecioglu IH, Dagli AF, Ozercan IH, Ustündag B, Sahin K. Epigallocatechin gallate attenuates experimental non-alcoholic steatohepatitis induced by high fat diet. J Gastroenterol Hepatol 2008;23:e465-70. [PMID: 17683497 DOI: 10.1111/j.1440-1746.2007.05052.x] [Cited by in Crossref: 45] [Cited by in F6Publishing: 44] [Article Influence: 3.0] [Reference Citation Analysis]
286 De Ridder RJJ, Schoon EJ, Smulders JF, Van Hout GCM, Stockbrügger RW, Koek GH. Review article: non-alcoholic fatty liver disease in morbidly obese patients and the effect of bariatric surgery: REVIEW ARTICLE: EFFECT OF BARIATRIC SURGERY ON NAFLD. Alimentary Pharmacology & Therapeutics 2007;26:195-201. [DOI: 10.1111/j.1365-2036.2007.03483.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 1.5] [Reference Citation Analysis]
287 Hjelkrem M, Stauch C, Shaw J, Harrison SA. Validation of the non-alcoholic fatty liver disease activity score. Aliment Pharmacol Ther. 2011;34:214-218. [PMID: 21585409 DOI: 10.1111/j.1365-2036.2011.04695.x] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 3.5] [Reference Citation Analysis]
288 Lee YM, Sutedja DS, Wai CT, Dan YY, Aung MO, Zhou L, Cheng CL, Wee A, Lim SG. A randomized controlled pilot study of Pentoxifylline in patients with non-alcoholic steatohepatitis (NASH). Hepatol Int 2008;2:196-201. [PMID: 19669304 DOI: 10.1007/s12072-008-9058-1] [Cited by in Crossref: 49] [Cited by in F6Publishing: 49] [Article Influence: 3.5] [Reference Citation Analysis]
289 Chon YE, Jung KS, Kim SU, Park JY, Park YN, Kim DY, Ahn SH, Chon CY, Lee HW, Park Y. Controlled attenuation parameter (CAP) for detection of hepatic steatosis in patients with chronic liver diseases: a prospective study of a native Korean population. Liver Int. 2014;34:102-109. [PMID: 24028214 DOI: 10.1111/liv.12282] [Cited by in Crossref: 99] [Cited by in F6Publishing: 92] [Article Influence: 11.0] [Reference Citation Analysis]
290 Rodríguez-Suárez E, Duce AM, Caballería J, Martínez Arrieta F, Fernández E, Gómara C, Alkorta N, Ariz U, Martínez-Chantar ML, Lu SC. Non-alcoholic fatty liver disease proteomics. Proteomics Clin Appl. 2010;4:362-371. [PMID: 21137056 DOI: 10.1002/prca.200900119] [Cited by in Crossref: 35] [Cited by in F6Publishing: 35] [Article Influence: 2.9] [Reference Citation Analysis]
291 Barker KB, Palekar NA, Bowers SP, Goldberg JE, Pulcini JP, Harrison SA. Non-alcoholic steatohepatitis: effect of Roux-en-Y gastric bypass surgery. Am J Gastroenterol. 2006;101:368-373. [PMID: 16454845 DOI: 10.1111/j.1572-0241.2006.00419.x] [Cited by in Crossref: 148] [Cited by in F6Publishing: 132] [Article Influence: 9.3] [Reference Citation Analysis]
292 Yoneda M, Imajo K, Takahashi H, Ogawa Y, Eguchi Y, Sumida Y, Yoneda M, Kawanaka M, Saito S, Tokushige K, Nakajima A. Clinical strategy of diagnosing and following patients with nonalcoholic fatty liver disease based on invasive and noninvasive methods. J Gastroenterol 2018;53:181-96. [PMID: 29177681 DOI: 10.1007/s00535-017-1414-2] [Cited by in Crossref: 38] [Cited by in F6Publishing: 42] [Article Influence: 7.6] [Reference Citation Analysis]
293 Chiappini F, Barrier A, Saffroy R, Domart MC, Dagues N, Azoulay D, Sebagh M, Franc B, Chevalier S, Debuire B. Exploration of global gene expression in human liver steatosis by high-density oligonucleotide microarray. Lab Invest. 2006;86:154-165. [PMID: 16344856 DOI: 10.1038/labinvest.3700374] [Cited by in Crossref: 69] [Cited by in F6Publishing: 63] [Article Influence: 4.3] [Reference Citation Analysis]
294 Giannitrapani L, Ingrao S, Soresi M, Florena AM, La Spada E, Sandonato L, D'Alessandro N, Cervello M, Montalto G. Cyclooxygenase-2 expression in chronic liver diseases and hepatocellular carcinoma: an immunohistochemical study . Ann N Y Acad Sci 2009;1155:293-9. [PMID: 19250220 DOI: 10.1111/j.1749-6632.2009.03698.x] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 2.6] [Reference Citation Analysis]
295 Anty R, Hastier A, Canivet CM, Patouraux S, Schneck AS, Ferrari-Panaia P, Ben-Amor I, Saint-Paul MC, Gugenheim J, Gual P, Iannelli A, Tran A. Severe Vitamin D Deficiency Is Not Associated with Liver Damage in Morbidly Obese Patients. Obes Surg 2016;26:2138-43. [PMID: 26787197 DOI: 10.1007/s11695-016-2070-y] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 4.3] [Reference Citation Analysis]
296 Maurice JB, Goldin R, Hall A, Price JC, Sebastiani G, Morse CG, Prat L, Perazzo H, Garvey L, Ingiliz P, Guaraldi G, Tsochatzis E, Lemoine M. Increased BMI and Type 2 diabetes are the main predictors of NAFLD and advanced fibrosis in liver biopsies of patients with HIV mono-infection. Clin Infect Dis 2020:ciaa1302. [PMID: 32877569 DOI: 10.1093/cid/ciaa1302] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
297 Congiu M, Ryan MC, Desmond PV. No increase in the expression of key unfolded protein response genes in HCV genotype 3 patients with severe steatosis. Virus Res 2011;160:420-3. [PMID: 21741418 DOI: 10.1016/j.virusres.2011.06.019] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
298 Yang F, Jia X, Lei P, He Y, Xiang Y, Jiao J, Zhou S, Qian W, Duan Q. Quantification of hepatic steatosis in histologic images by deep learning method. J Xray Sci Technol 2019;27:1033-45. [PMID: 31744039 DOI: 10.3233/XST-190570] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
299 Duseja A, Das R, Nanda M, Das A, Garewal G, Chawla Y. Nonalcoholic steatohepatitis in Asian Indians is neither associated with iron overload nor with HFE gene mutations. World J Gastroenterol 2005; 11(3): 393-395 [PMID: 15637751 DOI: 10.3748/wjg.v11.i3.393] [Cited by in CrossRef: 36] [Cited by in F6Publishing: 35] [Article Influence: 2.1] [Reference Citation Analysis]
300 Akuta N, Kawamura Y, Watanabe C, Nishimura A, Okubo M, Mori Y, Fujiyama S, Sezaki H, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Suzuki F, Suzuki Y, Arase Y, Ikeda K, Kumada H. Impact of sodium glucose cotransporter 2 inhibitor on histological features and glucose metabolism of non-alcoholic fatty liver disease complicated by diabetes mellitus. Hepatol Res. 2019;49:531-539. [PMID: 30577089 DOI: 10.1111/hepr.13304] [Cited by in Crossref: 47] [Cited by in F6Publishing: 39] [Article Influence: 15.7] [Reference Citation Analysis]
301 Tuyama AC, Chang CY. Non-alcoholic fatty liver disease: Non-alcoholic fatty liver disease. Journal of Diabetes 2012;4:266-80. [DOI: 10.1111/j.1753-0407.2012.00204.x] [Cited by in Crossref: 37] [Cited by in F6Publishing: 31] [Article Influence: 3.7] [Reference Citation Analysis]
302 Masarone M, Rosato V, Aglitti A, Bucci T, Caruso R, Salvatore T, Sasso FC, Tripodi MF, Persico M. Liver biopsy in type 2 diabetes mellitus: Steatohepatitis represents the sole feature of liver damage. PLoS One 2017;12:e0178473. [PMID: 28570615 DOI: 10.1371/journal.pone.0178473] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 5.0] [Reference Citation Analysis]
303 Ravaioli F, Anstee QM. Editorial: collagen proportionate area as a prognostic indicator in NAFLD. Aliment Pharmacol Ther 2019;49:1452-4. [PMID: 31074901 DOI: 10.1111/apt.15249] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
304 Das S, Singh SP, Parida PK, Mallik RN. Non-alcoholic fatty liver disease in subjects with type 2 diabetes mellitus and non-diabetics with special reference to insulin resistance and hepatic histopathological changes. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 2010;4:226-9. [DOI: 10.1016/j.dsx.2010.07.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
305 Pennington KA, Harper JL, Sigafoos AN, Beffa LM, Carleton SM, Phillips CL, Schulz LC. Effect of food restriction and leptin supplementation on fetal programming in mice. Endocrinology 2012;153:4556-67. [PMID: 22778222 DOI: 10.1210/en.2012-1119] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 1.9] [Reference Citation Analysis]
306 Shetty A, Cho W, Alazawi W, Syn WK. Methotrexate Hepatotoxicity and the Impact of Nonalcoholic Fatty Liver Disease. Am J Med Sci 2017;354:172-81. [PMID: 28864376 DOI: 10.1016/j.amjms.2017.03.014] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 4.2] [Reference Citation Analysis]
307 Chevaliez S, Hézode C, Bahrami S, Grare M, Pawlotsky JM. Long-term hepatitis B surface antigen (HBsAg) kinetics during nucleoside/nucleotide analogue therapy: finite treatment duration unlikely. J Hepatol. 2013;58:676-683. [PMID: 23219442 DOI: 10.1016/j.jhep] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
308 Quiroga AD, Comanzo CG, Heit Barbini FJ, Lucci A, Vera MC, Lorenzetti F, Ferretti AC, Ceballos MP, Alvarez ML, Carrillo MC. IFN-α-2b treatment protects against diet-induced obesity and alleviates non-alcoholic fatty liver disease in mice. Toxicol Appl Pharmacol 2019;379:114650. [PMID: 31299271 DOI: 10.1016/j.taap.2019.114650] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
309 Trépo E, Gustot T, Degré D, Lemmers A, Verset L, Demetter P, Ouziel R, Quertinmont E, Vercruysse V, Amininejad L. Common polymorphism in the PNPLA3/adiponutrin gene confers higher risk of cirrhosis and liver damage in alcoholic liver disease. J Hepatol. 2011;55:906-912. [PMID: 21334404 DOI: 10.1016/j.jhep.2011.01.028] [Cited by in Crossref: 102] [Cited by in F6Publishing: 104] [Article Influence: 9.3] [Reference Citation Analysis]
310 Sasaki M, Itatsu K, Minato H, Takamura H, Ohta T, Nakanuma Y. Flare-up of Nonalcoholic Steatohepatitis After Hepatectomy Resulted in Hepatic Failure in a Patient with Type 2 Diabetes Mellitus. Dig Dis Sci 2007;52:3473-6. [DOI: 10.1007/s10620-006-9662-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
311 Kim HC, Choi SH, Shin HW, Cheong JY, Lee KW, Lee HC, Huh KB, Kim DJ. Severity of ultrasonographic liver steatosis and metabolic syndrome in Korean men and women. World J Gastroenterol 2005; 11(34): 5314-5321 [PMID: 16149138 DOI: 10.3748/wjg.v11.i34.5314] [Cited by in CrossRef: 29] [Cited by in F6Publishing: 28] [Article Influence: 1.7] [Reference Citation Analysis]
312 Tran TT, Changsri C, Shackleton CR, Poordad FF, Nissen NN, Colquhoun S, Geller SA, Vierling JM, Martin P. Living donor liver transplantation: histological abnormalities found on liver biopsies of apparently healthy potential donors. J Gastroenterol Hepatol 2006;21:381-3. [PMID: 16509862 DOI: 10.1111/j.1440-1746.2005.03968.x] [Cited by in Crossref: 58] [Cited by in F6Publishing: 38] [Article Influence: 3.6] [Reference Citation Analysis]
313 Loomba R, Abraham M, Unalp A, Wilson L, Lavine J, Doo E, Bass NM; Nonalcoholic Steatohepatitis Clinical Research Network. Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis. Hepatology 2012;56:943-51. [PMID: 22505194 DOI: 10.1002/hep.25772] [Cited by in Crossref: 261] [Cited by in F6Publishing: 259] [Article Influence: 26.1] [Reference Citation Analysis]
314 Liccardo D, Mosca A, Petroni S, Valente P, Giordano U, Mico' AG, Pescosolido S, Buzzonetti L, Nobili V. The association between retinal microvascular changes, metabolic risk factors, and liver histology in pediatric patients with non-alcoholic fatty liver disease (NAFLD). J Gastroenterol 2015;50:903-12. [PMID: 25516385 DOI: 10.1007/s00535-014-1024-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
315 Ilamathi M, Prabu P, Ayyappa KA, Sivaramakrishnan V. Artesunate obliterates experimental hepatocellular carcinoma in rats through suppression of IL-6-JAK-STAT signalling. Biomedicine & Pharmacotherapy 2016;82:72-9. [DOI: 10.1016/j.biopha.2016.04.061] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
316 Xu Z, Li Y, Wang J, Wu B, Li J. Effect of omega-3 polyunsaturated fatty acids to reverse biopsy-proven parenteral nutrition-associated liver disease in adults. Clin Nutr. 2012;31:217-223. [PMID: 22035955 DOI: 10.1016/j.clnu.2011.10.001] [Cited by in Crossref: 55] [Cited by in F6Publishing: 47] [Article Influence: 5.0] [Reference Citation Analysis]
317 Solga S, Alkhuraishe AR, Clark JM, Torbenson M, Greenwald A, Diehl AM, Magnuson T. Dietary composition and nonalcoholic fatty liver disease. Dig Dis Sci. 2004;49:1578-1583. [PMID: 15573908 DOI: 10.1023/b:ddas.0000043367.69470.b7] [Cited by in Crossref: 144] [Cited by in F6Publishing: 56] [Article Influence: 8.0] [Reference Citation Analysis]
318 Okanoue T, Yamauchi N, Furutani M, Hirohama A, Sumida Y, Nakashima T. Predictors of Nonalcoholic Steatohepatitis in Japanese Patients: Thioredoxin and NASH. In: Okita K, editor. NASH and Nutritional Therapy. Tokyo: Springer-Verlag; 2005. pp. 64-72. [DOI: 10.1007/4-431-27172-4_5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
319 Dolman GE, Nieboer D, Steyerberg EW, Harris S, Ferguson A, Zaitoun AM, Ryder SD, James MW, Aithal GP, Guha IN. The performance of transient elastography compared to clinical acumen and routine tests - what is the incremental diagnostic value? Liver Int 2013;33:172-9. [DOI: 10.1111/liv.12017] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
320 Syn W, Nightingale P, Gunson B, Hubscher SG, Neuberger JM. Natural history of unexplained chronic hepatitis after liver transplantation. Liver Transpl 2007;13:984-9. [DOI: 10.1002/lt.21108] [Cited by in Crossref: 51] [Cited by in F6Publishing: 38] [Article Influence: 3.4] [Reference Citation Analysis]
321 Kitajima Y, Hyogo H, Sumida Y, Eguchi Y, Ono N, Kuwashiro T, Tanaka K, Takahashi H, Mizuta T, Ozaki I, Eguchi T, Kimura Y, Fujimoto K, Anzai K; Japan Nonalcoholic Fatty Liver Disease Study Group (JSG-NAFLD). Severity of non-alcoholic steatohepatitis is associated with substitution of adipose tissue in skeletal muscle. J Gastroenterol Hepatol. 2013;28:1507-1514. [PMID: 23577962 DOI: 10.1111/jgh.12227] [Cited by in Crossref: 63] [Cited by in F6Publishing: 62] [Article Influence: 7.9] [Reference Citation Analysis]
322 Tilg H, Kaser A. Treatment strategies in nonalcoholic fatty liver disease. Nat Clin Pract Gastroenterol Hepatol. 2005;2:148-155. [PMID: 16265156 DOI: 10.1038/ncpgasthep0116] [Cited by in Crossref: 46] [Cited by in F6Publishing: 47] [Article Influence: 2.7] [Reference Citation Analysis]
323 Pummoung S, Werawatganon D, Chayanupatkul M, Klaikeaw N, Siriviriyakul P. Genistein Modulated Lipid Metabolism, Hepatic PPARγ, and Adiponectin Expression in Bilateral Ovariectomized Rats with Nonalcoholic Steatohepatitis (NASH). Antioxidants (Basel) 2020;10:E24. [PMID: 33383845 DOI: 10.3390/antiox10010024] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
324 Burgueño AL, Cabrerizo R, Gonzales Mansilla N, Sookoian S, Pirola CJ. Maternal high-fat intake during pregnancy programs metabolic-syndrome-related phenotypes through liver mitochondrial DNA copy number and transcriptional activity of liver PPARGC1A. J Nutr Biochem 2013;24:6-13. [PMID: 22658649 DOI: 10.1016/j.jnutbio.2011.12.008] [Cited by in Crossref: 70] [Cited by in F6Publishing: 63] [Article Influence: 7.0] [Reference Citation Analysis]
325 Geng C, Zhang Y, Gao Y, Tao W, Zhang H, Liu X, Fang F, Chang Y. Mst1 regulates hepatic lipid metabolism by inhibiting Sirt1 ubiquitination in mice. Biochem Biophys Res Commun 2016;471:444-9. [PMID: 26903296 DOI: 10.1016/j.bbrc.2016.02.059] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
326 Qureshi K, Clements RH, Saeed F, Abrams GA. Comparative evaluation of whole body and hepatic insulin resistance using indices from oral glucose tolerance test in morbidly obese subjects with nonalcoholic Fatty liver disease. J Obes 2010;2010:741521. [PMID: 20798875 DOI: 10.1155/2010/741521] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
327 Alkhouri N, Morris-Stiff G, Campbell C, Lopez R, Tamimi TA, Yerian L, Zein NN, Feldstein AE. Neutrophil to lymphocyte ratio: a new marker for predicting steatohepatitis and fibrosis in patients with nonalcoholic fatty liver disease. Liver Int. 2012;32:297-302. [PMID: 22097893 DOI: 10.1111/j.1478-3231.2011.02639.x] [Cited by in Crossref: 135] [Cited by in F6Publishing: 141] [Article Influence: 12.3] [Reference Citation Analysis]
328 Agrawal S, Daruwala C. Metabolic syndrome and hepatic resection: improving outcome. HPB (Oxford). 2011;13:846-859. [PMID: 22081919 DOI: 10.1111/j.1477-2574.2011.00380.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
329 Valdecantos MP, Ruiz L, Pardo V, Castro-Sanchez L, García-Monzón C, Lanzón B, Rupérez J, Barbas C, Naylor J, Trevaskis JL, Grimsby J, Rondinone CM, Valverde ÁM. Differential Effects of a Glucagon-Like Peptide 1 Receptor Agonist in Non-Alcoholic Fatty Liver Disease and in Response to Hepatectomy. Sci Rep 2018;8:16461. [PMID: 30405191 DOI: 10.1038/s41598-018-33949-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
330 Papatheodoridis GV, Hadziyannis E, Tsochatzis E, Georgiou A, Kafiri G, Tiniakos DG, Margariti K, Manolakopoulos S, Manesis EK, Archimandritis AJ. Serum apoptotic caspase activity in chronic hepatitis C and nonalcoholic Fatty liver disease. J Clin Gastroenterol. 2010;44:e87-e95. [PMID: 19881359 DOI: 10.1097/mcg.0b013e3181c0945a] [Cited by in Crossref: 28] [Cited by in F6Publishing: 21] [Article Influence: 2.3] [Reference Citation Analysis]
331 Di Bisceglie AM, Sterling RK, Chung RT, Everhart JE, Dienstag JL, Bonkovsky HL, Wright EC, Everson GT, Lindsay KL, Lok AS. Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C Trial. J Hepatol. 2005;43:434-441. [PMID: 16136646 DOI: 10.1016/j.jhep.2005.03.019] [Cited by in Crossref: 208] [Cited by in F6Publishing: 195] [Article Influence: 12.2] [Reference Citation Analysis]
332 Harman DJ, Kaye PV, Harris R, Suzuki A, Gazis A, Aithal GP. Prevalence and natural history of histologically proven chronic liver disease in a longitudinal cohort of patients with type 1 diabetes. Hepatology 2014;60:158-68. [DOI: 10.1002/hep.27098] [Cited by in Crossref: 22] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
333 Pagano C, Soardo G, Esposito W, Fallo F, Basan L, Donnini D, Federspil G, Sechi LA, Vettor R. Plasma adiponectin is decreased in nonalcoholic fatty liver disease. Eur J Endocrinol. 2005;152:113-118. [PMID: 15762194 DOI: 10.1530/eje.1.01821] [Cited by in Crossref: 173] [Cited by in F6Publishing: 169] [Article Influence: 10.2] [Reference Citation Analysis]
334 Hünigen H, Mainzer K, Hirschberg RM, Custodis P, Gemeinhardt O, Al Masri S, Richardson KC, Hafez HM, Plendl J. Structure and age-dependent development of the turkey liver: a comparative study of a highly selected meat-type and a wild-type turkey line. Poult Sci 2016;95:901-11. [PMID: 26908884 DOI: 10.3382/ps/pev358] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
335 Liu F, Zhao J, Rao H, Yu W, Zhang W, Theise ND, Wee A, Wei L. Second Harmonic Generation Reveals Subtle Fibrosis Differences in Adult and Pediatric Nonalcoholic Fatty Liver Disease. American Journal of Clinical Pathology 2017;148:502-12. [DOI: 10.1093/ajcp/aqx104] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
336 Lemoine M, Ratziu V, Kim M, Maachi M, Wendum D, Paye F, Bastard JP, Poupon R, Housset C, Capeau J. Serum adipokine levels predictive of liver injury in non-alcoholic fatty liver disease. Liver Int. 2009;29:1431-1438. [PMID: 19422483 DOI: 10.1111/j.1478-3231.2009.02022.x] [Cited by in Crossref: 93] [Cited by in F6Publishing: 92] [Article Influence: 7.2] [Reference Citation Analysis]
337 Ratziu V, Charlotte F, Heurtier A, Gombert S, Giral P, Bruckert E, Grimaldi A, Capron F, Poynard T;  LIDO Study Group. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology. 2005;128:1898-1906. [PMID: 15940625 DOI: 10.1053/j.gastro.2005.03.084] [Cited by in Crossref: 1184] [Cited by in F6Publishing: 1125] [Article Influence: 69.6] [Reference Citation Analysis]
338 Bressler B. High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. Hepatology 2003;38:639-44. [DOI: 10.1053/jhep.2003.50350] [Cited by in Crossref: 254] [Cited by in F6Publishing: 243] [Article Influence: 13.4] [Reference Citation Analysis]
339 Gerhard GS, Chokshi R, Still CD, Benotti P, Wood GC, Freedman-Weiss M, Rider C, Petrick AT. The influence of iron status and genetic polymorphisms in the HFE gene on the risk for postoperative complications after bariatric surgery: a prospective cohort study in 1,064 patients. Patient Saf Surg 2011;5:1. [PMID: 21219652 DOI: 10.1186/1754-9493-5-1] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
340 Öztürk H, Gümrükçüoğlu HA, Yaman M, Akyol A, Öztürk Ş, Akdağ S, Şimşek H, Şahin M, Günaydın ZY. Hepatosteatosis and carotid intima-media thickness in patients with myocardial infarction. J Med Ultrason (2001) 2016;43:77-82. [PMID: 26703170 DOI: 10.1007/s10396-015-0649-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
341 de Mello VD, Matte A, Perfilyev A, Männistö V, Rönn T, Nilsson E, Käkelä P, Ling C, Pihlajamäki J. Human liver epigenetic alterations in non-alcoholic steatohepatitis are related to insulin action. Epigenetics 2017;12:287-95. [PMID: 28277977 DOI: 10.1080/15592294.2017.1294305] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 6.8] [Reference Citation Analysis]
342 Aller R, Fernández-Rodríguez C, Lo Iacono O, Bañares R, Abad J, Carrión JA, García-Monzón C, Caballería J, Berenguer M, Rodríguez-Perálvarez M, Miranda JL, Vilar-Gómez E, Crespo J, García-Cortés M, Reig M, Navarro JM, Gallego R, Genescà J, Arias-Loste MT, Pareja MJ, Albillos A, Muntané J, Jorquera F, Solà E, Hernández-Guerra M, Rojo MÁ, Salmerón J, Caballería L, Diago M, Molina E, Bataller R, Romero-Gómez M. Consensus document. Management of non-alcoholic fatty liver disease (NAFLD). Clinical practice guideline. Gastroenterol Hepatol 2018;41:328-49. [PMID: 29631866 DOI: 10.1016/j.gastrohep.2017.12.003] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 5.8] [Reference Citation Analysis]
343 Fukushima N, Kuromatsu R, Arinaga-Hino T, Ando E, Takata A, Sumie S, Nakano M, Kawaguchi T, Ide T, Torimura T. Adipocytokine involvement in hepatocellular carcinoma after sustained response to interferon for chronic hepatitis C. Hepatol Res. 2010;40:911-922. [PMID: 20887596 DOI: 10.1111/j.1872-034x.2010.00699.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
344 Oliveira A, Fernandes SA, Carteri RB, Tovo CV. EVALUATION OF REST ENERGY EXPENDITURE IN PATIENTS WITH NON ALCOHOLIC FATTY LIVER DISEASE. Arq Gastroenterol 2021;58:157-63. [PMID: 34190778 DOI: 10.1590/S0004-2803.202100000-27] [Reference Citation Analysis]
345 Piciocchi M, Cardin R, Cillo U, Vitale A, Cappon A, Mescoli C, Guido M, Rugge M, Burra P, Floreani A, Farinati F. Differential timing of oxidative DNA damage and telomere shortening in hepatitis C and B virus-related liver carcinogenesis. Transl Res 2016;168:122-33. [PMID: 26408804 DOI: 10.1016/j.trsl.2015.08.012] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
346 Pooler BD, Wiens CN, McMillan A, Artz NS, Schlein A, Covarrubias Y, Hooker J, Schwimmer JB, Funk LM, Campos GM, Greenberg JA, Jacobsen G, Horgan S, Wolfson T, Gamst AC, Sirlin CB, Reeder SB. Monitoring Fatty Liver Disease with MRI Following Bariatric Surgery: A Prospective, Dual-Center Study. Radiology 2019;290:682-90. [PMID: 30561273 DOI: 10.1148/radiol.2018181134] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
347 Festi D, Schiumerini R, Marasco G, Scaioli E, Pasqui F, Colecchia A. Non-invasive diagnostic approach to non-alcoholic fatty liver disease: current evidence and future perspectives. Expert Review of Gastroenterology & Hepatology 2015;9:1039-53. [DOI: 10.1586/17474124.2015.1049155] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
348 Potts JR, Verma S. Alcoholic hepatitis: diagnosis and management in 2012. Expert Rev Gastroenterol Hepatol. 2012;6:695-710. [PMID: 23237255 DOI: 10.1586/egh.12.57] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
349 Sahn B, De Matos V, Stein R, Ruchelli E, Masur S, Klink AJ, Baldassano RN, Piccoli DA, Russo P, Mamula P. Histological features of ileitis differentiating pediatric Crohn disease from ulcerative colitis with backwash ileitis. Dig Liver Dis 2018;50:147-53. [PMID: 29089273 DOI: 10.1016/j.dld.2017.10.006] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
350 Daemen S, Gainullina A, Kalugotla G, He L, Chan MM, Beals JW, Liss KH, Klein S, Feldstein AE, Finck BN, Artyomov MN, Schilling JD. Dynamic Shifts in the Composition of Resident and Recruited Macrophages Influence Tissue Remodeling in NASH. Cell Rep 2021;34:108626. [PMID: 33440159 DOI: 10.1016/j.celrep.2020.108626] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 14.0] [Reference Citation Analysis]
351 Zamin Jr. I, Mattos AAD, Mattos ÂZD, Migon E, Soares E, Perry MLS. Modelo experimental de esteatohepatite não-alcoólica com dieta deficiente em metionina e colina. Arq Gastroenterol 2009;46:69-74. [DOI: 10.1590/s0004-28032009000100017] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
352 Lonardo A, Loria P, Leonardi F, Borsatti A, Neri P, Pulvirenti M, Verrone A, Bagni A, Bertolotti M, Ganazzi D, Carulli N. Fasting insulin and uric acid levels but not indices of iron metabolism are independent predictors of non-alcoholic fatty liver disease. A case-control study. Digestive and Liver Disease 2002;34:204-11. [DOI: 10.1016/s1590-8658(02)80194-3] [Cited by in Crossref: 78] [Cited by in F6Publishing: 32] [Article Influence: 3.9] [Reference Citation Analysis]
353 Kim SU, Kim JK, Park YN, Han KH. Discordance between liver biopsy and Fibroscan® in assessing liver fibrosis in chronic hepatitis b: risk factors and influence of necroinflammation. PLoS One. 2012;7:e32233. [PMID: 22384189 DOI: 10.1371/journal.pone.0032233] [Cited by in Crossref: 31] [Cited by in F6Publishing: 41] [Article Influence: 3.1] [Reference Citation Analysis]
354 Henry ZH, Argo CK. How to Identify the Patient with Nonalcoholic Steatohepatitis Who Will Progress to Cirrhosis. Gastroenterology Clinics of North America 2020;49:45-62. [DOI: 10.1016/j.gtc.2019.09.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
355 Uslusoy HS, Nak SG, Gülten M. Noninvasive predictors for liver fibrosis in patients with nonalcoholic steatohepatitis. World J Hepatol 2011; 3(8): 219-227 [PMID: 21954411 DOI: 10.4254/wjh.v3.i8.219] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
356 Du J, Cao X, Diao J, Zhang Q, Peng C, Li J, Xiao X. Neonatal overfeeding in mice aggravates the development of methionine and choline-deficient diet-induced steatohepatitis in adulthood. Genes Dis 2019;6:68-77. [PMID: 30906835 DOI: 10.1016/j.gendis.2017.12.008] [Reference Citation Analysis]
357 Wang W, Zhou W, Wang B, Zhu H, Ye L, Feng M. Antioxidant effect of apolipoprotein A-I on high-fat diet-induced non-alcoholic fatty liver disease in rabbits. Acta Biochim Biophys Sin (Shanghai) 2013;45:95-103. [PMID: 23174676 DOI: 10.1093/abbs/gms100] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
358 Morikawa R, Nakamoto N, Amiya T, Chu PS, Koda Y, Teratani T, Suzuki T, Kurebayashi Y, Ueno A, Taniki N, Miyamoto K, Yamaguchi A, Shiba S, Katayama T, Yoshida K, Takada Y, Ishihara R, Ebinuma H, Sakamoto M, Kanai T. Role of CC chemokine receptor 9 in the progression of murine and human non-alcoholic steatohepatitis. J Hepatol 2021;74:511-21. [PMID: 33038434 DOI: 10.1016/j.jhep.2020.09.033] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
359 Hines CD, Yu H, Shimakawa A, McKenzie CA, Warner TF, Brittain JH, Reeder SB. Quantification of hepatic steatosis with 3-T MR imaging: validation in ob/ob mice. Radiology 2010;254:119-28. [PMID: 20032146 DOI: 10.1148/radiol.09090131] [Cited by in Crossref: 64] [Cited by in F6Publishing: 60] [Article Influence: 5.3] [Reference Citation Analysis]
360 Park M, Jang H, Lee J, Lee Y, Kim J, Park J, Park D. Effect of Hog Millet Supplementation on Hepatic Steatosis and Insulin Resistance in Mice Fed a High-fat Diet. Journal of the Korean Society of Food Science and Nutrition 2012;41:501-9. [DOI: 10.3746/jkfn.2012.41.4.501] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
361 Ortiz M, Soto-Alarcón SA, Orellana P, Espinosa A, Campos C, López-Arana S, Rincón MA, Illesca P, Valenzuela R, Videla LA. Suppression of high-fat diet-induced obesity-associated liver mitochondrial dysfunction by docosahexaenoic acid and hydroxytyrosol co-administration. Dig Liver Dis 2020;52:895-904. [PMID: 32620521 DOI: 10.1016/j.dld.2020.04.019] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 11.0] [Reference Citation Analysis]
362 Yin M, Glaser KJ, Talwalkar JA, Chen J, Manduca A, Ehman RL. Hepatic MR Elastography: Clinical Performance in a Series of 1377 Consecutive Examinations. Radiology. 2016;278:114-124. [PMID: 26162026 DOI: 10.1148/radiol.2015142141] [Cited by in Crossref: 156] [Cited by in F6Publishing: 136] [Article Influence: 22.3] [Reference Citation Analysis]
363 Satkunasingham J, Besa C, Bane O, Shah A, de Oliveira A, Gilson WD, Kannengiesser S, Taouli B. Liver fat quantification: Comparison of dual-echo and triple-echo chemical shift MRI to MR spectroscopy. Eur J Radiol. 2015;84:1452-1458. [PMID: 26047820 DOI: 10.1016/j.ejrad.2015.05.001] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
364 Jacome-Sosa MM, Borthwick F, Mangat R, Uwiera R, Reaney MJ, Shen J, Quiroga AD, Jacobs RL, Lehner R, Proctor SD. Diets enriched in trans-11 vaccenic acid alleviate ectopic lipid accumulation in a rat model of NAFLD and metabolic syndrome. J Nutr Biochem. 2014;25:692-701. [PMID: 24775093 DOI: 10.1016/j.jnutbio.2014.02.011] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 5.5] [Reference Citation Analysis]
365 Rastogi R, Gupta S, Garg B, Vohra S, Wadhawan M, Rastogi H. Comparative accuracy of CT, dual-echo MRI and MR spectroscopy for preoperative liver fat quantification in living related liver donors. Indian J Radiol Imaging 2016;26:5-14. [PMID: 27081218 DOI: 10.4103/0971-3026.178281] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
366 Sebastiani G, Gkouvatsos K, Plebani M. Non-invasive assessment of liver fibrosis: it is time for laboratory medicine. Clin Chem Lab Med. 2011;49:13-32. [PMID: 20961196 DOI: 10.1515/cclm.2011.001] [Cited by in Crossref: 16] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
367 Okamoto K, Koda M, Okamoto T, Onoyama T, Miyoshi K, Kishina M, Matono T, Kato J, Tokunaga S, Sugihara T, Hiramatsu A, Hyogo H, Tobita H, Sato S, Kawanaka M, Hara Y, Hino K, Chayama K, Murawaki Y, Isomoto H. Serum miR-379 expression is related to the development and progression of hypercholesterolemia in non-alcoholic fatty liver disease. PLoS One 2020;15:e0219412. [PMID: 32106257 DOI: 10.1371/journal.pone.0219412] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
368 Tsang SWC, Ng WF, Wu BPY, Chow DA, Li ETH, Wong TC. Predictors of fibrosis in Asian patients with non-alcoholic steatohepatitis. Journal of Gastroenterology and Hepatology 2006;21:116-21. [DOI: 10.1111/j.1440-1746.2005.04146.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 1.4] [Reference Citation Analysis]
369 Lackner C. Hepatocellular ballooning in nonalcoholic steatohepatitis: the pathologist’s perspective. Expert Rev Gastroenterol Hepatol. 2011;5:223-231. [PMID: 21476917 DOI: 10.1586/egh.11.8] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 3.6] [Reference Citation Analysis]
370 Tannapfel A, Denk H, Dienes HP, Langner C, Schirmacher P, Trauner M, Flott-Rahmel B. [Histopathological diagnosis of non-alcoholic and alcoholic fatty liver disease. Grade 2 consensus-based guidelines]. Pathologe. 2010;31:225-237. [PMID: 20221762 DOI: 10.1007/s00292-010-1298-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.1] [Reference Citation Analysis]
371 Hamaguchi M, Takeda N, Kojima T, Ohbora A, Kato T, Sarui H, Fukui M, Nagata C, Takeda J. Identification of individuals with non-alcoholic fatty liver disease by the diagnostic criteria for the metabolic syndrome. World J Gastroenterol 2012; 18(13): 1508-1516 [PMID: 22509083 DOI: 10.3748/wjg.v18.i13.1508] [Cited by in CrossRef: 52] [Cited by in F6Publishing: 55] [Article Influence: 5.2] [Reference Citation Analysis]
372 Nishikawa H, Enomoto H, Iwata Y, Kishino K, Shimono Y, Hasegawa K, Nakano C, Takata R, Yoh K, Nishimura T, Aizawa N, Sakai Y, Ikeda N, Takashima T, Ishii A, Iijima H, Nakamura H, Nishiguchi S. Clinical significance of serum Wisteria floribunda agglutinin positive Mac-2-binding protein level in non-alcoholic steatohepatitis. Hepatol Res 2016;46:1194-202. [PMID: 26836229 DOI: 10.1111/hepr.12662] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 4.2] [Reference Citation Analysis]
373 Roskams T, Yang SQ, Koteish A, Durnez A, DeVos R, Huang X, Achten R, Verslype C, Diehl AM. Oxidative stress and oval cell accumulation in mice and humans with alcoholic and nonalcoholic fatty liver disease. Am J Pathol. 2003;163:1301-1311. [PMID: 14507639 DOI: 10.1016/s0002-9440(10)63489-x] [Cited by in Crossref: 292] [Cited by in F6Publishing: 130] [Article Influence: 15.4] [Reference Citation Analysis]
374 Kukla M, Adamek B, Waluga M, Zalewska-Ziob M, Kasperczyk J, Gabriel A, Mazur W, Sobala-Szczygieł B, Bułdak RJ, Zajęcki W, Kępa L, Ziora K, Żwirska-Korczala K, Wiczkowski A, Hartleb M. Hepatic chemerin and chemokine-like receptor 1 expression in patients with chronic hepatitis C. Biomed Res Int 2014;2014:517820. [PMID: 25121101 DOI: 10.1155/2014/517820] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
375 Heit C, Marshall S, Singh S, Yu X, Charkoftaki G, Zhao H, Orlicky DJ, Fritz KS, Thompson DC, Vasiliou V. Catalase deletion promotes prediabetic phenotype in mice. Free Radic Biol Med 2017;103:48-56. [PMID: 27939935 DOI: 10.1016/j.freeradbiomed.2016.12.011] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 5.0] [Reference Citation Analysis]
376 Hussein O, Szvalb S, Van den Akker-Berman LM, Assy N. Liver regeneration is not altered in patients with nonalcoholic steatohepatitis (NASH) when compared to chronic hepatitis C infection with similar grade of inflammation. Dig Dis Sci 2002;47:1926-31. [PMID: 12353831 DOI: 10.1023/a:1019679603042] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
377 Weingarten TN, Swain JM, Kendrick ML, Charlton MR, Schroeder BJ, Lee RE, Narr BJ, Ribeiro TC, Schroeder DR, Sprung J. Nonalcoholic steatohepatitis (NASH) does not increase complications after laparoscopic bariatric surgery. Obes Surg. 2011;21:1714-1720. [PMID: 21948267 DOI: 10.1007/s11695-011-0521-z] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 3.2] [Reference Citation Analysis]
378 Mori S, Arima N, Ito M, Fujiyama S, Kamo Y, Ueki Y. Non-alcoholic steatohepatitis-like pattern in liver biopsy of rheumatoid arthritis patients with persistent transaminitis during low-dose methotrexate treatment. PLoS One 2018;13:e0203084. [PMID: 30142184 DOI: 10.1371/journal.pone.0203084] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
379 Torbenson M, Washington K. Pathology of liver disease: advances in the last 50 years. Hum Pathol 2020;95:78-98. [PMID: 31493428 DOI: 10.1016/j.humpath.2019.08.023] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
380 Saberi B, Dadabhai AS, Nanavati J, Wang L, Shinohara RT, Mullin GE. Vitamin D levels do not predict the stage of hepatic fibrosis in patients with non-alcoholic fatty liver disease: A PRISMA compliant systematic review and meta-analysis of pooled data. World J Hepatol 2018; 10(1): 142-154 [PMID: 29399288 DOI: 10.4254/wjh.v10.i1.142] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
381 Kugler N, Klein K, Zanger UM. MiR-155 and other microRNAs downregulate drug metabolizing cytochromes P450 in inflammation. Biochem Pharmacol 2020;171:113725. [PMID: 31758923 DOI: 10.1016/j.bcp.2019.113725] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
382 Heritage M, Jaskowski L, Bridle K, Campbell C, Briskey D, Britton L, Fletcher L, Vitetta L, Subramaniam VN, Crawford D. Combination curcumin and vitamin E treatment attenuates diet-induced steatosis in Hfe-/- mice. World J Gastrointest Pathophysiol 2017; 8(2): 67-76 [PMID: 28573069 DOI: 10.4291/wjgp.v8.i2.67] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
383 Fotiadu A, Gagalis A, Akriviadis E, Kotoula V, Sinakos E, Karkavelas G, Hytiroglou P. Clinicopathological correlations in a series of adult patients with non-alcoholic fatty liver disease. Pathol Int 2010;60:87-92. [PMID: 20398192 DOI: 10.1111/j.1440-1827.2009.02489.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
384 Goodman ZD. Grading and staging systems for inflammation and fibrosis in chronic liver diseases. J Hepatol. 2007;47:598-607. [PMID: 17692984 DOI: 10.1016/j.jhep.2007.07.006] [Cited by in Crossref: 444] [Cited by in F6Publishing: 390] [Article Influence: 29.6] [Reference Citation Analysis]
385 Sookoian S, Castaño G, Gianotti TF, Gemma C, Pirola CJ. Polymorphisms of MRP2 (ABCC2) are associated with susceptibility to nonalcoholic fatty liver disease. J Nutr Biochem 2009;20:765-70. [PMID: 18926681 DOI: 10.1016/j.jnutbio.2008.07.005] [Cited by in Crossref: 42] [Cited by in F6Publishing: 39] [Article Influence: 3.0] [Reference Citation Analysis]
386 Rensen SS, Slaats Y, Nijhuis J, Jans A, Bieghs V, Driessen A, Malle E, Greve JW, Buurman WA. Increased hepatic myeloperoxidase activity in obese subjects with nonalcoholic steatohepatitis. Am J Pathol. 2009;175:1473-1482. [PMID: 19729473 DOI: 10.2353/ajpath.2009.080999] [Cited by in Crossref: 131] [Cited by in F6Publishing: 132] [Article Influence: 10.1] [Reference Citation Analysis]
387 Miyaoka H, Michitaka K, Tokumoto Y, Miyake T, Shigematsu S, Soga Y, Abe M, Hiasa Y, Matsuura B, Horiike N, Onji M. LAPAROSCOPIC FEATURES AND INTEROBSERVER VARIATION OF HISTOLOGICAL DIAGNOSIS IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE: LAPAROSCOPY AND HISTOLOGY OF NAFLD. Digestive Endoscopy 2008;20:22-8. [DOI: 10.1111/j.1443-1661.2007.00771.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
388 Miele L, Cammarota G, Vero V, Racco S, Cefalo C, Marrone G, Pompili M, Rapaccini G, Bianco A, Landolfi R, Gasbarrini A, Grieco A. Non-alcoholic fatty liver disease is associated with high prevalence of gastro-oesophageal reflux symptoms. Dig Liver Dis 2012;44:1032-6. [PMID: 22963909 DOI: 10.1016/j.dld.2012.08.005] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
389 Malnick SD, Beergabel M, Knobler H. Non-alcoholic fatty liver: a common manifestation of a metabolic disorder. QJM. 2003;96:699-709. [PMID: 14500857 DOI: 10.1093/qjmed/hcg120] [Cited by in Crossref: 35] [Cited by in F6Publishing: 28] [Article Influence: 1.8] [Reference Citation Analysis]
390 Li M, Shen Z, Li YM. Potential role of Helicobacter pylori infection in nonalcoholic fatty liver disease. World J Gastroenterol 2013; 19(41): 7024-7031 [PMID: 24222944 DOI: 10.3748/wjg.v19.i41.7024] [Cited by in CrossRef: 27] [Cited by in F6Publishing: 25] [Article Influence: 3.0] [Reference Citation Analysis]
391 Méndez-sánchez N, Almeda-valdés P, Uribe M. Alcoholic liver disease. An update. Annals of Hepatology 2005;4:32-42. [DOI: 10.1016/s1665-2681(19)32083-6] [Cited by in Crossref: 21] [Article Influence: 1.2] [Reference Citation Analysis]
392 Alam S, Noor-E-Alam SM, Chowdhury ZR, Alam M, Kabir J. Nonalcoholic steatohepatitis in nonalcoholic fatty liver disease patients of Bangladesh. World J Hepatol 2013; 5(5): 281-287 [PMID: 23717739 DOI: 10.4254/wjh.v5.i5.281] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 2.1] [Reference Citation Analysis]
393 Canbakan B, Tahan V, Balci H, Hatemi I, Erer B, Ozbay G, Sut N, Hacibekiroglu M, Imeryuz N, Senturk H. Leptin in nonalcoholic fatty liver disease. Annals of Hepatology 2008;7:249-54. [DOI: 10.1016/s1665-2681(19)31856-3] [Cited by in Crossref: 32] [Article Influence: 2.3] [Reference Citation Analysis]
394 Liechti F, Dufour J. Treatment of NASH with ursodeoxycholic acid: Cons. Clinics and Research in Hepatology and Gastroenterology 2012;36:S46-52. [DOI: 10.1016/s2210-7401(12)70021-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
395 Brunt EM. Nonalcoholic steatohepatitis: pathologic features and differential diagnosis. Seminars in Diagnostic Pathology 2005;22:330-8. [DOI: 10.1053/j.semdp.2006.04.002] [Cited by in Crossref: 58] [Cited by in F6Publishing: 57] [Article Influence: 3.4] [Reference Citation Analysis]
396 Tzifi F, Fretzayas A, Chrousos G, Kanaka-Gantenbein C. Non-alcoholic fatty liver infiltration in children: an underdiagnosed evolving disease. Hormones (Athens) 2019;18:255-65. [PMID: 31140156 DOI: 10.1007/s42000-019-00107-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
397 Schmitt-Graeff A, Jing R, Nitschke R, Desmoulière A, Skalli O. Synemin expression is widespread in liver fibrosis and is induced in proliferating and malignant biliary epithelial cells. Hum Pathol. 2006;37:1200-1210. [PMID: 16938526 DOI: 10.1016/j.humpath.2006.04.017] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 1.6] [Reference Citation Analysis]
398 Gómez Dorronsoro ML, Vera R, Ortega L, Plaza C, Miquel R, García M, Díaz E, Ortiz MR, Pérez J, Hörndler C, Villar C, Antúnez J, Pereira S, López-Rios F, González-Cámpora R. Recommendations of a group of experts for the pathological assessment of tumour regression of liver metastases of colorectal cancer and damage of non-tumour liver tissue after neoadjuvant therapy. Clin Transl Oncol 2014;16:234-42. [PMID: 24019036 DOI: 10.1007/s12094-013-1104-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
399 Bugianesi E, Gentilcore E, Manini R, Natale S, Vanni E, Villanova N, David E, Rizzetto M, Marchesini G. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am J Gastroenterol 2005;100:1082-90. [PMID: 15842582 DOI: 10.1111/j.1572-0241.2005.41583.x] [Cited by in Crossref: 473] [Cited by in F6Publishing: 413] [Article Influence: 27.8] [Reference Citation Analysis]
400 Hebbard L, George J. Animal models of nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol. 2011;8:35-44. [PMID: 21119613 DOI: 10.1038/nrgastro.2010.191] [Cited by in Crossref: 295] [Cited by in F6Publishing: 292] [Article Influence: 24.6] [Reference Citation Analysis]
401 Vuppalanchi R, Unalp A, Van Natta ML, Cummings OW, Sandrasegaran KE, Hameed T, Tonascia J, Chalasani N. Effects of liver biopsy sample length and number of readings on sampling variability in nonalcoholic Fatty liver disease. Clin Gastroenterol Hepatol 2009;7:481-6. [PMID: 19162235 DOI: 10.1016/j.cgh.2008.12.015] [Cited by in Crossref: 110] [Cited by in F6Publishing: 102] [Article Influence: 7.9] [Reference Citation Analysis]
402 Wang Y, Niu M, Jia GL, Li RS, Zhang YM, Zhang CE, Meng YK, Cui HR, Ma ZJ, Li DH, Wang JB, Xiao XH. Untargeted Metabolomics Reveals Intervention Effects of Total Turmeric Extract in a Rat Model of Nonalcoholic Fatty Liver Disease. Evid Based Complement Alternat Med 2016;2016:8495953. [PMID: 27366193 DOI: 10.1155/2016/8495953] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
403 Tendler D, Lin S, Yancy WS, Mavropoulos J, Sylvestre P, Rockey DC, Westman EC. The Effect of a Low-Carbohydrate, Ketogenic Diet on Nonalcoholic Fatty Liver Disease: A Pilot Study. Dig Dis Sci 2007;52:589-93. [DOI: 10.1007/s10620-006-9433-5] [Cited by in Crossref: 124] [Cited by in F6Publishing: 119] [Article Influence: 8.3] [Reference Citation Analysis]
404 Clouston AD, Powell EE. Nonalcoholic fatty liver disease: is all the fat bad? Intern Med J. 2004;34:187-191. [PMID: 15086699 DOI: 10.1111/j.1444-0903.2004.00574.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 1.4] [Reference Citation Analysis]
405 Bugianesi E, Marchesini G, Gentilcore E, Cua IH, Vanni E, Rizzetto M, George J. Fibrosis in genotype 3 chronic hepatitis C and nonalcoholic fatty liver disease: Role of insulin resistance and hepatic steatosis. Hepatology. 2006;44:1648-1655. [PMID: 17133473 DOI: 10.1002/hep.21429] [Cited by in Crossref: 100] [Cited by in F6Publishing: 104] [Article Influence: 6.7] [Reference Citation Analysis]
406 Xia Y, Caputo M, Cansby E, Anand SK, Sütt S, Henricsson M, Porosk R, Marschall HU, Blüher M, Mahlapuu M. STE20-type kinase TAOK3 regulates hepatic lipid partitioning. Mol Metab 2021;54:101353. [PMID: 34634521 DOI: 10.1016/j.molmet.2021.101353] [Reference Citation Analysis]
407 Chavez-Tapia NC, Tellez-Avila FI, Barrientos-Gutierrez T, Mendez-Sanchez N, Lizardi-Cervera J, Uribe M. Bariatric surgery for non-alcoholic steatohepatitis in obese patients. Cochrane Database Syst Rev 2010;:CD007340. [PMID: 20091629 DOI: 10.1002/14651858.CD007340.pub2] [Cited by in Crossref: 100] [Cited by in F6Publishing: 86] [Article Influence: 8.3] [Reference Citation Analysis]
408 Monto A, Kakar S, Dove LM, Bostrom A, Miller EL, Wright TL. Contributions to hepatic fibrosis in HIV-HCV coinfected and HCV monoinfected patients. Am J Gastroenterol 2006;101:1509-15. [PMID: 16863554 DOI: 10.1111/j.1572-0241.2006.00613.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 1.3] [Reference Citation Analysis]
409 Ito S, Yukawa T, Uetake S, Yamauchi M. Serum intercellular adhesion molecule-1 in patients with nonalcoholic steatohepatitis: comparison with alcoholic hepatitis. Alcohol Clin Exp Res 2007;31:S83-7. [PMID: 17331172 DOI: 10.1111/j.1530-0277.2006.00292.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 1.8] [Reference Citation Analysis]
410 Costa MLV, Lima-júnior RCP, Aragão KS, Medeiros RP, Marques-neto RD, de Sá Grassi L, Leite LL, Nunes LG, de Mesquita Neto JWB, de Castro Brito GA, de Souza MHLP, de Almeida PRC, Ribeiro RA. Chemotherapy-associated steatohepatitis induced by irinotecan: a novel animal model. Cancer Chemother Pharmacol 2014;74:711-20. [DOI: 10.1007/s00280-014-2434-8] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
411 Burt A. Steatosis and steatohepatitis. Current Diagnostic Pathology 2001;7:141-7. [DOI: 10.1054/cdip.2001.0062] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
412 Zaman MB, Leonard MO, Ryan EJ, Nolan NP, Hoti E, Maguire D, Mulcahy H, Traynor O, Taylor CT, Hegarty JE, Geoghegan JG, O'Farrelly C. Lower expression of Nrf2 mRNA in older donor livers: a possible contributor to increased ischemia-reperfusion injury? Transplantation 2007;84:1272-8. [PMID: 18049112 DOI: 10.1097/01.tp.0000288229.53064.e2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
413 Giannini C, Feldstein AE, Santoro N, Kim G, Kursawe R, Pierpont B, Caprio S. Circulating levels of FGF-21 in obese youth: associations with liver fat content and markers of liver damage. J Clin Endocrinol Metab. 2013;98:2993-3000. [PMID: 23626003 DOI: 10.1210/jc.2013-1250] [Cited by in Crossref: 59] [Cited by in F6Publishing: 55] [Article Influence: 6.6] [Reference Citation Analysis]
414 Furusho H, Miyauchi M, Hyogo H, Inubushi T, Ao M, Ouhara K, Hisatune J, Kurihara H, Sugai M, Hayes CN, Nakahara T, Aikata H, Takahashi S, Chayama K, Takata T. Dental infection of Porphyromonas gingivalis exacerbates high fat diet-induced steatohepatitis in mice. J Gastroenterol 2013;48:1259-70. [PMID: 23307045 DOI: 10.1007/s00535-012-0738-1] [Cited by in Crossref: 60] [Cited by in F6Publishing: 57] [Article Influence: 6.7] [Reference Citation Analysis]
415 Stadlbauer V, Mookerjee RP, Wright GA, Davies NA, Jürgens G, Hallström S, Jalan R. Role of Toll-like receptors 2, 4, and 9 in mediating neutrophil dysfunction in alcoholic hepatitis. Am J Physiol Gastrointest Liver Physiol. 2009;296:G15-G22. [PMID: 19033535 DOI: 10.1152/ajpqi.90512.2008] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
416 Tokushige K, Hashimoto E, Yatsuji S, Tobari M, Taniai M, Torii N, Shiratori K. Prospective study of hepatocellular carcinoma in nonalcoholic steatohepatitis in comparison with hepatocellular carcinoma caused by chronic hepatitis C. J Gastroenterol. 2010;45:960-967. [PMID: 20376504 DOI: 10.1007/s00535-010-0237-1] [Cited by in Crossref: 46] [Cited by in F6Publishing: 46] [Article Influence: 3.8] [Reference Citation Analysis]
417 Mas E, Danjoux M, Garcia V, Carpentier S, Ségui B, Levade T. IL-6 deficiency attenuates murine diet-induced non-alcoholic steatohepatitis. PLoS One. 2009;4:e7929. [PMID: 19936233 DOI: 10.1371/journal.pone.0007929] [Cited by in Crossref: 57] [Cited by in F6Publishing: 55] [Article Influence: 4.4] [Reference Citation Analysis]
418 Arias-Loste MT, Iruzubieta P, Puente Á, Ramos D, Santa Cruz C, Estébanez Á, Llerena S, Alonso-Martín C, San Segundo D, Álvarez L, López Useros A, Fábrega E, López-Hoyos M, Crespo J. Increased Expression Profile and Functionality of TLR6 in Peripheral Blood Mononuclear Cells and Hepatocytes of Morbidly Obese Patients with Non-Alcoholic Fatty Liver Disease. Int J Mol Sci 2016;17:E1878. [PMID: 27834919 DOI: 10.3390/ijms17111878] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
419 Grant LM, Lisker-melman M. Nonalcoholic fatty liver disease. Annals of Hepatology 2004;3:93-9. [DOI: 10.1016/s1665-2681(19)32100-3] [Cited by in Crossref: 26] [Article Influence: 1.4] [Reference Citation Analysis]
420 Nomoto K, Tsuneyama K, Takahashi H, Murai Y, Takano Y. Cytoplasmic fine granular expression of 8-hydroxydeoxyguanosine reflects early mitochondrial oxidative DNA damage in nonalcoholic fatty liver disease. Appl Immunohistochem Mol Morphol. 2008;16:71-75. [PMID: 18091316 DOI: 10.1097/pai.0b013e31803156d5] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
421 Su Y, Liu Z, Yang L, Li Y, Jiang S, Yao H, Du G. PPARγ gene Pro12Ala variants reduce the risk of obese individuals to non-alcoholic fatty liver: A study in Uygur Chinese population residing in Northwestern China. Clin Res Hepatol Gastroenterol 2020;44:894-904. [PMID: 32505733 DOI: 10.1016/j.clinre.2020.02.005] [Reference Citation Analysis]
422 Mohammadghasemi F, Abbasi M, Rudkhaneei K, Aghajany-nasab M. Beneficial effect of apple vinegar on reproductive parameters in male rat model of nonalcoholic fatty liver disease. Andrologia 2018;50:e13065. [DOI: 10.1111/and.13065] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
423 Nasr P, Hilliges A, Thorelius L, Kechagias S, Ekstedt M. Contrast-enhanced ultrasonography could be a non-invasive method for differentiating none or mild from severe fibrosis in patients with biopsy proven non-alcoholic fatty liver disease. Scandinavian Journal of Gastroenterology 2016;51:1126-32. [DOI: 10.3109/00365521.2016.1172336] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
424 Tovo CV, de Mattos AZ, Coral GP, Branco FS, Suwa E, de Mattos AA. Noninvasive imaging assessment of non-alcoholic fatty liver disease: Focus on liver scintigraphy. World J Gastroenterol 2015; 21(15): 4432-4439 [PMID: 25914452 DOI: 10.3748/wjg.v21.i15.4432] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
425 Bharath R, Mishra PK, Rajalakshmi P. Automated quantification of ultrasonic fatty liver texture based on curvelet transform and SVD. Biocybernetics and Biomedical Engineering 2018;38:145-57. [DOI: 10.1016/j.bbe.2017.12.004] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
426 Neuschwander-tetri BA. Non-alcoholic steatohepatitis: . Current Opinion in Endocrinology & Diabetes 2006;13:119-26. [DOI: 10.1097/01.med.0000216959.98385.02] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
427 Meex RC, Hoy AJ, Morris A, Brown RD, Lo JC, Burke M, Goode RJ, Kingwell BA, Kraakman MJ, Febbraio MA. Fetuin B Is a Secreted Hepatocyte Factor Linking Steatosis to Impaired Glucose Metabolism. Cell Metab. 2015;22:1078-1089. [PMID: 26603189 DOI: 10.1016/j.cmet.2015.09.023] [Cited by in Crossref: 112] [Cited by in F6Publishing: 107] [Article Influence: 16.0] [Reference Citation Analysis]
428 Kawada N, Imanaka K, Kawaguchi T, Tamai C, Ishihara R, Matsunaga T, Gotoh K, Yamada T, Tomita Y. Hepatocellular carcinoma arising from non-cirrhotic nonalcoholic steatohepatitis. J Gastroenterol. 2009;44:1190-1194. [PMID: 19672551 DOI: 10.1007/s00535-009-0112-0] [Cited by in Crossref: 144] [Cited by in F6Publishing: 141] [Article Influence: 12.0] [Reference Citation Analysis]
429 Ruffillo G, Fassio E, Alvarez E, Landeira G, Longo C, Domínguez N, Gualano G. Comparison of NAFLD fibrosis score and BARD score in predicting fibrosis in nonalcoholic fatty liver disease. Journal of Hepatology 2011;54:160-3. [DOI: 10.1016/j.jhep.2010.06.028] [Cited by in Crossref: 49] [Cited by in F6Publishing: 44] [Article Influence: 4.5] [Reference Citation Analysis]
430 Loria P, Lonardo A, Carulli N. Should nonalcoholic fatty liver disease be renamed? Dig Dis. 2005;23:72-82. [PMID: 15920328 DOI: 10.1159/000084728] [Cited by in Crossref: 46] [Cited by in F6Publishing: 43] [Article Influence: 2.7] [Reference Citation Analysis]
431 Shin HK, Park JH, Yu JH, Jin YJ, Suh YJ, Lee JW, Kim W; Korean Nonalcoholic Fatty Liver Study Group (KNSG). Association between telomere length and hepatic fibrosis in non-alcoholic fatty liver disease. Sci Rep 2021;11:18004. [PMID: 34504179 DOI: 10.1038/s41598-021-97385-2] [Reference Citation Analysis]
432 Fatani S, Itua I, Clark P, Wong C, Naderali EK. The effects of diet-induced obesity on hepatocyte insulin signaling pathways and induction of non-alcoholic liver damage. Int J Gen Med. 2011;4:211-219. [PMID: 21475632 DOI: 10.2147/ijgm.s17376] [Cited by in Crossref: 5] [Cited by in F6Publishing: 15] [Article Influence: 0.5] [Reference Citation Analysis]
433 Mouzaki M, Wang AY, Bandsma R, Comelli EM, Arendt BM, Zhang L, Fung S, Fischer SE, McGilvray IG, Allard JP. Bile Acids and Dysbiosis in Non-Alcoholic Fatty Liver Disease. PLoS One. 2016;11:e0151829. [PMID: 27203081 DOI: 10.1371/journal.pone.0151829] [Cited by in Crossref: 167] [Cited by in F6Publishing: 170] [Article Influence: 27.8] [Reference Citation Analysis]
434 Hall A, Covelli C, Manuguerra R, Luong TV, Buzzetti E, Tsochatzis E, Pinzani M, Dhillon AP. Transaminase abnormalities and adaptations of the liver lobule manifest at specific cut-offs of steatosis. Sci Rep 2017;7:40977. [PMID: 28106158 DOI: 10.1038/srep40977] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
435 Gornicka A, Morris-Stiff G, Thapaliya S, Papouchado BG, Berk M, Feldstein AE. Transcriptional profile of genes involved in oxidative stress and antioxidant defense in a dietary murine model of steatohepatitis. Antioxid Redox Signal 2011;15:437-45. [PMID: 21194384 DOI: 10.1089/ars.2010.3815] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 3.6] [Reference Citation Analysis]
436 Auguet T, Berlanga A, Guiu-Jurado E, Terra X, Martinez S, Aguilar C, Filiu E, Alibalic A, Sabench F, Hernández M, Del Castillo D, Richart C. Endocannabinoid receptors gene expression in morbidly obese women with nonalcoholic fatty liver disease. Biomed Res Int 2014;2014:502542. [PMID: 24864249 DOI: 10.1155/2014/502542] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
437 Fassio E, Alvarez E, Domínguez N, Landeira G, Longo C. Natural history of nonalcoholic steatohepatitis: a longitudinal study of repeat liver biopsies. Hepatology. 2004;40:820-826. [PMID: 15382171 DOI: 10.1002/hep.20410] [Cited by in Crossref: 45] [Cited by in F6Publishing: 128] [Article Influence: 2.5] [Reference Citation Analysis]
438 Pataky Z, Genton L, Spahr L, Lazarevic V, Terraz S, Gaïa N, Rubbia-brandt L, Golay A, Schrenzel J, Pichard C. Impact of Hypocaloric Hyperproteic Diet on Gut Microbiota in Overweight or Obese Patients with Nonalcoholic Fatty Liver Disease: A Pilot Study. Dig Dis Sci 2016;61:2721-31. [DOI: 10.1007/s10620-016-4179-1] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 6.0] [Reference Citation Analysis]
439 Fan JG, Zhong L, Tia LY, Xu ZJ, Li MS, Wang GL. Effects of ursodeoxycholic acid and/or low-calorie diet on steatohepatitis in rats with obesity and hyperlipidemia. World J Gastroenterol 2005; 11(15): 2346-2350 [PMID: 15818751 DOI: 10.3748/wjg.v11.i15.2346] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 14] [Article Influence: 0.7] [Reference Citation Analysis]
440 Villela-Nogueira CA, Leite NC, Cardoso CR, Salles GF. NAFLD and Increased Aortic Stiffness: Parallel or Common Physiopathological Mechanisms? Int J Mol Sci 2016;17:E460. [PMID: 27104526 DOI: 10.3390/ijms17040460] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 3.3] [Reference Citation Analysis]
441 Malaguarnera L, Madeddu R, Palio E, Arena N, Malaguarnera M. Heme oxygenase-1 levels and oxidative stress-related parameters in non-alcoholic fatty liver disease patients. J Hepatol 2005;42:585-91. [PMID: 15763346 DOI: 10.1016/j.jhep.2004.11.040] [Cited by in Crossref: 100] [Cited by in F6Publishing: 93] [Article Influence: 5.9] [Reference Citation Analysis]
442 Li Q, Lu C, Li W, Huang Y, Chen L. The gamma-glutamyl transpeptidase to platelet ratio for non-invasive assessment of liver fibrosis in patients with chronic hepatitis B and non-alcoholic fatty liver disease. Oncotarget 2017;8:28641-9. [PMID: 28415736 DOI: 10.18632/oncotarget.16162] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
443 Cengiz M, Ozenirler S, Kocabiyik M. Serum β-trophin level as a new marker for noninvasive assessment of nonalcoholic fatty liver disease and liver fibrosis: . European Journal of Gastroenterology & Hepatology 2016;28:57-63. [DOI: 10.1097/meg.0000000000000502] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
444 Mennesson N, Dumortier J, Hervieu V, Milot L, Guillaud O, Scoazec J, Pilleul F. Liver Steatosis Quantification Using Magnetic Resonance Imaging: A Prospective Comparative Study With Liver Biopsy. Journal of Computer Assisted Tomography 2009;33:672-7. [DOI: 10.1097/rct.0b013e318199d883] [Cited by in Crossref: 31] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
445 Vangipurapu J, Stančáková A, Pihlajamäki J, Kuulasmaa TM, Kuulasmaa T, Paananen J, Kuusisto J, Ferrannini E, Laakso M. Association of indices of liver and adipocyte insulin resistance with 19 confirmed susceptibility loci for type 2 diabetes in 6,733 non-diabetic Finnish men. Diabetologia 2011;54:563-71. [PMID: 21153532 DOI: 10.1007/s00125-010-1977-4] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 2.3] [Reference Citation Analysis]
446 Shimizu H, Phuong V, Maia M, Kroh M, Chand B, Schauer PR, Brethauer SA. Bariatric surgery in patients with liver cirrhosis. Surg Obes Relat Dis. 2013;9:1-6. [PMID: 23201210 DOI: 10.1016/j.soard.2012.07.021] [Cited by in Crossref: 83] [Cited by in F6Publishing: 64] [Article Influence: 8.3] [Reference Citation Analysis]
447 Wang J, Li J, Zou Y, Cheng W, Lu C, Zhang L, Ge J, Huang C, Jin Y, Lv X, Hu C, Liu L. Preventive effects of total flavonoids of Litsea coreana leve on hepatic steatosis in rats fed with high fat diet. Journal of Ethnopharmacology 2009;121:54-60. [DOI: 10.1016/j.jep.2008.09.029] [Cited by in Crossref: 42] [Cited by in F6Publishing: 35] [Article Influence: 3.2] [Reference Citation Analysis]
448 Neri S, Pulvirenti D, Signorelli S, Ignaccolo L, Tsami A, Mauceri B, Misseri M, Interlandi D, Cutuli N, Castellino P. The HFE gene heterozygosis H63D: a cofactor for liver damage in patients with steatohepatitis? Epidemiological and clinical considerations. Intern Med J 2008;38:254-8. [PMID: 17916170 DOI: 10.1111/j.1445-5994.2007.01474.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
449 Akbari R, Yaghooti H, Jalali MT, Khorsandi LS, Mohammadtaghvaei N. Capparis spinosa improves the high fat diet-induced non-alcoholic steatohepatitis in rats: the possible role of FGF21. BMC Res Notes 2020;13:356. [PMID: 32723353 DOI: 10.1186/s13104-020-05200-4] [Reference Citation Analysis]
450 Beale G, Chattopadhyay D, Gray J, Stewart S, Hudson M, Day C, Trerotoli P, Giannelli G, Manas D, Reeves H. AFP, PIVKAII, GP3, SCCA-1 and follisatin as surveillance biomarkers for hepatocellular cancer in non-alcoholic and alcoholic fatty liver disease. BMC Cancer 2008;8:200. [PMID: 18638391 DOI: 10.1186/1471-2407-8-200] [Cited by in Crossref: 83] [Cited by in F6Publishing: 79] [Article Influence: 5.9] [Reference Citation Analysis]
451 Verdi H, Sare Koytak E, Önder O, Arslan Ergül A, Cinar K, Idilman R, Erden E, Mithat Bozdayi A, Yurdaydin C, Uzunalimoglu Ö, Bozkaya H. Peroxisome Proliferator-Activated Receptor α L162V Polymorphism in Nonalcoholic Steatohepatitis and Genotype 1 Hepatitis C Virus-Related Liver Steatosis: . Journal of Investigative Medicine 2005;53:353-9. [DOI: 10.2310/6650.2005.53706] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
452 Bunnoy A, Saenphet K, Lumyong S, Saenphet S, Chomdej S. Monascus purpureus-fermented Thai glutinous rice reduces blood and hepatic cholesterol and hepatic steatosis concentrations in diet-induced hypercholesterolemic rats. BMC Complement Altern Med 2015;15:88. [PMID: 25880551 DOI: 10.1186/s12906-015-0624-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
453 Wu J, Zhao MY, Zheng H, Zhang H, Jiang Y. Pentoxifylline alleviates high-fat diet-induced non-alcoholic steatohepatitis and early atherosclerosis in rats by inhibiting AGE and RAGE expression. Acta Pharmacol Sin. 2010;31:1367-1375. [PMID: 20835270 DOI: 10.1038/aps.2010.110] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
454 Oliveira VB, Ferreira AV, Oliveira MC, Teixeira MM, Brandão MG. Effects of Xylopia aromatica (Lam.) Mart. fruit on metabolic and inflammatory dysfunction induced by high refined carbohydrate-containing-diet in mice. Food Research International 2014;62:541-50. [DOI: 10.1016/j.foodres.2014.03.066] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
455 Shoji H, Yoshio S, Mano Y, Kumagai E, Sugiyama M, Korenaga M, Arai T, Itokawa N, Atsukawa M, Aikata H, Hyogo H, Chayama K, Ohashi T, Ito K, Yoneda M, Nozaki Y, Kawaguchi T, Torimura T, Abe M, Hiasa Y, Fukai M, Kamiyama T, Taketomi A, Mizokami M, Kanto T. Interleukin-34 as a fibroblast-derived marker of liver fibrosis in patients with non-alcoholic fatty liver disease. Sci Rep 2016;6:28814. [PMID: 27363523 DOI: 10.1038/srep28814] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 4.7] [Reference Citation Analysis]
456 Yamaguchi K, Itoh Y, Yokomizo C, Nishimura T, Niimi T, Fujii H, Okanoue T, Yoshikawa T. Blockade of interleukin-6 signaling enhances hepatic steatosis but improves liver injury in methionine choline-deficient diet-fed mice. Lab Invest. 2010;90:1169-1178. [PMID: 20368703 DOI: 10.1038/labinvest.2010.75] [Cited by in Crossref: 64] [Cited by in F6Publishing: 65] [Article Influence: 5.3] [Reference Citation Analysis]
457 Hewing B, Parathath S, Mai CK, Fiel MI, Guo L, Fisher EA. Rapid regression of atherosclerosis with MTP inhibitor treatment. Atherosclerosis 2013;227:125-9. [PMID: 23332773 DOI: 10.1016/j.atherosclerosis.2012.12.026] [Cited by in Crossref: 39] [Cited by in F6Publishing: 39] [Article Influence: 4.3] [Reference Citation Analysis]
458 Trasino SE, Tang XH, Jessurun J, Gudas LJ. A retinoic acid receptor β2 agonist reduces hepatic stellate cell activation in nonalcoholic fatty liver disease. J Mol Med (Berl) 2016;94:1143-51. [PMID: 27271256 DOI: 10.1007/s00109-016-1434-z] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 3.3] [Reference Citation Analysis]
459 Virarkar M, Morani AC, Taggart MW, Bhosale P. Liver Fibrosis Assessment. Semin Ultrasound CT MR 2021;42:381-9. [PMID: 34130850 DOI: 10.1053/j.sult.2021.03.003] [Reference Citation Analysis]
460 Amougou MA, Atangana PJA, Afouba AGN, Moundipa PF, Pineau P, Njouom R. Dichotomous associations of liver pathology with hepatocellular carcinoma morphology in Middle Africa: the situation in Cameroon. BMC Res Notes 2018;11:451. [PMID: 29986749 DOI: 10.1186/s13104-018-3560-x] [Reference Citation Analysis]
461 Lemoine M, Barbu V, Girard PM, Kim M, Bastard JP, Wendum D, Paye F, Housset C, Capeau J, Serfaty L. Altered hepatic expression of SREBP-1 and PPARgamma is associated with liver injury in insulin-resistant lipodystrophic HIV-infected patients. AIDS. 2006;20:387-395. [PMID: 16439872 DOI: 10.1097/01.aids.0000206503.01536.11] [Cited by in Crossref: 78] [Cited by in F6Publishing: 73] [Article Influence: 4.9] [Reference Citation Analysis]
462 Nguyen-khac E, Chatelain D, Tramier B, Decrombecque C, Robert B, Joly J, Brevet M, Grignon P, Lion S, Le Page L, Dupas J. Assessment of asymptomatic liver fibrosis in alcoholic patients using fibroscan: prospective comparison with seven non-invasive laboratory tests. Alimentary Pharmacology & Therapeutics 2008;28:1188-98. [DOI: 10.1111/j.1365-2036.2008.03831.x] [Cited by in Crossref: 145] [Cited by in F6Publishing: 120] [Article Influence: 10.4] [Reference Citation Analysis]
463 Guo XL, Zhang L, Yang ZX. Correlation between 13C-methacetine breath test and pathological changes of non-alcoholic fatty liver. Shijie Huaren Xiaohua Zazhi 2004; 12(10): 2356-2359 [DOI: 10.11569/wcjd.v12.i10.2356] [Reference Citation Analysis]
464 Monteiro JM, Monteiro GM, Caroli-Bottino A, Pannain VL. Nonalcoholic fatty liver disease: different classifications concordance and relationship between degrees of morphological features and spectrum of the disease. Anal Cell Pathol (Amst) 2014;2014:526979. [PMID: 25763333 DOI: 10.1155/2014/526979] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
465 Madan K, Bhardwaj P, Thareja S, Gupta SD, Saraya A. Oxidant stress and antioxidant status among patients with nonalcoholic fatty liver disease (NAFLD). J Clin Gastroenterol. 2006;40:930-935. [PMID: 17063114 DOI: 10.1097/01.mcg.0000212608.59090.08] [Cited by in Crossref: 95] [Cited by in F6Publishing: 89] [Article Influence: 6.3] [Reference Citation Analysis]
466 Homeyer A, Schenk A, Arlt J, Dahmen U, Dirsch O, Hahn HK. Fast and accurate identification of fat droplets in histological images. Computer Methods and Programs in Biomedicine 2015;121:59-65. [DOI: 10.1016/j.cmpb.2015.05.009] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
467 Speletas M, Argentou N, Germanidis G, Vasiliadis T, Mantzoukis K, Patsiaoura K, Nikolaidis P, Karanikas V, Ritis K, Germenis AE. Foxp3 expression in liver correlates with the degree but not the cause of inflammation. Mediators Inflamm. 2011;2011:827565. [PMID: 21772667 DOI: 10.1155/2011/827565] [Cited by in Crossref: 24] [Cited by in F6Publishing: 29] [Article Influence: 2.2] [Reference Citation Analysis]
468 Pereira RR, de Abreu IC, Guerra JF, Lage NN, Lopes JM, Silva M, de Lima WG, Silva ME, Pedrosa ML. Açai (Euterpe oleracea Mart.) Upregulates Paraoxonase 1 Gene Expression and Activity with Concomitant Reduction of Hepatic Steatosis in High-Fat Diet-Fed Rats. Oxid Med Cell Longev 2016;2016:8379105. [PMID: 27642496 DOI: 10.1155/2016/8379105] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
469 Kalupahana NS, Claycombe K, Newman SJ, Stewart T, Siriwardhana N, Matthan N, Lichtenstein AH, Moustaid-moussa N. Eicosapentaenoic Acid Prevents and Reverses Insulin Resistance in High-Fat Diet-Induced Obese Mice via Modulation of Adipose Tissue Inflammation. The Journal of Nutrition 2010;140:1915-22. [DOI: 10.3945/jn.110.125732] [Cited by in Crossref: 184] [Cited by in F6Publishing: 171] [Article Influence: 15.3] [Reference Citation Analysis]
470 Lindbäck SM, Gabbert C, Johnson BL, Smorodinsky E, Sirlin CB, Garcia N, Pardee PE, Kistler KD, Schwimmer JB. Pediatric Nonalcoholic Fatty Liver Disease: A Comprehensive Review. Advances in Pediatrics 2010;57:85-140. [DOI: 10.1016/j.yapd.2010.08.006] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 2.4] [Reference Citation Analysis]
471 Rensen SS, Slaats Y, Driessen A, Peutz-Kootstra CJ, Nijhuis J, Steffensen R, Greve JW, Buurman WA. Activation of the complement system in human nonalcoholic fatty liver disease. Hepatology. 2009;50:1809-1817. [PMID: 19821522 DOI: 10.1002/hep.23228] [Cited by in Crossref: 83] [Cited by in F6Publishing: 83] [Article Influence: 6.4] [Reference Citation Analysis]
472 Okanoue T, Umemura A, Yasui K, Itoh Y. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in Japan. J Gastroenterol Hepatol. 2011;26 Suppl 1:153-162. [PMID: 21199527 DOI: 10.1111/j.1440-1746.2010.06547.x] [Cited by in Crossref: 75] [Cited by in F6Publishing: 73] [Article Influence: 6.8] [Reference Citation Analysis]
473 Lannerstedt H, Konopski Z, Sandvik L, Haaland T, Løberg EM, Haukeland JW. Combining transient elastography with FIB4 enhances sensitivity in detecting advanced fibrosis of the liver. Scand J Gastroenterol. 2013;48:93-100. [PMID: 23205894 DOI: 10.3109/00365521.2012.746389] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
474 Zhang YN, Fowler KJ, Hamilton G, Cui JY, Sy EZ, Balanay M, Hooker JC, Szeverenyi N, Sirlin CB. Liver fat imaging-a clinical overview of ultrasound, CT, and MR imaging. Br J Radiol. 2018;91:20170959. [PMID: 29722568 DOI: 10.1259/bjr.20170959] [Cited by in Crossref: 41] [Cited by in F6Publishing: 39] [Article Influence: 10.3] [Reference Citation Analysis]
475 Anty R, Marjoux S, Iannelli A, Patouraux S, Schneck AS, Bonnafous S, Gire C, Amzolini A, Ben-Amor I, Saint-Paul MC. Regular coffee but not espresso drinking is protective against fibrosis in a cohort mainly composed of morbidly obese European women with NAFLD undergoing bariatric surgery. J Hepatol. 2012;57:1090-1096. [PMID: 22820478 DOI: 10.1016/j.jhep.2012.07.014] [Cited by in Crossref: 94] [Cited by in F6Publishing: 81] [Article Influence: 9.4] [Reference Citation Analysis]
476 Lahelma M, Luukkonen PK, Qadri S, Ahlholm N, Lallukka-Brück S, Porthan K, Juuti A, Sammalkorpi H, Penttilä AK, Arola J, Orho-Melander M, Yki-Järvinen H. Assessment of Lifestyle Factors Helps to Identify Liver Fibrosis Due to Non-Alcoholic Fatty Liver Disease in Obesity. Nutrients 2021;13:E169. [PMID: 33429859 DOI: 10.3390/nu13010169] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
477 Qureshi K, Abrams GA. Metabolic liver disease of obesity and role of adipose tissue in the pathogenesis of nonalcoholic fatty liver disease. World J Gastroenterol 2007; 13(26): 3540-3553 [PMID: 17659704 DOI: 10.3748/wjg.v13.i26.3540] [Cited by in CrossRef: 160] [Cited by in F6Publishing: 148] [Article Influence: 10.7] [Reference Citation Analysis]
478 Cheung O, Kapoor A, Puri P, Sistrun S, Luketic VA, Sargeant CC, Contos MJ, Shiffman ML, Stravitz RT, Sterling RK. The impact of fat distribution on the severity of nonalcoholic fatty liver disease and metabolic syndrome. Hepatology. 2007;46:1091-1100. [PMID: 17610277 DOI: 10.1002/hep.21803] [Cited by in Crossref: 78] [Cited by in F6Publishing: 66] [Article Influence: 5.2] [Reference Citation Analysis]
479 Elvira-Torales LI, Navarro-González I, Rodrigo-García J, Seva J, García-Alonso J, Periago-Castón MJ. Consumption of Spinach and Tomato Modifies Lipid Metabolism, Reducing Hepatic Steatosis in Rats. Antioxidants (Basel) 2020;9:E1041. [PMID: 33114278 DOI: 10.3390/antiox9111041] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
480 El Aggan H, Farahat N, El Deeb N, Zeid A, El-Shendidi A. Peripheral blood and hepatic Toll-like receptor 7 expression and interferon lambda 1 levels in chronic hepatitis C: Relation to virus replication and liver injury. Microb Pathog 2019;131:65-74. [PMID: 30926417 DOI: 10.1016/j.micpath.2019.03.032] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
481 Mannery YO, McClain CJ, Vos MB. Keratin 18, Apoptosis, and Liver Disease in Children. Curr Pediatr Rev 2011;7:310-5. [PMID: 25346653 DOI: 10.2174/157339611796892364] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
482 Taketani H, Sumida Y, Tanaka S, Imajo K, Yoneda M, Hyogo H, Ono M, Fujii H, Eguchi Y, Kanemasa K, Chayama K, Itoh Y, Yoshikawa T, Saibara T, Fujimoto K, Nakajima A; Japan Study Group of NAFLD (JSG-NAFLD). The association of insomnia with gastroesophageal reflux symptoms in biopsy-proven nonalcoholic fatty liver disease. J Gastroenterol 2014;49:1163-74. [DOI: 10.1007/s00535-013-0871-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
483 Kumar A, Sharma A, Duseja A, Das A, Dhiman RK, Chawla YK, Kohli KK, Bhansali A. Patients with Nonalcoholic Fatty Liver Disease (NAFLD) have Higher Oxidative Stress in Comparison to Chronic Viral Hepatitis. J Clin Exp Hepatol 2013;3:12-8. [PMID: 25755466 DOI: 10.1016/j.jceh.2012.10.009] [Cited by in Crossref: 36] [Cited by in F6Publishing: 31] [Article Influence: 3.6] [Reference Citation Analysis]
484 Liu CH, Ampuero J, Pavlides M, Wong VW, Fan JG, Bai L, Li H, Wu DB, Zhou LY, Du LY, Yang TK, Jiang W, Shi Y, Gil-Gómez A, Zhang WT, Liang JX, Romero-Gómez M, Tang H. Simple non-invasive scoring systems and histological scores in predicting mortality in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis. J Gastroenterol Hepatol 2021;36:1754-68. [PMID: 33569851 DOI: 10.1111/jgh.15431] [Reference Citation Analysis]
485 Duseja A, Das A, Das R, Dhiman RK, Chawla Y, Bhansali A, Kalra N. The clinicopathological profile of Indian patients with nonalcoholic fatty liver disease (NAFLD) is different from that in the West. Dig Dis Sci. 2007;52:2368-2374. [PMID: 17420951 DOI: 10.1007/s10620-006-9136-y] [Cited by in Crossref: 58] [Cited by in F6Publishing: 55] [Article Influence: 3.9] [Reference Citation Analysis]
486 Brunt EM, Kleiner DE, Wilson LA, Unalp A, Behling CE, Lavine JE, Neuschwander-Tetri BA; NASH Clinical Research NetworkA list of members of the Nonalcoholic Steatohepatitis Clinical Research Network can be found in the Appendix. Portal chronic inflammation in nonalcoholic fatty liver disease (NAFLD): a histologic marker of advanced NAFLD-Clinicopathologic correlations from the nonalcoholic steatohepatitis clinical research network. Hepatology 2009;49:809-20. [PMID: 19142989 DOI: 10.1002/hep.22724] [Cited by in Crossref: 243] [Cited by in F6Publishing: 222] [Article Influence: 18.7] [Reference Citation Analysis]
487 Ai Z, Zhu C, Min M, Wang J, Lan C, Fan L, Sun W, Chen D. The Role of Hepatic Liver X Receptor α-and Sterol Regulatory Element Binding Protein-1c-Mediated Lipid Disorder in the Pathogenesis of Non-Alcoholic Steatohepatitis in Rats. J Int Med Res 2011;39:1219-29. [DOI: 10.1177/147323001103900410] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
488 Munsterman ID, van Erp M, Weijers G, Bronkhorst C, de Korte CL, Drenth JPH, van der Laak JAWM, Tjwa ETTL. A Novel Automatic Digital Algorithm that Accurately Quantifies Steatosis in NAFLD on Histopathological Whole-Slide Images. Cytometry B Clin Cytom 2019;96:521-8. [PMID: 31173462 DOI: 10.1002/cyto.b.21790] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
489 Vander Borght S, Libbrecht L, Katoonizadeh A, van Pelt J, Cassiman D, Nevens F, Van Lommel A, Petersen BE, Fevery J, Jansen PL. Breast cancer resistance protein (BCRP/ABCG2) is expressed by progenitor cells/reactive ductules and hepatocytes and its expression pattern is influenced by disease etiology and species type: possible functional consequences. J Histochem Cytochem. 2006;54:1051-1059. [PMID: 16709727 DOI: 10.1369/jhc.5A6912.2006] [Cited by in Crossref: 52] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
490 Margariti A, Kontogianni MD, Tileli N, Georgoulis M, Deutsch M, Zafeiropoulou R, Tiniakos D, Manios Y, Pectasides D, Papatheodoridis GV. Increased abdominal fat levels measured by bioelectrical impedance are associated with histological lesions of nonalcoholic steatohepatitis. Eur J Gastroenterol Hepatol 2015;27:907-13. [PMID: 26011231 DOI: 10.1097/MEG.0000000000000381] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
491 Cave M, Falkner KC, Ray M, Joshi-Barve S, Brock G, Khan R, Bon Homme M, McClain CJ. Toxicant-associated steatohepatitis in vinyl chloride workers. Hepatology. 2010;51:474-481. [PMID: 19902480 DOI: 10.1002/hep.23321] [Cited by in Crossref: 97] [Cited by in F6Publishing: 87] [Article Influence: 8.1] [Reference Citation Analysis]
492 Kogiso T, Sagawa T, Kodama K, Taniai M, Hashimoto E, Tokushige K. Outcomes of Japanese patients with non-alcoholic fatty liver disease according to genetic background and lifestyle-related diseases. Ann Hepatol 2021;21:100260. [PMID: 32987175 DOI: 10.1016/j.aohep.2020.09.004] [Reference Citation Analysis]
493 Rao MS, Reddy JK. PPAR? in the pathogenesis of fatty liver disease. Hepatology 2004;40:783-6. [DOI: 10.1002/hep.20453] [Cited by in Crossref: 59] [Cited by in F6Publishing: 58] [Article Influence: 3.3] [Reference Citation Analysis]
494 Claudel T, Trauner M. Adiponectin, bile acids, and burnt-out nonalcoholic steatohepatitis: new light on an old paradox. Hepatology 2013;57:2106-9. [PMID: 23447428 DOI: 10.1002/hep.26340] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
495 Kumagai E, Mano Y, Yoshio S, Shoji H, Sugiyama M, Korenaga M, Ishida T, Arai T, Itokawa N, Atsukawa M, Hyogo H, Chayama K, Ohashi T, Ito K, Yoneda M, Kawaguchi T, Torimura T, Nozaki Y, Watanabe S, Mizokami M, Kanto T. Serum YKL-40 as a marker of liver fibrosis in patients with non-alcoholic fatty liver disease. Sci Rep 2016;6:35282. [PMID: 27739482 DOI: 10.1038/srep35282] [Cited by in Crossref: 48] [Cited by in F6Publishing: 46] [Article Influence: 8.0] [Reference Citation Analysis]
496 Schwenger KJP, Kiu A, AlAli M, Alhanaee A, Fischer SE, Allard JP. Comparison of bioelectrical impedance analysis, mass index, and waist circumference in assessing risk for non-alcoholic steatohepatitis. Nutrition 2021;93:111491. [PMID: 34739937 DOI: 10.1016/j.nut.2021.111491] [Reference Citation Analysis]
497 Okuyama T, Shirakawa J, Tajima K, Ino Y, Vethe H, Togashi Y, Kyohara M, Inoue R, Miyashita D, Li J, Goto N, Ichikawa T, Yamasaki S, Ohnuma H, Takayanagi R, Kimura Y, Hirano H, Terauchi Y. Linagliptin Ameliorates Hepatic Steatosis via Non-Canonical Mechanisms in Mice Treated with a Dual Inhibitor of Insulin Receptor and IGF-1 Receptor. Int J Mol Sci 2020;21:E7815. [PMID: 33105604 DOI: 10.3390/ijms21217815] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
498 Mulhall BP, Ong JP, Younossi ZM. Non-alcoholic fatty liver disease: an overview. J Gastroenterol Hepatol. 2002;17:1136-1143. [PMID: 12453271 DOI: 10.1046/j.1440-1746.2002.02881.x] [Cited by in Crossref: 135] [Cited by in F6Publishing: 119] [Article Influence: 7.1] [Reference Citation Analysis]
499 Minohara S, Bae SK, Sugiyama S, Shibata N, Gushima T, Motoshita J, Shimoda S, Takagi A, Ikeda Y, Takahashi K. A case of non-alcoholic steatohepatitis complicated with severe acute pancreatitis induced by decreased lipoprotein lipase and hepatic triglyceride lipase activity levels in a young Japanese woman. Clin Case Rep 2018;6:1769-73. [PMID: 30214760 DOI: 10.1002/ccr3.1706] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
500 Burra P, Loreno M, Russo FP, Germani G, Galligioni A, Senzolo M, Cillo U, Zanus G, Fagiuoli S, Rugge M. Donor livers with steatosis are safe to use in hepatitis C virus-positive recipients. Liver Transpl. 2009;15:619-628. [PMID: 19479805 DOI: 10.1002/lt.21761] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 2.5] [Reference Citation Analysis]
501 Parsi A, Torkashvand M, Hajiani E, Rahimlou M, Sadeghi N. The effects of crocus sativus extract on serum lipid profile and liver enzymes in patients with non-alcoholic fatty liver disease: A randomized placebo-controlled study. Obesity Medicine 2020;17:100165. [DOI: 10.1016/j.obmed.2019.100165] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
502 Sharkey FE, Lytvak I, Prihoda TJ, Speeg KV, Washburn WK, Halff GA. High-grade microsteatosis and delay in hepatic function after orthotopic liver transplantation. Hum Pathol 2011;42:1337-42. [PMID: 21420717 DOI: 10.1016/j.humpath.2010.12.004] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
503 Fujita N, Nishie A, Asayama Y, Ishigami K, Ushijima Y, Takayama Y, Okamoto D, Shirabe K, Yoshizumi T, Kotoh K, Furusyo N, Hida T, Oda Y, Fujioka T, Honda H. Fibrosis in nonalcoholic fatty liver disease: Noninvasive assessment using computed tomography volumetry. World J Gastroenterol 2016; 22(40): 8949-8955 [PMID: 27833386 DOI: 10.3748/wjg.v22.i40.8949] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
504 Maffazioli GD, Stanford FC, Campoverde Reyes KJ, Stanley TL, Singhal V, Corey KE, Pratt JS, Bredella MA, Misra M. Comparing Outcomes of Two Types of Bariatric Surgery in an Adolescent Obese Population: Roux-en-Y Gastric Bypass vs. Sleeve Gastrectomy. Front Pediatr 2016;4:78. [PMID: 27508205 DOI: 10.3389/fped.2016.00078] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
505 Appourchaux K, Dokmak S, Resche-Rigon M, Treton X, Lapalus M, Gattolliat CH, Porchet E, Martinot-Peignoux M, Boyer N, Vidaud M, Bedossa P, Marcellin P, Bièche I, Estrabaud E, Asselah T. MicroRNA-based diagnostic tools for advanced fibrosis and cirrhosis in patients with chronic hepatitis B and C. Sci Rep 2016;6:34935. [PMID: 27731343 DOI: 10.1038/srep34935] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 4.8] [Reference Citation Analysis]
506 Kontogianni MD, Tileli N, Margariti A, Georgoulis M, Deutsch M, Tiniakos D, Fragopoulou E, Zafiropoulou R, Manios Y, Papatheodoridis G. Adherence to the Mediterranean diet is associated with the severity of non-alcoholic fatty liver disease. Clin Nutr. 2014;33:678-683. [PMID: 24064253 DOI: 10.1016/j.clnu.2013.08.014] [Cited by in Crossref: 110] [Cited by in F6Publishing: 101] [Article Influence: 12.2] [Reference Citation Analysis]
507 Motosugi U, Hernando D, Bannas P, Holmes JH, Wang K, Shimakawa A, Iwadate Y, Taviani V, Rehm JL, Reeder SB. Quantification of liver fat with respiratory-gated quantitative chemical shift encoded MRI. J Magn Reson Imaging 2015;42:1241-8. [PMID: 25828696 DOI: 10.1002/jmri.24896] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
508 Comhair TM, Garcia Caraballo SC, Dejong CH, Lamers WH, Köhler SE. Dietary cholesterol, female gender and n-3 fatty acid deficiency are more important factors in the development of non-alcoholic fatty liver disease than the saturation index of the fat. Nutr Metab (Lond) 2011;8:4. [PMID: 21261989 DOI: 10.1186/1743-7075-8-4] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 2.9] [Reference Citation Analysis]
509 Fujiwara Y, Kuroda H, Abe T, Ishida K, Oguri T, Noguchi S, Sugai T, Kamiyama N, Takikawa Y. The B-Mode Image-Guided Ultrasound Attenuation Parameter Accurately Detects Hepatic Steatosis in Chronic Liver Disease. Ultrasound Med Biol. 2018;44:2223-2232. [PMID: 30077415 DOI: 10.1016/j.ultrasmedbio.2018.06.017] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 8.5] [Reference Citation Analysis]
510 Dioguardi Burgio M, Grégory J, Ronot M, Sartoris R, Chatellier G, Vilgrain V; group SSI-SWE. 2D-shear wave elastography: number of acquisitions can be reduced according to clinical setting. Insights Imaging 2021;12:145. [PMID: 34674032 DOI: 10.1186/s13244-021-01090-7] [Reference Citation Analysis]
511 Dossi CG, Tapia GS, Espinosa A, Videla LA, D'Espessailles A. Reversal of high-fat diet-induced hepatic steatosis by n-3 LCPUFA: role of PPAR-α and SREBP-1c. J Nutr Biochem 2014;25:977-84. [PMID: 24993917 DOI: 10.1016/j.jnutbio.2014.04.011] [Cited by in Crossref: 39] [Cited by in F6Publishing: 36] [Article Influence: 4.9] [Reference Citation Analysis]
512 Schmilovitz-Weiss H, Hochhauser E, Cohen M, Chepurko Y, Yitzhaki S, Grossman E, Leibowitz A, Ackerman Z, Ben-Ari Z. Rosiglitazone and bezafibrate modulate gene expression in a rat model of non-alcoholic fatty liver disease--a historical prospective. Lipids Health Dis 2013;12:41. [PMID: 23531105 DOI: 10.1186/1476-511X-12-41] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
513 Dang HW, Kim SU, Park JY, Ahn SH, Han KH, Chon CY, Park YN, Choi EH, Kim DY. How many valid measurements are necessary to assess liver fibrosis using FibroScan® in patients with chronic viral hepatitis? An analysis of subjects with at least 10 valid measurements. Yonsei Med J. 2012;53:337-345. [PMID: 22318821 DOI: 10.3349/2012.53.2.337] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
514 Alzahrani B, Iseli TJ, Hebbard LW. Non-viral causes of liver cancer: does obesity led inflammation play a role? Cancer Lett. 2014;345:223-229. [PMID: 24007864 DOI: 10.1016/j.canlet.2013.08.036] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 4.0] [Reference Citation Analysis]
515 Tiniakos DG, Anstee QM, Burt AD. Fatty Liver Disease. Macsween's Pathology of the Liver. Elsevier; 2018. pp. 308-71. [DOI: 10.1016/b978-0-7020-6697-9.00005-4] [Cited by in Crossref: 7] [Article Influence: 1.8] [Reference Citation Analysis]
516 Heeringa M, Hastings A, Yamazaki S, de Koning P. Serum biomarkers in nonalcoholic steatohepatitis: value for assessing drug effects? Biomark Med. 2012;6:743-757. [PMID: 23227839 DOI: 10.2217/bmm.12.87] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
517 Moore MP, Cunningham RP, Davis RAH, Deemer SE, Roberts BM, Plaisance EP, Rector RS. A dietary ketone ester mitigates histological outcomes of NAFLD and markers of fibrosis in high-fat diet fed mice. Am J Physiol Gastrointest Liver Physiol 2021;320:G564-72. [PMID: 33501889 DOI: 10.1152/ajpgi.00259.2020] [Reference Citation Analysis]
518 Männistö V, Kaminska D, Käkelä P, Neuvonen M, Niemi M, Alvarez M, Pajukanta P, Romeo S, Nieuwdorp M, Groen AK, Pihlajamäki J. Protein Phosphatase 1 Regulatory Subunit 3B Genotype at rs4240624 Has a Major Effect on Gallbladder Bile Composition. Hepatol Commun 2021;5:244-57. [PMID: 33553972 DOI: 10.1002/hep4.1630] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
519 Craven L, Rahman A, Nair Parvathy S, Beaton M, Silverman J, Qumosani K, Hramiak I, Hegele R, Joy T, Meddings J, Urquhart B, Harvie R, Mckenzie C, Summers K, Reid G, Burton JP, Silverman M. Allogenic Fecal Microbiota Transplantation in Patients With Nonalcoholic Fatty Liver Disease Improves Abnormal Small Intestinal Permeability: A Randomized Control Trial. Am J Gastroenterol 2020;115:1055-65. [DOI: 10.14309/ajg.0000000000000661] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 18.5] [Reference Citation Analysis]
520 Goldstein NS, Hastah F, Galan MV, Gordon SC. Fibrosis heterogeneity in nonalcoholic steatohepatitis and hepatitis C virus needle core biopsy specimens. Am J Clin Pathol. 2005;123:382-387. [PMID: 15716234 DOI: 10.1309/ey72f1en9xcb1kxx] [Cited by in Crossref: 66] [Cited by in F6Publishing: 1] [Article Influence: 3.9] [Reference Citation Analysis]
521 Konerman MA, Mehta SH, Sutcliffe CG, Vu T, Higgins Y, Torbenson MS, Moore RD, Thomas DL, Sulkowski MS. Fibrosis progression in human immunodeficiency virus/hepatitis C virus coinfected adults: prospective analysis of 435 liver biopsy pairs. Hepatology 2014;59:767-75. [PMID: 24436062 DOI: 10.1002/hep.26741] [Cited by in Crossref: 63] [Cited by in F6Publishing: 60] [Article Influence: 7.9] [Reference Citation Analysis]
522 Luo F, Ishigami M, Achiwa K, Ishizu Y, Kuzuya T, Honda T, Hayashi K, Ishikawa T, Katano Y, Goto H. Raloxifene Ameliorates Liver Fibrosis of Nonalcoholic Steatohepatitis Induced by Choline-Deficient High-Fat Diet in Ovariectomized Mice. Dig Dis Sci 2015;60:2730-9. [PMID: 25868633 DOI: 10.1007/s10620-015-3660-6] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
523 Standish RA, Cholongitas E, Dhillon A, Burroughs AK, Dhillon AP. An appraisal of the histopathological assessment of liver fibrosis. Gut 2006;55:569-78. [PMID: 16531536 DOI: 10.1136/gut.2005.084475] [Cited by in Crossref: 275] [Cited by in F6Publishing: 246] [Article Influence: 17.2] [Reference Citation Analysis]
524 Toshikuni N, Tsutsumi M, Arisawa T. Clinical differences between alcoholic liver disease and nonalcoholic fatty liver disease. World J Gastroenterol 2014; 20(26): 8393-8406 [PMID: 25024597 DOI: 10.3748/wjg.v20.i26.8393] [Cited by in CrossRef: 58] [Cited by in F6Publishing: 51] [Article Influence: 7.3] [Reference Citation Analysis]
525 Costa-Silva L, Ferolla SM, Lima AS, Vidigal PVT, Ferrari TCA. MR elastography is effective for the non-invasive evaluation of fibrosis and necroinflammatory activity in patients with nonalcoholic fatty liver disease. Eur J Radiol. 2018;98:82-89. [PMID: 29279175 DOI: 10.1016/j.ejrad.2017.11.003] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 4.6] [Reference Citation Analysis]
526 Walle P, Takkunen M, Männistö V, Vaittinen M, Lankinen M, Kärjä V, Käkelä P, Ågren J, Tiainen M, Schwab U, Kuusisto J, Laakso M, Pihlajamäki J. Fatty acid metabolism is altered in non-alcoholic steatohepatitis independent of obesity. Metabolism 2016;65:655-66. [PMID: 27085774 DOI: 10.1016/j.metabol.2016.01.011] [Cited by in Crossref: 46] [Cited by in F6Publishing: 48] [Article Influence: 7.7] [Reference Citation Analysis]
527 Morris-Stiff G, Feldstein AE. Fibroblast growth factor 21 as a biomarker for NAFLD: integrating pathobiology into clinical practice. J Hepatol 2010;53:795-6. [PMID: 20800308 DOI: 10.1016/j.jhep.2010.07.003] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
528 Bergasa NV, Mehlman J, Bir K. Aerobic exercise: a potential therapeutic intervention for patients with liver disease. Medical Hypotheses 2004;62:935-41. [DOI: 10.1016/j.mehy.2003.12.041] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
529 Mofrad P, Contos MJ, Haque M, Sargeant C, Fisher RA, Luketic VA, Sterling RK, Shiffman ML, Stravitz RT, Sanyal AJ. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology. 2003;37:1286-1292. [PMID: 12774006 DOI: 10.1053/jhep.2003.50229] [Cited by in Crossref: 709] [Cited by in F6Publishing: 659] [Article Influence: 37.3] [Reference Citation Analysis]
530 Bedossa P, Patel K. Biopsy and Noninvasive Methods to Assess Progression of Nonalcoholic Fatty Liver Disease. Gastroenterology. 2016;150:1811-1822.e4. [PMID: 27003601 DOI: 10.1053/j.gastro.2016.03.008] [Cited by in Crossref: 64] [Cited by in F6Publishing: 57] [Article Influence: 10.7] [Reference Citation Analysis]
531 García-galiano D, Sánchez-garrido MA, Espejo I, Montero JL, Costán G, Marchal T, Membrives A, Gallardo-valverde JM, Muñoz-castañeda JR, Arévalo E, De la Mata M, Muntané J. IL-6 and IGF-1 are Independent Prognostic Factors of Liver Steatosis and Non-Alcoholic Steatohepatitis in Morbidly Obese Patients. OBES SURG 2007;17:493-503. [DOI: 10.1007/s11695-007-9087-1] [Cited by in Crossref: 66] [Cited by in F6Publishing: 67] [Article Influence: 4.4] [Reference Citation Analysis]
532 Targher G, Bertolini L, Rodella S, Zoppini G, Zenari L, Falezza G. Associations between liver histology and cortisol secretion in subjects with nonalcoholic fatty liver disease. Clin Endocrinol (Oxf). 2006;64:337-341. [PMID: 16487446 DOI: 10.1111/j.1365-2265.2006.02466.x] [Cited by in Crossref: 53] [Cited by in F6Publishing: 54] [Article Influence: 3.3] [Reference Citation Analysis]
533 Morrison MC, Mulder P, Salic K, Verheij J, Liang W, van Duyvenvoorde W, Menke A, Kooistra T, Kleemann R, Wielinga PY. Intervention with a caspase-1 inhibitor reduces obesity-associated hyperinsulinemia, non-alcoholic steatohepatitis and hepatic fibrosis in LDLR-/-.Leiden mice. Int J Obes (Lond) 2016;40:1416-23. [PMID: 27121255 DOI: 10.1038/ijo.2016.74] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 4.2] [Reference Citation Analysis]
534 Aragonès G, Auguet T, Armengol S, Berlanga A, Guiu-Jurado E, Aguilar C, Martínez S, Sabench F, Porras JA, Ruiz MD, Hernández M, Sirvent JJ, Del Castillo D, Richart C. PNPLA3 Expression Is Related to Liver Steatosis in Morbidly Obese Women with Non-Alcoholic Fatty Liver Disease. Int J Mol Sci 2016;17:E630. [PMID: 27128907 DOI: 10.3390/ijms17050630] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
535 Uetake Y, Ikeda H, Irie R, Tejima K, Matsui H, Ogura S, Wang H, Mu S, Hirohama D, Ando K, Sawamura T, Yatomi Y, Fujita T, Shimosawa T. High-salt in addition to high-fat diet may enhance inflammation and fibrosis in liver steatosis induced by oxidative stress and dyslipidemia in mice. Lipids Health Dis 2015;14:6. [PMID: 25888871 DOI: 10.1186/s12944-015-0002-9] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
536 Barchetta I, Chiappetta C, Ceccarelli V, Cimini FA, Bertoccini L, Gaggini M, Cristofano CD, Silecchia G, Lenzi A, Leonetti F, Baroni MG, Gastaldelli A, Cavallo MG. Angiopoietin-Like Protein 4 Overexpression in Visceral Adipose Tissue from Obese Subjects with Impaired Glucose Metabolism and Relationship with Lipoprotein Lipase. Int J Mol Sci 2020;21:E7197. [PMID: 33003532 DOI: 10.3390/ijms21197197] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
537 Magliano DC, Bargut TC, de Carvalho SN, Aguila MB, Mandarim-de-Lacerda CA, Souza-Mello V. Peroxisome proliferator-activated receptors-alpha and gamma are targets to treat offspring from maternal diet-induced obesity in mice. PLoS One. 2013;8:e64258. [PMID: 23700465 DOI: 10.1371/journal.pone.0064258] [Cited by in Crossref: 52] [Cited by in F6Publishing: 49] [Article Influence: 5.8] [Reference Citation Analysis]
538 Wiegand J, Mössner J, Tillmann HL. [Non-alcoholic fatty liver disease and non-alcoholic steatohepatitis]. Internist (Berl) 2007;48:154-63. [PMID: 17226007 DOI: 10.1007/s00108-006-1796-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
539 Guzmán-aroca F, Frutos-bernal MD, Bas A, Luján-mompeán JA, Reus M, de Dios Berná-serna J, Parrilla P. Detection of non-alcoholic steatohepatitis in patients with morbid obesity before bariatric surgery: preliminary evaluation with acoustic radiation force impulse imaging. Eur Radiol 2012;22:2525-32. [DOI: 10.1007/s00330-012-2505-3] [Cited by in Crossref: 40] [Cited by in F6Publishing: 37] [Article Influence: 4.0] [Reference Citation Analysis]
540 Papageorgiou MV, Hadziyannis E, Tiniakos D, Georgiou A, Margariti A, Kostas A, Papatheodoridis GV. Serum levels of vascular endothelial growth factor in non-alcoholic fatty liver disease. Ann Gastroenterol 2017;30:209-16. [PMID: 28243042 DOI: 10.20524/aog.2016.0107] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
541 Engin A, Dincer S, Ercan SZ, Memis L, Bukan N, Bozkurt S. REGULATION OF FIBROGENESIS DURING THE EARLY PHASE OF COMMON BILE DUCT OBSTRUCTION. ANZ J Surg 2006;76:645-8. [DOI: 10.1111/j.1445-2197.2006.03789.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
542 Daryani NE, Daryani NE, Alavian SM, Zare A, Fereshtehnejad SM, Keramati MR, Pashaei MR, Habibollahi P. Non-alcoholic steatohepatitis and influence of age and gender on histopathologic findings. World J Gastroenterol 2010; 16(33): 4169-4175 [PMID: 20806434 DOI: 10.3748/wjg.v16.i33.4169] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
543 Piña-zentella RM, Rosado JL, Gallegos-corona MA, Madrigal-pérez LA, García OP, Ramos-gomez M. Lycopene Improves Diet-Mediated Recuperation in Rat Model of Nonalcoholic Fatty Liver Disease. Journal of Medicinal Food 2016;19:607-14. [DOI: 10.1089/jmf.2015.0123] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 3.3] [Reference Citation Analysis]
544 Li J, He X, Yang Y, Li M, Xu C, Yu R. Risk assessment of silica nanoparticles on liver injury in metabolic syndrome mice induced by fructose. Sci Total Environ 2018;628-629:366-74. [PMID: 29448021 DOI: 10.1016/j.scitotenv.2018.02.047] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
545 Sanyal AJ, Friedman SL, McCullough AJ, Dimick-Santos L; American Association for the Study of Liver Diseases; United States Food and Drug Administration. Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: findings and recommendations from an American Association for the Study of Liver Diseases-U.S. Food and Drug Administration Joint Workshop. Hepatology. 2015;61:1392-1405. [PMID: 25557690 DOI: 10.1002/hep.27678] [Cited by in Crossref: 213] [Cited by in F6Publishing: 194] [Article Influence: 30.4] [Reference Citation Analysis]
546 Law K, Brunt EM. Nonalcoholic fatty liver disease. Clin Liver Dis. 2010;14:591-604. [PMID: 21055684 DOI: 10.1016/j.cld.2010.07.006] [Cited by in Crossref: 46] [Cited by in F6Publishing: 47] [Article Influence: 4.2] [Reference Citation Analysis]
547 Sehgal R, Ilha M, Vaittinen M, Kaminska D, Männistö V, Kärjä V, Tuomainen M, Hanhineva K, Romeo S, Pajukanta P, Pihlajamäki J, de Mello VD. Indole-3-Propionic Acid, a Gut-Derived Tryptophan Metabolite, Associates with Hepatic Fibrosis. Nutrients 2021;13:3509. [PMID: 34684510 DOI: 10.3390/nu13103509] [Reference Citation Analysis]
548 Zhou YJ, Zheng KI, Ma HL, Li G, Pan XY, Zhu PW, Targher G, Byrne CD, Wang XD, Chen YP, Li XB, Zheng MH. Association between positivity of serum autoantibodies and liver disease severity in patients with biopsy-proven NAFLD. Nutr Metab Cardiovasc Dis 2021;31:552-60. [PMID: 33250371 DOI: 10.1016/j.numecd.2020.10.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
549 Phillips ML, Boase S, Wahlroos S, Dugar M, Kow L, Stahl J, Slavotinek JP, Valentine R, Toouli J, Thompson CH. Associates of change in liver fat content in the morbidly obese after laparoscopic gastric banding surgery. Diabetes Obes Metab. 2008;10:661-667. [PMID: 17941875 DOI: 10.1111/j.1463-1326.2007.00793.x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 1.8] [Reference Citation Analysis]
550 Brunt EM, Neuschwander-tetri BA, Burt AD. Fatty liver disease. MacSween's Pathology of the Liver. Elsevier; 2012. pp. 293-359. [DOI: 10.1016/b978-0-7020-3398-8.00006-4] [Cited by in Crossref: 9] [Article Influence: 0.9] [Reference Citation Analysis]
551 Rosselli MS, Burgueño AL, Carabelli J, Schuman M, Pirola CJ, Sookoian S. Losartan reduces liver expression of plasminogen activator inhibitor-1 (PAI-1) in a high fat-induced rat nonalcoholic fatty liver disease model. Atherosclerosis 2009;206:119-26. [DOI: 10.1016/j.atherosclerosis.2009.01.026] [Cited by in Crossref: 40] [Cited by in F6Publishing: 37] [Article Influence: 3.1] [Reference Citation Analysis]
552 Morris-Stiff G, Tan YM, Vauthey JN. Hepatic complications following preoperative chemotherapy with oxaliplatin or irinotecan for hepatic colorectal metastases. Eur J Surg Oncol. 2008;34:609-614. [PMID: 17764887 DOI: 10.1016/j.ejso.2007.07.007] [Cited by in Crossref: 81] [Cited by in F6Publishing: 72] [Article Influence: 5.4] [Reference Citation Analysis]
553 Hu KQ, Currie SL, Shen H, Cheung RC, Ho SB, Bini EJ, McCracken JD, Morgan T, Bräu N, Schmidt WN. Clinical implications of hepatic steatosis in patients with chronic hepatitis C: a multicenter study of U.S. veterans. Dig Dis Sci. 2007;52:570-578. [PMID: 17226072 DOI: 10.1007/s10620-006-9418-4] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
554 Hayman AV, Sofair AN, Manos MM, Thomas A, Terrault N, Ness GV, Stabach N, Robert M, Rumore G, Corless C, Bell B, Bialek S, Zaman A. Prevalence and predictors of hepatic steatosis in adults with newly diagnosed chronic liver disease due to hepatitis C. Medicine (Baltimore) 2009;88:302-6. [PMID: 19745689 DOI: 10.1097/MD.0b013e3181b954f4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
555 Tokushige K, Hyogo H, Nakajima T, Ono M, Kawaguchi T, Honda K, Eguchi Y, Nozaki Y, Kawanaka M, Tanaka S, Imajo K, Sumida Y, Kamada Y, Fujii H, Suzuki Y, Kogiso T, Karino Y, Munekage K, Kuromatsu R, Oeda S, Yanase M, Mori K, Ogawa Y, Seko Y, Takehara T, Itoh Y, Nakajima A, Kanemasa K, Nishino K, Masaki N, Takahashi H, Seike M, Torimura T, Saibara T, Toyota J, Chayama K, Hashimoto E. Hepatocellular carcinoma in Japanese patients with nonalcoholic fatty liver disease and alcoholic liver disease: multicenter survey. J Gastroenterol 2016;51:586-96. [PMID: 26456168 DOI: 10.1007/s00535-015-1129-1] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 4.1] [Reference Citation Analysis]
556 Kühn JP, Hernando D, Muñoz del Rio A, Evert M, Kannengiesser S, Völzke H, Mensel B, Puls R, Hosten N, Reeder SB. Effect of multipeak spectral modeling of fat for liver iron and fat quantification: correlation of biopsy with MR imaging results. Radiology 2012;265:133-42. [PMID: 22923718 DOI: 10.1148/radiol.12112520] [Cited by in Crossref: 121] [Cited by in F6Publishing: 119] [Article Influence: 12.1] [Reference Citation Analysis]
557 Tan CH, Al-Kalifah N, Ser KH, Lee YC, Chen JC, Lee WJ. Long-term effect of bariatric surgery on resolution of nonalcoholic steatohepatitis (NASH): An external validation and application of a clinical NASH score. Surg Obes Relat Dis 2018;14:1600-6. [PMID: 30077664 DOI: 10.1016/j.soard.2018.05.024] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
558 Namikawa C, Shu-Ping Z, Vyselaar JR, Nozaki Y, Nemoto Y, Ono M, Akisawa N, Saibara T, Hiroi M, Enzan H. Polymorphisms of microsomal triglyceride transfer protein gene and manganese superoxide dismutase gene in non-alcoholic steatohepatitis. J Hepatol. 2004;40:781-786. [PMID: 15094225 DOI: 10.1016/j.jhep.2004.01.028] [Cited by in Crossref: 164] [Cited by in F6Publishing: 158] [Article Influence: 9.1] [Reference Citation Analysis]
559 Haybaeck J, Stumptner C, Thueringer A, Kolbe T, Magin TM, Hesse M, Fickert P, Tsybrovskyy O, Müller H, Trauner M, Zatloukal K, Denk H. Genetic background effects of keratin 8 and 18 in a DDC-induced hepatotoxicity and Mallory-Denk body formation mouse model. Lab Invest 2012;92:857-67. [PMID: 22449798 DOI: 10.1038/labinvest.2012.49] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 3.2] [Reference Citation Analysis]
560 Cayón A, Crespo J, Mayorga M, Guerra A, Pons-Romero F. Increased expression of Ob-Rb and its relationship with the overexpression of TGF-beta1 and the stage of fibrosis in patients with nonalcoholic steatohepatitis. Liver Int 2006;26:1065-71. [PMID: 17032406 DOI: 10.1111/j.1478-3231.2006.01337.x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 2.1] [Reference Citation Analysis]
561 Caballero F, Fernández A, De Lacy AM, Fernández-Checa JC, Caballería J, García-Ruiz C. Enhanced free cholesterol, SREBP-2 and StAR expression in human NASH. J Hepatol. 2009;50:789-796. [PMID: 19231010 DOI: 10.1016/j.jhep.2008.12.016] [Cited by in Crossref: 222] [Cited by in F6Publishing: 207] [Article Influence: 17.1] [Reference Citation Analysis]
562 Pai SA, Munshi RP, Panchal FH, Gaur I, Mestry SN, Gursahani MS, Juvekar AR. Plumbagin reduces obesity and nonalcoholic fatty liver disease induced by fructose in rats through regulation of lipid metabolism, inflammation and oxidative stress. Biomedicine & Pharmacotherapy 2019;111:686-94. [DOI: 10.1016/j.biopha.2018.12.139] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 5.7] [Reference Citation Analysis]
563 Nakahara T, Hyogo H, Ono A, Nagaoki Y, Kawaoka T, Miki D, Tsuge M, Hiraga N, Hayes CN, Hiramatsu A, Imamura M, Kawakami Y, Aikata H, Ochi H, Abe-Chayama H, Furusho H, Shintani T, Kurihara H, Miyauchi M, Takata T, Arihiro K, Chayama K. Involvement of Porphyromonas gingivalis in the progression of non-alcoholic fatty liver disease. J Gastroenterol 2018;53:269-80. [PMID: 28741270 DOI: 10.1007/s00535-017-1368-4] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 6.6] [Reference Citation Analysis]
564 Konishi I, Hiasa Y, Shigematsu S, Hirooka M, Furukawa S, Abe M, Matsuura B, Michitaka K, Horiike N, Onji M. Diabetes pattern on the 75 g oral glucose tolerance test is a risk factor for hepatocellular carcinoma in patients with hepatitis C virus. Liver Int 2009;29:1194-201. [PMID: 19422477 DOI: 10.1111/j.1478-3231.2009.02043.x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 2.2] [Reference Citation Analysis]
565 Waghorn PA, Ferreira DS, Erstad DJ, Rotile NJ, Masia R, Jones CM, Tu C, Sojoodi M, Chen YI, Schlerman F, Wellen J, Martinez RVP, Tanabe KK, Fuchs BC, Caravan P. Quantitative, noninvasive MRI characterization of disease progression in a mouse model of non-alcoholic steatohepatitis. Sci Rep 2021;11:6105. [PMID: 33731798 DOI: 10.1038/s41598-021-85679-4] [Reference Citation Analysis]
566 Seo S, Maganti K, Khehra M, Ramsamooj R, Tsodikov A, Bowlus C, McVicar J, Zern M, Torok N. De novo nonalcoholic fatty liver disease after liver transplantation. Liver Transpl. 2007;13:844-847. [PMID: 17029282 DOI: 10.1002/lt.20932] [Cited by in Crossref: 127] [Cited by in F6Publishing: 98] [Article Influence: 8.5] [Reference Citation Analysis]
567 Sumida Y, Yoneda M, Hyogo H, Yamaguchi K, Ono M, Fujii H, Eguchi Y, Suzuki Y, Imai S, Kanemasa K, Fujita K, Chayama K, Yasui K, Saibara T, Kawada N, Fujimoto K, Kohgo Y, Okanoue T; Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG-NAFLD). A simple clinical scoring system using ferritin, fasting insulin, and type IV collagen 7S for predicting steatohepatitis in nonalcoholic fatty liver disease. J Gastroenterol. 2011;46:257-268. [PMID: 20842510 DOI: 10.1007/s00535-010-0305-6] [Cited by in Crossref: 131] [Cited by in F6Publishing: 116] [Article Influence: 10.9] [Reference Citation Analysis]
568 Huet N, Denis I, Martino A, Gallix B, Sturm N, Leroy V, Bricault I. Ultrasonographic assessment of liver fibrosis with computer-assisted analysis of liver surface irregularities. Diagnostic and Interventional Imaging 2015;96:941-6. [DOI: 10.1016/j.diii.2015.02.010] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
569 Sambasiva Rao M, Reddy JK. PPARα in the pathogenesis of fatty liver disease. Hepatology 2004;40:783-6. [DOI: 10.1002/hep.1840400405] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
570 Zhou Z, Zhang Q, Wu W, Lin YH, Tai DI, Tseng JH, Lin YR, Wu S, Tsui PH. Hepatic steatosis assessment using ultrasound homodyned-K parametric imaging: the effects of estimators. Quant Imaging Med Surg 2019;9:1932-47. [PMID: 31929966 DOI: 10.21037/qims.2019.08.03] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
571 Magalotti D, Marchesini G, Ramilli S, Berzigotti A, Bianchi G, Zoli M. Splanchnic haemodynamics in non-alcoholic fatty liver disease: effect of a dietary/pharmacological treatment. A pilot study. Dig Liver Dis 2004;36:406-11. [PMID: 15248381 DOI: 10.1016/j.dld.2004.01.023] [Cited by in Crossref: 5] [Cited by in F6Publishing: 14] [Article Influence: 0.3] [Reference Citation Analysis]
572 Latif HA, Assal HS, Mahmoud M, Rasheed WI. Role of serum adiponectin level in the development of liver cirrhosis in patients with hepatitis C virus. Clin Exp Med 2011;11:123-9. [PMID: 20714777 DOI: 10.1007/s10238-010-0108-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
573 Lohöfer FK, Kaissis GA, Müller-Leisse C, Franz D, Katemann C, Hock A, Peeters JM, Rummeny EJ, Karampinos D, Braren RF. Acceleration of chemical shift encoding-based water fat MRI for liver proton density fat fraction and T2* mapping using compressed sensing. PLoS One 2019;14:e0224988. [PMID: 31730658 DOI: 10.1371/journal.pone.0224988] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
574 Illam SP, Kandiyil SP, Narayanankutty A, Veetil SV, Babu TD, Uppu RM, Raghavamenon AC. Virgin coconut oil complements with its polyphenol components mitigate sodium fluoride toxicity in vitro and in vivo. Drug Chem Toxicol 2021;:1-7. [PMID: 34407699 DOI: 10.1080/01480545.2021.1962691] [Reference Citation Analysis]
575 Tiwari-Heckler S, Yee EU, Yalcin Y, Park J, Nguyen DT, Gao W, Csizmadia E, Afdhal N, Mukamal KJ, Robson SC, Lai M, Schwartz RE, Jiang ZG. Adenosine deaminase 2 produced by infiltrative monocytes promotes liver fibrosis in nonalcoholic fatty liver disease. Cell Rep 2021;37:109897. [PMID: 34706243 DOI: 10.1016/j.celrep.2021.109897] [Reference Citation Analysis]
576 Fracanzani AL, Valenti L, Bugianesi E, Andreoletti M, Colli A, Vanni E, Bertelli C, Fatta E, Bignamini D, Marchesini G, Fargion S. Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes. Hepatology. 2008;48:792-798. [PMID: 18752331 DOI: 10.1002/hep.22429] [Cited by in Crossref: 392] [Cited by in F6Publishing: 366] [Article Influence: 28.0] [Reference Citation Analysis]
577 Schwimmer JB, Deutsch R, Rauch JB, Behling C, Newbury R, Lavine JE. Obesity, insulin resistance, and other clinicopathological correlates of pediatric nonalcoholic fatty liver disease. J Pediatr. 2003;143:500-505. [PMID: 14571229 DOI: 10.1067/s0022-3476(03)00325-1] [Cited by in Crossref: 327] [Cited by in F6Publishing: 114] [Article Influence: 17.2] [Reference Citation Analysis]
578 Ye Q, Zou B, Yeo YH, Li J, Huang DQ, Wu Y, Yang H, Liu C, Kam LY, Tan XXE, Chien N, Trinh S, Henry L, Stave CD, Hosaka T, Cheung RC, Nguyen MH. Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020;5:739-752. [PMID: 32413340 DOI: 10.1016/s2468-1253(20)30077-7] [Cited by in Crossref: 85] [Cited by in F6Publishing: 38] [Article Influence: 42.5] [Reference Citation Analysis]
579 Su Z, Shan H, He B, Lv W, Meng X, Wang J, Zhu K, Yang Y, Chen G. Selection of the most powerful predictors for the evaluation of hepatic steatosis grade: An experimental study. European Journal of Radiology 2009;72:118-24. [DOI: 10.1016/j.ejrad.2008.06.020] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
580 Angelico F, Del Ben M, Conti R, Francioso S, Feole K, Maccioni D, Antonini TM, Alessandri C. Non-alcoholic fatty liver syndrome: a hepatic consequence of common metabolic diseases. J Gastroenterol Hepatol. 2003;18:588-594. [PMID: 12702052 DOI: 10.1046/j.1440-1746.2003.02958.x] [Cited by in Crossref: 119] [Cited by in F6Publishing: 108] [Article Influence: 6.3] [Reference Citation Analysis]
581 Shigefuku R, Takahashi H, Kobayashi M, Ikeda H, Matsunaga K, Okuse C, Matsumoto N, Maeyama S, Sase S, Suzuki M. Pathophysiological analysis of nonalcoholic fatty liver disease by evaluation of fatty liver changes and blood flow using xenon computed tomography: can early-stage nonalcoholic steatohepatitis be distinguished from simple steatosis? J Gastroenterol. 2012;47:1238-1247. [PMID: 22576023 DOI: 10.1007/s00535-012-0581-4] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
582 Watanabe S, Hashimoto E, Ikejima K, Uto H, Ono M, Sumida Y, Seike M, Takei Y, Takehara T, Tokushige K, Nakajima A, Yoneda M, Saibara T, Shiota G, Sakaida I, Nakamuta M, Mizuta T, Tsubouchi H, Sugano K, Shimosegawa T. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. J Gastroenterol 2015;50:364-77. [DOI: 10.1007/s00535-015-1050-7] [Cited by in Crossref: 122] [Cited by in F6Publishing: 61] [Article Influence: 17.4] [Reference Citation Analysis]
583 Yunianingtias D, Volker D. Nutritional aspects of non-alcoholic steatohepatitis treatment. Nutrition & Dietetics 2006;63:79-90. [DOI: 10.1111/j.1747-0080.2006.00054.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
584 Contos MJ, Sanyal AJ. The clinicopathologic spectrum and management of nonalcoholic fatty liver disease. Adv Anat Pathol. 2002;9:37-51. [PMID: 11756758 DOI: 10.1097/00125480-200201000-00005] [Cited by in Crossref: 45] [Cited by in F6Publishing: 43] [Article Influence: 2.3] [Reference Citation Analysis]
585 Invernizzi G, Modina S, Corbani D, Bronzo V, Pisani L, Caputo J, Agazzi A, Dell’orto V, Savoini G. Hepatic and subcutaneous adipose tissue variations in transition dairy goats fed saturated or unsaturated fat supplemented diets. Small Ruminant Research 2016;144:211-9. [DOI: 10.1016/j.smallrumres.2016.09.009] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
586 Shimada M, Hashimoto E, Taniai M, Hasegawa K, Okuda H, Hayashi N, Takasaki K, Ludwig J. Hepatocellular carcinoma in patients with non-alcoholic steatohepatitis. J Hepatol. 2002;37:154-160. [PMID: 12076877 DOI: 10.1016/s0168-8278(02)00099-5] [Cited by in Crossref: 247] [Cited by in F6Publishing: 75] [Article Influence: 13.0] [Reference Citation Analysis]
587 Sookoian S, Pirola CJ. Obstructive sleep apnea is associated with fatty liver and abnormal liver enzymes: a meta-analysis. Obes Surg. 2013;23:1815-1825. [PMID: 23740153 DOI: 10.1007/s11695-13-0981-4] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
588 Gao X, van der Veen JN, Zhu L, Chaba T, Ordoñez M, Lingrell S, Koonen DP, Dyck JR, Gomez-Muñoz A, Vance DE, Jacobs RL. Vagus nerve contributes to the development of steatohepatitis and obesity in phosphatidylethanolamine N-methyltransferase deficient mice. J Hepatol 2015;62:913-20. [PMID: 25433161 DOI: 10.1016/j.jhep.2014.11.026] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
589 Chitturi S, Farrell G, Frost L, Kriketos A, Lin R, Liddle C, Samarasinghe D, George J. Serum leptin in NASH correlates with hepatic steatosis but not fibrosis: A manifestation of lipotoxicity?: Serum leptin in NASH correlates with hepatic steatosis but not fibrosis: A manifestation of lipotoxicity? Hepatology 2002;36:403-9. [DOI: 10.1053/jhep.2002.34738] [Cited by in Crossref: 231] [Cited by in F6Publishing: 217] [Article Influence: 12.2] [Reference Citation Analysis]
590 Dong H, Wang J, Li C, Hirose A, Nozaki Y, Takahashi M, Ono M, Akisawa N, Iwasaki S, Saibara T. The phosphatidylethanolamine N-methyltransferase gene V175M single nucleotide polymorphism confers the susceptibility to NASH in Japanese population. J Hepatol. 2007;46:915-920. [PMID: 17391797 DOI: 10.1016/j.jhep.2006.12.012] [Cited by in Crossref: 75] [Cited by in F6Publishing: 75] [Article Influence: 5.0] [Reference Citation Analysis]
591 Vanwagner LB, Bhave M, Te HS, Feinglass J, Alvarez L, Rinella ME. Patients transplanted for nonalcoholic steatohepatitis are at increased risk for postoperative cardiovascular events. Hepatology. 2012;56:1741-1750. [PMID: 22611040 DOI: 10.1002/hep.25855] [Cited by in Crossref: 137] [Cited by in F6Publishing: 124] [Article Influence: 15.2] [Reference Citation Analysis]
592 Cataldo I, Sarcognato S, Sacchi D, Cacciatore M, Baciorri F, Mangia A, Cazzagon N, Guido M. Pathology of non-alcoholic fatty liver disease. Pathologica 2021;113:194-202. [PMID: 34294937 DOI: 10.32074/1591-951X-242] [Reference Citation Analysis]
593 Hajong R, Dhal MR, Naku N, Kapa B. Incidence of nonalcoholic fatty liver disease in patients undergoing laparoscopic cholecystectomy. J Family Med Prim Care 2018;7:1375-8. [PMID: 30613527 DOI: 10.4103/jfmpc.jfmpc_193_18] [Reference Citation Analysis]
594 Seko Y, Sumida Y, Tanaka S, Mori K, Taketani H, Ishiba H, Hara T, Okajima A, Umemura A, Nishikawa T, Yamaguchi K, Moriguchi M, Kanemasa K, Yasui K, Imai S, Shimada K, Itoh Y. Effect of sodium glucose cotransporter 2 inhibitor on liver function tests in Japanese patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus. Hepatol Res. 2017;47:1072-1078. [PMID: 27925353 DOI: 10.1111/hepr.12834] [Cited by in Crossref: 43] [Cited by in F6Publishing: 45] [Article Influence: 7.2] [Reference Citation Analysis]
595 Tzeng TF, Lu HJ, Liou SS, Chang CJ, Liu IM. Vinegar-Baked Radix Bupleuri Regulates Lipid Disorders via a Pathway Dependent on Peroxisome-Proliferator-Activated Receptor-α in High-Fat-Diet-Induced Obese Rats. Evid Based Complement Alternat Med 2012;2012:827278. [PMID: 22253647 DOI: 10.1155/2012/827278] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
596 Karanjia RN, Crossey MME, Cox IJ, Fye HKS, Njie R, Goldin RD, Taylor-Robinson SD. Hepatic steatosis and fibrosis: Non-invasive assessment. World J Gastroenterol 2016; 22(45): 9880-9897 [PMID: 28018096 DOI: 10.3748/wjg.v22.i45.9880] [Cited by in CrossRef: 27] [Cited by in F6Publishing: 25] [Article Influence: 4.5] [Reference Citation Analysis]
597 Iñiguez M, Pérez-Matute P, Villanueva-Millán MJ, Recio-Fernández E, Roncero-Ramos I, Pérez-Clavijo M, Oteo JA. Agaricus bisporus supplementation reduces high-fat diet-induced body weight gain and fatty liver development. J Physiol Biochem 2018;74:635-46. [PMID: 30288689 DOI: 10.1007/s13105-018-0649-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
598 Salgado Júnior W, Santos JSD, Sankarankutty AK, Castro e Silva OD. Nonalcoholic fatty liver disease and obesity. Acta Cir Bras 2006;21:72-8. [DOI: 10.1590/s0102-86502006000700017] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
599 Morita S, Neto Dde S, Morita FH, Morita NK, Lobo SM. Prevalence of Non-alcoholic Fatty Liver Disease and Steatohepatitis Risk Factors in Patients Undergoing Bariatric Surgery. Obes Surg 2015;25:2335-43. [PMID: 25920616 DOI: 10.1007/s11695-015-1696-5] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
600 Kan H, Kimura Y, Hyogo H, Fukuhara T, Fujino H, Naeshiro N, Honda Y, Kawaoka T, Tsuge M, Hiramatsu A, Imamura M, Kawakami Y, Aikata H, Ochi H, Arihiro K, Chayama K. Non-invasive assessment of liver steatosis in non-alcoholic fatty liver disease: L/S ratio of liver steatosis. Hepatol Res 2014;44:E420-7. [DOI: 10.1111/hepr.12330] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
601 Isoda H, Takahashi H, Eguchi Y, Kojima M, Inoue K, Murayama K, Matsuda Y, Anzai K. Re-evaluation of glycated hemoglobin and glycated albumin with continuous glucose monitoring system as markers of glycemia in patients with liver cirrhosis. Biomed Rep 2017;6:51-6. [PMID: 28123707 DOI: 10.3892/br.2016.808] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
602 Guillén-Enríquez C, López-Teros V, Martín-Orozco U, López-Díaz JA, Del Hierro-Ochoa J, Ramos-Jiménez A, Astiazarán-García H, Martínez-Ruiz NDR, Wall-Medrano A. Selected Physiological Effects of a Garcinia Gummi-Gutta Extract in Rats Fed with Different Hypercaloric Diets. Nutrients 2018;10:E565. [PMID: 29734675 DOI: 10.3390/nu10050565] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
603 Kimura S, Tanaka K, Oeda S, Inoue K, Inadomi C, Kubotsu Y, Yoshioka W, Okada M, Isoda H, Kuwashiro T, Akiyama T, Kurashige A, Oshima A, Oshima M, Matsumoto Y, Kawaguchi A, Anzai K, Sueoka E, Aishima S, Takahashi H. Effect of skin-capsular distance on controlled attenuation parameter for diagnosing liver steatosis in patients with nonalcoholic fatty liver disease. Sci Rep 2021;11:15641. [PMID: 34341368 DOI: 10.1038/s41598-021-94970-3] [Reference Citation Analysis]
604 Honda Y, Imajo K, Kobayashi T, Kessoku T, Ogawa Y, Tomeno W, Yoneda M, Kobayashi N, Saito S, Nakajima A. Autotaxin is a valuable biomarker for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. Hepatol Res 2019;49:1136-46. [PMID: 31144415 DOI: 10.1111/hepr.13382] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
605 Régnier M, Polizzi A, Guillou H, Loiseau N. Sphingolipid metabolism in non-alcoholic fatty liver diseases. Biochimie 2019;159:9-22. [PMID: 30071259 DOI: 10.1016/j.biochi.2018.07.021] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 4.3] [Reference Citation Analysis]
606 Kim HP, Idowu MO, Mospan AR, Allmon AG, Roden M, Newsome P, Lok AS, Thuluvath PJ, Taunk J, Fried MW, Sanyal AJ, Barritt AS 4th; TARGET-NASH Investigators. Liver biopsy in the real world-reporting, expert concordance and correlation with a pragmatic clinical diagnosis. Aliment Pharmacol Ther 2021;54:1472-80. [PMID: 34694013 DOI: 10.1111/apt.16674] [Reference Citation Analysis]
607 Konishi K, Miyake T, Furukawa S, Senba H, Kanzaki S, Nakaguchi H, Yukimoto A, Nakamura Y, Watanabe T, Koizumi Y, Yoshida O, Tokumoto Y, Hirooka M, Kumagi T, Abe M, Matsuura B, Hiasa Y. Advanced fibrosis of non-alcoholic steatohepatitis affects the significance of lipoprotein(a) as a cardiovascular risk factor. Atherosclerosis 2020;299:32-7. [PMID: 32203743 DOI: 10.1016/j.atherosclerosis.2020.02.026] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
608 White DL, Richardson PA, Al-Saadi M, Fitzgerald SJ, Green L, Amaratunge C, Anand M, El-Serag HB. Dietary history and physical activity and risk of advanced liver disease in veterans with chronic hepatitis C infection. Dig Dis Sci 2011;56:1835-47. [PMID: 21188525 DOI: 10.1007/s10620-010-1505-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
609 Hall AR, Green AC, Luong T, Burroughs AK, Wyatt J, Dhillon AP. The use of guideline images to improve histological estimation of hepatic steatosis. Liver Int 2014;34:1414-27. [DOI: 10.1111/liv.12614] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
610 Auguet T, Aragonès G, Berlanga A, Martínez S, Sabench F, Binetti J, Aguilar C, Porras JA, Molina A, Del Castillo D, Richart C. Hepcidin in morbidly obese women with non-alcoholic fatty liver disease. PLoS One 2017;12:e0187065. [PMID: 29065180 DOI: 10.1371/journal.pone.0187065] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
611 Demir M, Lang S, Schlattjan M, Drebber U, Wedemeyer I, Nierhoff D, Kaul I, Sowa J, Canbay A, Töx U, Steffen HM. NIKEI: a new inexpensive and non-invasive scoring system to exclude advanced fibrosis in patients with NAFLD. PLoS One 2013;8:e58360. [PMID: 23555578 DOI: 10.1371/journal.pone.0058360] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 2.7] [Reference Citation Analysis]
612 Yalniz M, Bahcecioglu IH, Kuzu N, Poyrazoglu OK, Bulmus O, Celebi S, Ustundag B, Ozercan IH, Sahin K. Preventive role of genistein in an experimental non-alcoholic steatohepatitis model. J Gastroenterol Hepatol. 2007;22:2009-2014. [PMID: 17914984 DOI: 10.1111/j.1440-1746.2006.04681.x] [Cited by in Crossref: 45] [Cited by in F6Publishing: 46] [Article Influence: 3.2] [Reference Citation Analysis]
613 Kim SG. [Pediatric obesity and non-alcoholic fatty liver disease: is it really problematic?]. Korean J Gastroenterol 2011;57:141-3. [PMID: 21519160 DOI: 10.4166/kjg.2011.57.3.141] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
614 Tonan T, Fujimoto K, Qayyum A, Kawaguchi T, Kawaguchi A, Nakashima O, Okuda K, Hayabuchi N, Sata M. Quantification of hepatic iron concentration in chronic viral hepatitis: usefulness of T2-weighted single-shot spin-echo echo-planar MR imaging. PLoS One 2012;7:e33868. [PMID: 22439008 DOI: 10.1371/journal.pone.0033868] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
615 Alatalo P, Koivisto H, Kultti J, Bloigu R, Niemelä O. Evaluation of reference intervals for biomarkers sensitive to alcohol consumption, excess body weight and oxidative stress. Scand J Clin Lab Invest 2010;70:104-11. [PMID: 20073674 DOI: 10.3109/00365510903548818] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
616 Targher G. Associations between liver histology and early carotid atherosclerosis in subjects with nonalcoholic fatty liver disease. Hepatology. 2005;42:974-975; discussion 975. [PMID: 16175589 DOI: 10.1002/hep.20894] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.1] [Reference Citation Analysis]
617 Kawamura Y, Saitoh S, Arase Y, Ikeda K, Fukushima T, Hara T, Seko Y, Hosaka T, Kobayashi M, Sezaki H, Akuta N, Suzuki F, Suzuki Y, Fukuzawa K, Hamada Y, Takahashi J, Kobayashi M, Kumada H. Three-dimensional magnetic resonance imaging for stringent diagnosis of advanced fibrosis associated with nonalcoholic steatohepatitis. Hepatol Int 2013;7:850-8. [DOI: 10.1007/s12072-012-9419-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
618 Lee JY, Kim KM, Lee SG, Yu E, Lim Y, Lee HC, Chung Y, Lee YS, Suh D. Prevalence and risk factors of non-alcoholic fatty liver disease in potential living liver donors in Korea: A review of 589 consecutive liver biopsies in a single center. Journal of Hepatology 2007;47:239-44. [DOI: 10.1016/j.jhep.2007.02.007] [Cited by in Crossref: 176] [Cited by in F6Publishing: 159] [Article Influence: 11.7] [Reference Citation Analysis]
619 Kessoku T, Imajo K, Kobayashi T, Ozaki A, Iwaki M, Honda Y, Kato T, Ogawa Y, Tomeno W, Kato S, Higurashi T, Yoneda M, Kirikoshi H, Kubota K, Taguri M, Yamanaka T, Usuda H, Wada K, Kobayashi N, Saito S, Nakajima A. Lubiprostone in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled, phase 2a trial. Lancet Gastroenterol Hepatol 2020;5:996-1007. [PMID: 32805205 DOI: 10.1016/S2468-1253(20)30216-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
620 Omar N, Koshy M, Hanafiah M, Hatta SFWM, Shah FZM, Johari B, Zamhuri I, Kasim SS, Rahman TA, Ghani RA. Relationships between severity of steatosis with glycemic control and carotid intima-media thickness among diabetic patients with ischemic heart disease. J Res Med Sci 2020;25:64. [PMID: 33088301 DOI: 10.4103/jrms.JRMS_560_17] [Reference Citation Analysis]
621 Hjelkrem M, Morales A, Williams CD, Harrison SA. Unconjugated hyperbilirubinemia is inversely associated with non-alcoholic steatohepatitis (NASH). Aliment Pharmacol Ther. 2012;35:1416-1423. [PMID: 22540836 DOI: 10.1111/j.1365-2036.2012.05114.x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 2.8] [Reference Citation Analysis]
622 McDonald N, Eddowes PJ, Hodson J, Semple SIK, Davies NP, Kelly CJ, Kin S, Phillips M, Herlihy AH, Kendall TJ, Brown RM, Neil DAH, Hübscher SG, Hirschfield GM, Fallowfield JA. Multiparametric magnetic resonance imaging for quantitation of liver disease: a two-centre cross-sectional observational study. Sci Rep 2018;8:9189. [PMID: 29907829 DOI: 10.1038/s41598-018-27560-5] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 5.8] [Reference Citation Analysis]
623 Schwenzer NF, Springer F, Schraml C, Stefan N, Machann J, Schick F. Non-invasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance. J Hepatol. 2009;51:433-445. [PMID: 19604596 DOI: 10.1016/j.jhep.2009.05.023] [Cited by in Crossref: 472] [Cited by in F6Publishing: 433] [Article Influence: 36.3] [Reference Citation Analysis]
624 Benedict M, Zhang X. Non-alcoholic fatty liver disease: An expanded review. World J Hepatol 2017; 9(16): 715-732 [PMID: 28652891 DOI: 10.4254/wjh.v9.i16.715] [Cited by in Crossref: 304] [Cited by in F6Publishing: 267] [Article Influence: 60.8] [Reference Citation Analysis]
625 Nascimbeni F, Ballestri S, Di Tommaso L, Piccoli M, Lonardo A. Inflammatory hepatocellular adenomatosis, metabolic syndrome, polycystic ovary syndrome and non-alcoholic steatohepatitis: chance tetrad or association by necessity? Dig Liver Dis 2014;46:288-9. [PMID: 24183950 DOI: 10.1016/j.dld.2013.09.018] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
626 Rabinowich L, Shibolet O. Drug Induced Steatohepatitis: An Uncommon Culprit of a Common Disease. Biomed Res Int 2015;2015:168905. [PMID: 26273591 DOI: 10.1155/2015/168905] [Cited by in Crossref: 51] [Cited by in F6Publishing: 49] [Article Influence: 7.3] [Reference Citation Analysis]
627 Nair S, Diehl AM, Wiseman M, Farr GH, Perrillo RP. Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial: METFORMIN IN NASH. Alimentary Pharmacology & Therapeutics 2004;20:23-8. [DOI: 10.1111/j.1365-2036.2004.02025.x] [Cited by in Crossref: 254] [Cited by in F6Publishing: 226] [Article Influence: 14.1] [Reference Citation Analysis]
628 Ghosh S, Kaw M, Patel PR, Ledford KJ, Bowman TA, McInerney MF, Erickson SK, Bourey RE, Najjar SM. Mice with null mutation of Ceacam I develop nonalcoholic steatohepatitis. Hepat Med 2010;2010:69-78. [PMID: 21949477 DOI: 10.2147/HMER.S8902] [Cited by in Crossref: 3] [Cited by in F6Publishing: 17] [Article Influence: 0.3] [Reference Citation Analysis]
629 Paternostro R, Staufer K, Traussnigg S, Stättermayer AF, Halilbasic E, Keritam O, Meyer EL, Stift J, Wrba F, Sipos B, Canbay A, Schlattjan M, Aigner E, Datz C, Stickel F, Schafmayer C, Hampe J, Buch S, Prager G, Munda P, Mandorfer M, Ferenci P, Trauner M. Combined effects of PNPLA3, TM6SF2 and HSD17B13 variants on severity of biopsy-proven non-alcoholic fatty liver disease. Hepatol Int 2021;15:922-33. [PMID: 34076851 DOI: 10.1007/s12072-021-10200-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
630 Targher G, Bertolini L, Rodella S, Zoppini G, Scala L, Zenari L, Falezza G. Associations between plasma adiponectin concentrations and liver histology in patients with nonalcoholic fatty liver disease. Clin Endocrinol (Oxf). 2006;64:679-683. [PMID: 16712671 DOI: 10.1111/j.1365-2265.2006.02527.x] [Cited by in Crossref: 130] [Cited by in F6Publishing: 133] [Article Influence: 8.1] [Reference Citation Analysis]
631 Seko Y, Yamaguchi K, Tochiki N, Yano K, Takahashi A, Okishio S, Kataoka S, Okuda K, Umemura A, Moriguchi M, Itoh Y. The Effect of Genetic Polymorphism in Response to Body Weight Reduction in Japanese Patients with Nonalcoholic Fatty Liver Disease. Genes (Basel) 2021;12:628. [PMID: 33922278 DOI: 10.3390/genes12050628] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
632 Cotler SJ, Guzman G, Layden-Almer J, Mazzone T, Layden TJ, Zhou XJ. Measurement of liver fat content using selective saturation at 3.0 T. J Magn Reson Imaging. 2007;25:743-748. [PMID: 17347995 DOI: 10.1002/jmri.20865] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 1.5] [Reference Citation Analysis]
633 Aguirre L, Palacios-Ortega S, Fernández-Quintela A, Hijona E, Bujanda L, Portillo MP. Pterostilbene Reduces Liver Steatosis and Modifies Hepatic Fatty Acid Profile in Obese Rats. Nutrients 2019;11:E961. [PMID: 31035507 DOI: 10.3390/nu11050961] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
634 Kiani A, Brun V, Lainé F, Turlin B, Morcet J, Michalak S, Le Gruyer A, Legros L, Bardou-Jacquet E, Gandon Y, Moirand R. Acoustic radiation force impulse imaging for assessing liver fibrosis in alcoholic liver disease. World J Gastroenterol 2016; 22(20): 4926-4935 [PMID: 27239119 DOI: 10.3748/wjg.v22.i20.4926] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
635 Mizuno K, Haga H, Okumoto K, Hoshikawa K, Katsumi T, Nishina T, Saito T, Katagiri H, Ueno Y. Intrahepatic distribution of nerve fibers and alterations due to fibrosis in diseased liver. PLoS One 2021;16:e0249556. [PMID: 33852613 DOI: 10.1371/journal.pone.0249556] [Reference Citation Analysis]
636 Wong VW, Chan HL, Hui AY, Chan KF, Liew CT, Chan FK, Sung JJ. Clinical and histological features of non-alcoholic fatty liver disease in Hong Kong Chinese. Aliment Pharmacol Ther 2004;20:45-9. [PMID: 15225170 DOI: 10.1111/j.1365-2036.2004.02012.x] [Cited by in Crossref: 38] [Cited by in F6Publishing: 38] [Article Influence: 2.1] [Reference Citation Analysis]
637 Chen T, Wong R, Wong P, Rollet-kurhajec KC, Alshaalan R, Deschenes M, Ghali P, Sebastiani G. Occult cirrhosis diagnosed by transient elastography is a frequent and under-monitored clinical entity. Liver Int 2015;35:2285-93. [DOI: 10.1111/liv.12802] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
638 Hennig EE, Mikula M, Goryca K, Paziewska A, Ledwon J, Nesteruk M, Woszczynski M, Walewska-Zielecka B, Pysniak K, Ostrowski J. Extracellular matrix and cytochrome P450 gene expression can distinguish steatohepatitis from steatosis in mice. J Cell Mol Med 2014;18:1762-72. [PMID: 24913135 DOI: 10.1111/jcmm.12328] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
639 Talwalkar JA, Yin M, Venkatesh S, Rossman PJ, Grimm RC, Manduca A, Romano A, Kamath PS, Ehman RL. Feasibility of in vivo MR elastographic splenic stiffness measurements in the assessment of portal hypertension. AJR Am J Roentgenol. 2009;193:122-127. [PMID: 19542403 DOI: 10.2214/ajr.07.3504] [Cited by in Crossref: 137] [Cited by in F6Publishing: 55] [Article Influence: 10.5] [Reference Citation Analysis]
640 Villesen IF, Daniels SJ, Leeming DJ, Karsdal MA, Nielsen MJ. Review article: the signalling and functional role of the extracellular matrix in the development of liver fibrosis. Aliment Pharmacol Ther 2020;52:85-97. [PMID: 32419162 DOI: 10.1111/apt.15773] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
641 Yoshikawa S, Iijima H, Saito M, Tanaka H, Imanishi H, Yoshimoto N, Yoshimoto T, Futatsugi-Yumikura S, Nakanishi K, Tsujimura T, Nishigami T, Kudo A, Arii S, Nishiguchi S. Crucial role of impaired Kupffer cell phagocytosis on the decreased Sonazoid-enhanced echogenicity in a liver of a nonalchoholic steatohepatitis rat model. Hepatol Res 2010;40:823-31. [PMID: 20557367 DOI: 10.1111/j.1872-034X.2010.00670.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
642 Chitturi S, Farrell GC, Hashimoto E, Saibara T, Lau GK, Sollano JD; Asia-Pacific Working Party on NAFLD. Non-alcoholic fatty liver disease in the Asia-Pacific region: definitions and overview of proposed guidelines. J Gastroenterol Hepatol. 2007;22:778-787. [PMID: 17565630 DOI: 10.1111/j.1440-1746.2007.05001.x] [Cited by in Crossref: 208] [Cited by in F6Publishing: 201] [Article Influence: 13.9] [Reference Citation Analysis]
643 Kumar D, Farrell GC, Kench J, George J. Hepatic steatosis and the risk of hepatocellular carcinoma in chronic hepatitis C. J Gastroenterol Hepatol. 2005;20:1395-1400. [PMID: 16105127 DOI: 10.1111/j.1440-1746.2005.04007.x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 1.9] [Reference Citation Analysis]
644 Qayyum A, Nystrom M, Noworolski SM, Chu P, Mohanty A, Merriman R. MRI Steatosis Grading: Development and Initial Validation of a Color Mapping System. American Journal of Roentgenology 2012;198:582-8. [DOI: 10.2214/ajr.11.6729] [Cited by in Crossref: 29] [Cited by in F6Publishing: 13] [Article Influence: 2.9] [Reference Citation Analysis]
645 Sumida Y, Yonei Y, Tanaka S, Mori K, Kanemasa K, Imai S, Taketani H, Hara T, Seko Y, Ishiba H, Okajima A, Yamaguchi K, Moriguchi M, Mitsuyoshi H, Yasui K, Minami M, Itoh Y. Lower levels of insulin-like growth factor-1 standard deviation score are associated with histological severity of non-alcoholic fatty liver disease: IGF-1 in advanced NASH. Hepatol Res 2015;45:771-81. [DOI: 10.1111/hepr.12408] [Cited by in Crossref: 40] [Cited by in F6Publishing: 33] [Article Influence: 5.0] [Reference Citation Analysis]
646 Tabibian JH, Lazo M, Durazo FA, Yeh HC, Tong MJ, Clark JM. Nonalcoholic fatty liver disease across ethno-racial groups: do Asian-American adults represent a new at-risk population? J Gastroenterol Hepatol. 2011;26:501-509. [PMID: 21332546 DOI: 10.1111/j.1440-1746.2010.06443.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
647 Barchetta I, Cimini FA, Leonetti F, Capoccia D, Di Cristofano C, Silecchia G, Orho-melander M, Melander O, Cavallo MG. Increased Plasma Proneurotensin Levels Identify NAFLD in Adults With and Without Type 2 Diabetes. The Journal of Clinical Endocrinology & Metabolism 2018;103:2253-60. [DOI: 10.1210/jc.2017-02751] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 5.8] [Reference Citation Analysis]
648 Kim D, Kim W, Joo SK, Kim JH, Harrison SA, Younossi ZM, Ahmed A. Predictors of nonalcoholic steatohepatitis and significant fibrosis in non-obese nonalcoholic fatty liver disease. Liver Int 2019;39:332-41. [DOI: 10.1111/liv.13983] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 4.8] [Reference Citation Analysis]
649 Lennerz JK, Hurov JB, White LS, Lewandowski KT, Prior JL, Planer GJ, Gereau RW 4th, Piwnica-Worms D, Schmidt RE, Piwnica-Worms H. Loss of Par-1a/MARK3/C-TAK1 kinase leads to reduced adiposity, resistance to hepatic steatosis, and defective gluconeogenesis. Mol Cell Biol 2010;30:5043-56. [PMID: 20733003 DOI: 10.1128/MCB.01472-09] [Cited by in Crossref: 31] [Cited by in F6Publishing: 22] [Article Influence: 2.6] [Reference Citation Analysis]
650 Ito T, Ishigami M, Ishizu Y, Kuzuya T, Honda T, Hayashi K, Nishimura D, Toyoda H, Kumada T, Goto H, Hirooka Y. Utility and limitations of noninvasive fibrosis markers for predicting prognosis in biopsy-proven Japanese non-alcoholic fatty liver disease patients: Noninvasive fibrosis markers for non-alcoholic fatty liver disease. Journal of Gastroenterology and Hepatology 2019;34:207-14. [DOI: 10.1111/jgh.14448] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
651 Pickhardt PJ, Park SH, Hahn L, Lee SG, Bae KT, Yu ES. Specificity of unenhanced CT for non-invasive diagnosis of hepatic steatosis: implications for the investigation of the natural history of incidental steatosis. Eur Radiol. 2012;22:1075-1082. [PMID: 22138733 DOI: 10.1007/s00330-011-2349-2] [Cited by in Crossref: 95] [Cited by in F6Publishing: 83] [Article Influence: 8.6] [Reference Citation Analysis]
652 Harris N, Nadebaum D, Christie M, Gorelik A, Nicoll A, Sood S, Gibson R. Acoustic radiation force impulse accuracy and the impact of hepatic steatosis on liver fibrosis staging. J Med Imaging Radiat Oncol 2016;60:587-92. [PMID: 27324199 DOI: 10.1111/1754-9485.12482] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
653 M. Brunt E, G. Tiniakos D. Fatty Liver Disease. Surgical Pathology of the GI Tract, Liver, Biliary Tract, and Pancreas. Elsevier; 2009. pp. 1087-114. [DOI: 10.1016/b978-141604059-0.50044-8] [Cited by in Crossref: 8] [Article Influence: 0.6] [Reference Citation Analysis]
654 Tsochatzis E, Papatheodoridis GV, Manesis EK, Kafiri G, Tiniakos DG, Archimandritis AJ. Metabolic syndrome is associated with severe fibrosis in chronic viral hepatitis and non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2008;27:80-89. [PMID: 17919273 DOI: 10.1111/j.1365-2036.2007.03538.x] [Cited by in Crossref: 48] [Cited by in F6Publishing: 47] [Article Influence: 3.2] [Reference Citation Analysis]
655 Jichitu A, Bungau S, Stanescu AMA, Vesa CM, Toma MM, Bustea C, Iurciuc S, Rus M, Bacalbasa N, Diaconu CC. Non-Alcoholic Fatty Liver Disease and Cardiovascular Comorbidities: Pathophysiological Links, Diagnosis, and Therapeutic Management. Diagnostics (Basel) 2021;11:689. [PMID: 33921359 DOI: 10.3390/diagnostics11040689] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
656 Kumagai E, Korenaga K, Korenaga M, Imamura M, Ueyama M, Aoki Y, Sugiyama M, Murata K, Masaki N, Kanto T, Mizokami M, Watanabe S. Appropriate use of virtual touch quantification and FibroScan® M and XL probes according to the skin capsular distance. J Gastroenterol 2016;51:496-505. [DOI: 10.1007/s00535-015-1127-3] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
657 Modares Mousavi SR, Geramizadeh B, Anushiravani A, Ejtehadi F, Anbardar MH, Moini M. Correlation between Serum Ferritin Level and Histopathological Disease Severity in Non-alcoholic Fatty Liver Disease. Middle East J Dig Dis 2018;10:90-5. [PMID: 30013757 DOI: 10.15171/mejdd.2018.96] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
658 Goh GB, Leow WQ, Liang S, Wan WK, Lim TKH, Tan CK, Chang PE. Quantification of hepatic steatosis in chronic liver disease using novel automated method of second harmonic generation and two-photon excited fluorescence. Sci Rep 2019;9:2975. [PMID: 30814650 DOI: 10.1038/s41598-019-39783-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
659 Cataldegirmen G, Zeng S, Feirt N, Ippagunta N, Dun H, Qu W, Lu Y, Rong LL, Hofmann MA, Kislinger T. RAGE limits regeneration after massive liver injury by coordinated suppression of TNF-alpha and NF-kappaB. J Exp Med. 2005;201:473-484. [PMID: 15699076 DOI: 10.1084/jem.20040934] [Cited by in Crossref: 104] [Cited by in F6Publishing: 101]